{
"company_details": [
{
"company_id": "0000794172",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000794172.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000794172.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000794172.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000794172_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000794172_main_keyfigs.svg",
"name": "Meridian Bioscience INC",
"rank": 1,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000794172.svg",
"report_text": "The relative strengths and weaknesses of Meridian Bioscience INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Meridian Bioscience INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 117% points.The greatest weakness of Meridian Bioscience INC is the variable Other Expenses, reducing the Economic Capital Ratio by 27% points.
The company's Economic Capital Ratio, given in the ranking table, is 279%, being 143% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000794172_2016_Meridian_Bioscience_INC.pdf",
"shrinked_graph_json": {
"2009": {
"Liabilities, Non-Current": "1.55",
"Liabilities": "21.8",
"Stockholders Equity": "51.4",
"ECR before LimitedLiability": "62.8",
"Liabilities, Current": "18.5",
"Other Liabilities": "2.31",
"Property, Plant and Equipment, Net": "-0.449",
"Assets": "2.99",
"Other Assets": "-1.08",
"Assets, Current": "3.82",
"Assets, Non-Current": "0.609",
"Goodwill": "0.588",
"General and Administrative Expense": "29.9",
"Expenses": "20.1",
"Revenues": "-1.56",
"Net Income": "18.9",
"Other Expenses": "-6.87",
"Research and Development": "-3.78",
"Other Revenues": "-1.56",
"Comprehensive Net Income": "19.0",
"Economic Capital Ratio": "62.0"
},
"2010": {
"Other Liabilities": "6.11",
"Liabilities": "74.1",
"Stockholders Equity": "61.8",
"ECR before LimitedLiability": "99.5",
"Liabilities, Current": "29.2",
"Liabilities, Non-Current": "50.9",
"Goodwill": "0.732",
"Assets": "0.843",
"Assets, Current": "1.06",
"Assets, Non-Current": "1.69",
"Other Assets": "-1.80",
"Other Expenses": "-35.7",
"Expenses": "-1.55",
"Revenues": "29.3",
"Net Income": "31.7",
"General and Administrative Expense": "28.8",
"Research and Development": "2.56",
"Other Revenues": "29.3",
"Other Net Income": "4.05",
"Comprehensive Net Income": "31.8",
"Economic Capital Ratio": "101"
},
"2011": {
"Liabilities, Current": "58.6",
"Liabilities": "85.5",
"Stockholders Equity": "78.4",
"ECR before LimitedLiability": "185",
"Liabilities, Non-Current": "21.8",
"Other Liabilities": "22.8",
"Property, Plant and Equipment, Net": "0.429",
"Assets": "1.64",
"Assets, Non-Current": "2.86",
"Other Assets": "-2.25",
"Goodwill": "1.26",
"General and Administrative Expense": "39.3",
"Expenses": "17.5",
"Revenues": "58.2",
"Net Income": "65.8",
"Research and Development": "10.9",
"Other Expenses": "-36.3",
"Other Revenues": "58.2",
"Comprehensive Net Income": "65.8",
"Other Net Income": "-9.05",
"Economic Capital Ratio": "123"
},
"2012": {
"Liabilities, Current": "39.8",
"Liabilities": "79.5",
"Stockholders Equity": "64.2",
"ECR before LimitedLiability": "149",
"Liabilities, Non-Current": "22.2",
"Other Liabilities": "35.6",
"Assets": "0.880",
"Other Assets": "-2.35",
"Assets, Non-Current": "2.77",
"Property, Plant and Equipment, Net": "0.258",
"Goodwill": "0.840",
"Other Expenses": "-31.6",
"Expenses": "19.1",
"Revenues": "58.3",
"Net Income": "74.7",
"Research and Development": "12.8",
"General and Administrative Expense": "35.1",
"Other Revenues": "58.3",
"Other Net Income": "-0.427",
"Comprehensive Net Income": "74.8",
"Economic Capital Ratio": "116"
},
"2013": {
"Liabilities, Current": "46.1",
"Liabilities": "84.8",
"Stockholders Equity": "66.0",
"ECR before LimitedLiability": "159",
"Other Liabilities": "27.4",
"Liabilities, Non-Current": "31.5",
"Goodwill": "0.317",
"Assets": "0.688",
"Assets, Non-Current": "2.49",
"Other Assets": "-2.60",
"Assets, Current": "1.11",
"General and Administrative Expense": "30.8",
"Expenses": "15.5",
"Revenues": "64.2",
"Net Income": "74.3",
"Research and Development": "9.97",
"Other Expenses": "-27.5",
"Other Revenues": "64.2",
"Other Net Income": "-4.07",
"Comprehensive Net Income": "74.4",
"Economic Capital Ratio": "119"
},
"2014": {
"Liabilities, Non-Current": "34.4",
"Liabilities": "114",
"Stockholders Equity": "103",
"ECR before LimitedLiability": "198",
"Liabilities, Current": "82.2",
"Other Liabilities": "26.3",
"Assets, Current": "0.686",
"Assets": "0.853",
"Other Assets": "0.236",
"Assets, Non-Current": "-0.327",
"Property, Plant and Equipment, Net": "0.187",
"Other Expenses": "-42.2",
"Expenses": "15.8",
"Revenues": "68.9",
"Net Income": "84.0",
"Research and Development": "12.0",
"General and Administrative Expense": "41.5",
"Other Revenues": "68.9",
"Other Net Income": "2.00",
"Comprehensive Net Income": "84.0",
"Economic Capital Ratio": "149"
},
"2015": {
"Other Liabilities": "35.8",
"Liabilities": "117",
"Assets": "0.339",
"Stockholders Equity": "94.1",
"ECR before LimitedLiability": "189",
"Liabilities, Current": "76.2",
"Liabilities, Non-Current": "39.1",
"Assets, Current": "1.40",
"Other Assets": "-0.503",
"Assets, Non-Current": "-0.368",
"Research and Development": "7.18",
"Expenses": "7.41",
"Revenues": "74.9",
"Net Income": "81.7",
"General and Administrative Expense": "25.7",
"Other Expenses": "-27.4",
"Other Revenues": "74.9",
"Comprehensive Net Income": "81.3",
"Other Net Income": "0.696",
"Other Compr. Net Income": "-0.515",
"Economic Capital Ratio": "143"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000794172_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "117,147",
"Assets, Non-Current": "18,376",
"General and Administrative Expense": "35,576",
"Goodwill": "17,183",
"Liabilities, Current": "16,752",
"Liabilities, Non-Current": "0",
"Other Assets": "-17,183",
"Other Compr. Net Income": "0",
"Other Expenses": "72,055",
"Other Liabilities": "0",
"Other Net Income": "544",
"Other Revenues": "148,274",
"Property, Plant and Equipment, Net": "20,474",
"Research and Development": "8,428"
},
"output_variables": {
"Liabilities": "16,752",
"Assets": "155,997",
"Expenses": "116,059",
"Revenues": "148,274",
"Stockholders Equity": "139,245",
"Net Income": "32,759",
"Comprehensive Net Income": "32,759",
"BaseVar": "218,813",
"ECR before LimitedLiability": "259%",
"Economic Capital Ratio": "278%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "94,020",
"Assets, Non-Current": "38,048",
"General and Administrative Expense": "37,527",
"Goodwill": "36,809",
"Liabilities, Current": "14,147",
"Liabilities, Non-Current": "0",
"Other Assets": "-36,809",
"Other Compr. Net Income": "0",
"Other Expenses": "70,518",
"Other Liabilities": "0",
"Other Net Income": "262",
"Other Revenues": "143,000",
"Property, Plant and Equipment, Net": "22,717",
"Research and Development": "8,570"
},
"output_variables": {
"Liabilities": "14,147",
"Assets": "154,785",
"Expenses": "116,615",
"Revenues": "143,000",
"Stockholders Equity": "140,638",
"Net Income": "26,647",
"Comprehensive Net Income": "26,647",
"BaseVar": "214,404",
"ECR before LimitedLiability": "260%",
"Economic Capital Ratio": "279%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "90,354",
"Assets, Non-Current": "38,600",
"General and Administrative Expense": "47,655",
"Goodwill": "34,071",
"Liabilities, Current": "15,264",
"Liabilities, Non-Current": "0",
"Other Assets": "-34,071",
"Other Compr. Net Income": "0",
"Other Expenses": "75,882",
"Other Liabilities": "0",
"Other Net Income": "467",
"Other Revenues": "159,723",
"Property, Plant and Equipment, Net": "26,539",
"Research and Development": "9,822"
},
"output_variables": {
"Liabilities": "15,264",
"Assets": "155,493",
"Expenses": "133,359",
"Revenues": "159,723",
"Stockholders Equity": "140,229",
"Net Income": "26,831",
"Comprehensive Net Income": "26,831",
"BaseVar": "232,153",
"ECR before LimitedLiability": "256%",
"Economic Capital Ratio": "276%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "96,590",
"Assets, Non-Current": "38,636",
"General and Administrative Expense": "49,294",
"Goodwill": "33,410",
"Liabilities, Current": "18,462",
"Liabilities, Non-Current": "0",
"Other Assets": "-33,410",
"Other Compr. Net Income": "0",
"Other Expenses": "81,022",
"Other Liabilities": "0",
"Other Net Income": "420",
"Other Revenues": "173,542",
"Property, Plant and Equipment, Net": "26,155",
"Research and Development": "10,275"
},
"output_variables": {
"Liabilities": "18,462",
"Assets": "161,381",
"Expenses": "140,591",
"Revenues": "173,542",
"Stockholders Equity": "142,919",
"Net Income": "33,371",
"Comprehensive Net Income": "33,371",
"BaseVar": "247,198",
"ECR before LimitedLiability": "255%",
"Economic Capital Ratio": "275%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "114,088",
"Assets, Non-Current": "36,569",
"General and Administrative Expense": "52,943",
"Goodwill": "31,172",
"Liabilities, Current": "21,703",
"Liabilities, Non-Current": "0",
"Other Assets": "-31,172",
"Other Compr. Net Income": "650",
"Other Expenses": "86,972",
"Other Liabilities": "0",
"Other Net Income": "48",
"Other Revenues": "188,686",
"Property, Plant and Equipment, Net": "26,091",
"Research and Development": "10,787"
},
"output_variables": {
"Liabilities": "21,703",
"Assets": "176,748",
"Expenses": "150,702",
"Revenues": "188,686",
"Stockholders Equity": "155,045",
"Net Income": "38,032",
"Comprehensive Net Income": "38,357",
"BaseVar": "269,268",
"ECR before LimitedLiability": "253%",
"Economic Capital Ratio": "273%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "112,748",
"Assets, Non-Current": "342",
"General and Administrative Expense": "52,299",
"Goodwill": "31,006",
"Liabilities, Current": "13,735",
"Liabilities, Non-Current": "2,165",
"Other Assets": "5,223",
"Other Compr. Net Income": "-436",
"Other Expenses": "88,954",
"Other Liabilities": "0",
"Other Net Income": "-284",
"Other Revenues": "188,832",
"Property, Plant and Equipment, Net": "27,610",
"Research and Development": "12,552"
},
"output_variables": {
"Liabilities": "15,900",
"Assets": "176,929",
"Expenses": "153,805",
"Revenues": "188,832",
"Stockholders Equity": "161,029",
"Net Income": "34,743",
"Comprehensive Net Income": "34,525",
"BaseVar": "268,093",
"ECR before LimitedLiability": "265%",
"Economic Capital Ratio": "282%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "122,853",
"Assets, Non-Current": "384",
"General and Administrative Expense": "53,217",
"Goodwill": "28,280",
"Liabilities, Current": "15,251",
"Liabilities, Non-Current": "2,158",
"Other Assets": "4,273",
"Other Compr. Net Income": "-2,639",
"Other Expenses": "92,471",
"Other Liabilities": "0",
"Other Net Income": "-997",
"Other Revenues": "194,830",
"Property, Plant and Equipment, Net": "27,492",
"Research and Development": "12,605"
},
"output_variables": {
"Liabilities": "17,409",
"Assets": "183,282",
"Expenses": "158,293",
"Revenues": "194,830",
"Stockholders Equity": "165,873",
"Net Income": "35,540",
"Comprehensive Net Income": "34,220",
"BaseVar": "278,725",
"ECR before LimitedLiability": "261%",
"Economic Capital Ratio": "279%"
}
}
},
"top_rated": true,
"trend": 1.0,
"value": 2.7928447822894933,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000794172.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000794172.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000794172.svg"
},
{
"company_id": "0000885462",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000885462.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000885462.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000885462.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000885462_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000885462_main_keyfigs.svg",
"name": "GULF Resources INC",
"rank": 2,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000885462.svg",
"report_text": "The relative strengths and weaknesses of GULF Resources INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of GULF Resources INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 130% points.The greatest weakness of GULF Resources INC is the variable Other Compr. Net Income, reducing the Economic Capital Ratio by 4.2% points.
The company's Economic Capital Ratio, given in the ranking table, is 278%, being 142% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000885462_2016_GULF_Resources_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "58.2",
"Liabilities": "78.6",
"Assets": "1.19",
"Stockholders Equity": "109",
"ECR before LimitedLiability": "196",
"Liabilities, Non-Current": "18.5",
"Other Liabilities": "15.1",
"Property, Plant and Equipment, Net": "2.06",
"Assets, Non-Current": "2.81",
"Other Assets": "-0.918",
"General and Administrative Expense": "5.94",
"Expenses": "32.9",
"Revenues": "28.8",
"Net Income": "52.7",
"Research and Development": "15.6",
"Other Expenses": "12.3",
"Other Revenues": "28.8",
"Comprehensive Net Income": "55.8",
"Other Net Income": "-7.64",
"Other Compr. Net Income": "3.57",
"Economic Capital Ratio": "134"
},
"2012": {
"Liabilities, Current": "33.6",
"Liabilities": "57.9",
"Stockholders Equity": "119",
"ECR before LimitedLiability": "152",
"Liabilities, Non-Current": "14.0",
"Other Liabilities": "19.3",
"Assets, Current": "0.692",
"Assets": "9.77",
"Other Assets": "-4.46",
"Assets, Non-Current": "14.7",
"Property, Plant and Equipment, Net": "11.6",
"Goodwill": "-0.899",
"Other Expenses": "19.7",
"Expenses": "36.6",
"Revenues": "2.24",
"Net Income": "38.3",
"Research and Development": "12.9",
"General and Administrative Expense": "5.14",
"Other Revenues": "2.24",
"Comprehensive Net Income": "38.6",
"Economic Capital Ratio": "119"
},
"2013": {
"Liabilities, Current": "43.0",
"Liabilities": "68.3",
"Assets": "4.81",
"Stockholders Equity": "122",
"ECR before LimitedLiability": "169",
"Other Liabilities": "15.4",
"Liabilities, Non-Current": "21.8",
"Assets, Non-Current": "5.03",
"Property, Plant and Equipment, Net": "4.00",
"Other Assets": "-2.12",
"General and Administrative Expense": "1.75",
"Expenses": "35.7",
"Revenues": "8.78",
"Net Income": "41.5",
"Research and Development": "11.6",
"Other Expenses": "23.2",
"Other Revenues": "8.78",
"Other Net Income": "-2.47",
"Comprehensive Net Income": "43.4",
"Other Compr. Net Income": "2.17",
"Economic Capital Ratio": "129"
},
"2014": {
"Liabilities, Non-Current": "23.9",
"Liabilities": "82.0",
"Stockholders Equity": "148",
"ECR before LimitedLiability": "200",
"Liabilities, Current": "59.8",
"Other Liabilities": "13.0",
"Assets, Current": "2.40",
"Assets": "5.67",
"Other Assets": "-1.62",
"Assets, Non-Current": "3.31",
"Property, Plant and Equipment, Net": "2.58",
"Other Expenses": "15.6",
"Expenses": "36.2",
"Revenues": "7.48",
"Net Income": "44.2",
"Research and Development": "13.0",
"General and Administrative Expense": "8.84",
"Other Revenues": "7.48",
"Other Net Income": "1.45",
"Comprehensive Net Income": "44.1",
"Economic Capital Ratio": "150"
},
"2015": {
"Other Liabilities": "22.3",
"Liabilities": "88.5",
"Stockholders Equity": "130",
"ECR before LimitedLiability": "188",
"Liabilities, Current": "57.0",
"Liabilities, Non-Current": "29.4",
"Assets, Current": "2.57",
"Assets": "6.69",
"Other Assets": "-3.71",
"Assets, Non-Current": "8.19",
"Property, Plant and Equipment, Net": "4.00",
"Research and Development": "11.0",
"Expenses": "31.3",
"Revenues": "21.4",
"Net Income": "51.9",
"General and Administrative Expense": "-3.26",
"Other Expenses": "24.0",
"Other Revenues": "21.4",
"Comprehensive Net Income": "48.2",
"Other Compr. Net Income": "-4.21",
"Economic Capital Ratio": "142"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000885462_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "105,517",
"Assets, Non-Current": "152,811",
"General and Administrative Expense": "107,413",
"Goodwill": "0",
"Liabilities, Current": "12,178",
"Liabilities, Non-Current": "0",
"Other Assets": "-147,201",
"Other Compr. Net Income": "12,493",
"Other Expenses": "26,274",
"Other Liabilities": "3,037",
"Other Net Income": "57",
"Other Revenues": "164,980",
"Property, Plant and Equipment, Net": "147,201",
"Research and Development": "399"
},
"output_variables": {
"Liabilities": "15,215",
"Assets": "258,328",
"Expenses": "134,085",
"Revenues": "164,980",
"Stockholders Equity": "243,113",
"Net Income": "30,953",
"Comprehensive Net Income": "37,199",
"BaseVar": "292,579",
"ECR before LimitedLiability": "271%",
"Economic Capital Ratio": "287%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "107,259",
"Assets, Non-Current": "170,934",
"General and Administrative Expense": "80,231",
"Goodwill": "0",
"Liabilities, Current": "11,016",
"Liabilities, Non-Current": "0",
"Other Assets": "-165,943",
"Other Compr. Net Income": "733",
"Other Expenses": "6,622",
"Other Liabilities": "2,953",
"Other Net Income": "313",
"Other Revenues": "101,701",
"Property, Plant and Equipment, Net": "165,943",
"Research and Development": "165"
},
"output_variables": {
"Liabilities": "13,969",
"Assets": "278,193",
"Expenses": "87,018",
"Revenues": "101,701",
"Stockholders Equity": "264,224",
"Net Income": "14,996",
"Comprehensive Net Income": "15,362",
"BaseVar": "240,963",
"ECR before LimitedLiability": "258%",
"Economic Capital Ratio": "278%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "158,073",
"Assets, Non-Current": "151,172",
"General and Administrative Expense": "92,772",
"Goodwill": "0",
"Liabilities, Current": "11,306",
"Liabilities, Non-Current": "0",
"Other Assets": "-146,400",
"Other Compr. Net Income": "9,258",
"Other Expenses": "4,851",
"Other Liabilities": "2,944",
"Other Net Income": "340",
"Other Revenues": "118,392",
"Property, Plant and Equipment, Net": "146,400",
"Research and Development": "140"
},
"output_variables": {
"Liabilities": "14,250",
"Assets": "309,245",
"Expenses": "97,764",
"Revenues": "118,392",
"Stockholders Equity": "294,995",
"Net Income": "20,967",
"Comprehensive Net Income": "25,597",
"BaseVar": "274,624",
"ECR before LimitedLiability": "266%",
"Economic Capital Ratio": "283%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "194,128",
"Assets, Non-Current": "128,854",
"General and Administrative Expense": "88,899",
"Goodwill": "0",
"Liabilities, Current": "8,082",
"Liabilities, Non-Current": "0",
"Other Assets": "-124,351",
"Other Compr. Net Income": "-1,078",
"Other Expenses": "7,035",
"Other Liabilities": "2,826",
"Other Net Income": "280",
"Other Revenues": "113,660",
"Property, Plant and Equipment, Net": "124,351",
"Research and Development": "134"
},
"output_variables": {
"Liabilities": "10,909",
"Assets": "322,982",
"Expenses": "96,068",
"Revenues": "113,660",
"Stockholders Equity": "312,073",
"Net Income": "17,872",
"Comprehensive Net Income": "17,333",
"BaseVar": "272,488",
"ECR before LimitedLiability": "266%",
"Economic Capital Ratio": "284%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "190,821",
"Assets, Non-Current": "165,922",
"General and Administrative Expense": "115,705",
"Goodwill": "29,559",
"Liabilities, Current": "16,076",
"Liabilities, Non-Current": "0",
"Other Assets": "-157,430",
"Other Compr. Net Income": "-21,741",
"Other Expenses": "12,589",
"Other Liabilities": "2,556",
"Other Net Income": "275",
"Other Revenues": "162,317",
"Property, Plant and Equipment, Net": "127,871",
"Research and Development": "231"
},
"output_variables": {
"Liabilities": "18,632",
"Assets": "356,743",
"Expenses": "128,524",
"Revenues": "162,317",
"Stockholders Equity": "338,111",
"Net Income": "34,068",
"Comprehensive Net Income": "23,198",
"BaseVar": "344,116",
"ECR before LimitedLiability": "259%",
"Economic Capital Ratio": "278%"
}
}
},
"top_rated": true,
"trend": -1.0,
"value": 2.7818387078599573,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000885462.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000885462.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000885462.svg"
},
{
"company_id": "0000711377",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000711377.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000711377.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000711377.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000711377_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000711377_main_keyfigs.svg",
"name": "Neogen CORP",
"rank": 3,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000711377.svg",
"report_text": "The relative strengths and weaknesses of Neogen CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Neogen CORP compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 101% points.The greatest weakness of Neogen CORP is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 24% points.
The company's Economic Capital Ratio, given in the ranking table, is 261%, being 125% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000711377_2016_Neogen_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "46.8",
"Liabilities": "58.2",
"Stockholders Equity": "75.5",
"ECR before LimitedLiability": "161",
"Liabilities, Non-Current": "16.5",
"Property, Plant and Equipment, Net": "-0.558",
"Assets": "8.68",
"Assets, Non-Current": "11.8",
"Other Assets": "-6.01",
"Goodwill": "4.29",
"Assets, Current": "2.07",
"General and Administrative Expense": "38.8",
"Expenses": "22.5",
"Revenues": "33.8",
"Net Income": "48.0",
"Research and Development": "11.6",
"Other Expenses": "-30.7",
"Other Revenues": "33.8",
"Comprehensive Net Income": "48.3",
"Other Net Income": "-7.82",
"Economic Capital Ratio": "99.4"
},
"2012": {
"Liabilities, Current": "33.2",
"Liabilities": "54.6",
"Stockholders Equity": "73.6",
"ECR before LimitedLiability": "128",
"Liabilities, Non-Current": "16.3",
"Other Liabilities": "12.8",
"Assets, Current": "3.17",
"Assets": "8.82",
"Other Assets": "-6.41",
"Assets, Non-Current": "10.0",
"Goodwill": "4.58",
"Other Expenses": "23.3",
"Expenses": "23.2",
"Revenues": "27.8",
"Net Income": "49.2",
"Research and Development": "13.0",
"General and Administrative Expense": "-13.6",
"Other Revenues": "27.8",
"Other Net Income": "-0.548",
"Comprehensive Net Income": "49.1",
"Economic Capital Ratio": "95.3"
},
"2013": {
"Liabilities, Current": "45.4",
"Liabilities": "66.4",
"Stockholders Equity": "82.9",
"ECR before LimitedLiability": "146",
"Other Liabilities": "6.02",
"Liabilities, Non-Current": "24.5",
"Goodwill": "3.48",
"Assets": "7.39",
"Assets, Non-Current": "8.31",
"Other Assets": "-5.65",
"Assets, Current": "3.34",
"General and Administrative Expense": "-16.1",
"Expenses": "20.2",
"Revenues": "34.0",
"Net Income": "50.1",
"Research and Development": "10.7",
"Other Expenses": "24.7",
"Other Revenues": "34.0",
"Other Net Income": "-3.01",
"Comprehensive Net Income": "50.0",
"Economic Capital Ratio": "106"
},
"2014": {
"Liabilities, Non-Current": "27.6",
"Liabilities": "82.3",
"Stockholders Equity": "106",
"ECR before LimitedLiability": "175",
"Liabilities, Current": "60.7",
"Other Liabilities": "6.66",
"Assets, Current": "3.02",
"Assets": "9.76",
"Goodwill": "4.14",
"Other Assets": "-5.85",
"Assets, Non-Current": "10.4",
"Other Expenses": "18.2",
"Expenses": "21.2",
"Revenues": "34.6",
"Net Income": "55.6",
"Research and Development": "13.3",
"General and Administrative Expense": "-10.6",
"Other Revenues": "34.6",
"Other Net Income": "1.53",
"Comprehensive Net Income": "56.0",
"Economic Capital Ratio": "125"
},
"2015": {
"Other Liabilities": "15.4",
"Liabilities": "89.5",
"Stockholders Equity": "101",
"ECR before LimitedLiability": "171",
"Liabilities, Current": "60.1",
"Liabilities, Non-Current": "32.0",
"Assets, Current": "4.32",
"Assets": "6.65",
"Other Assets": "-6.55",
"Goodwill": "3.96",
"Assets, Non-Current": "8.56",
"Research and Development": "9.64",
"Expenses": "14.6",
"Revenues": "41.8",
"Net Income": "55.7",
"General and Administrative Expense": "-24.3",
"Other Expenses": "27.5",
"Other Revenues": "41.8",
"Comprehensive Net Income": "55.6",
"Other Net Income": "0.768",
"Economic Capital Ratio": "125"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000711377_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "122,502",
"Assets, Non-Current": "74,820",
"General and Administrative Expense": "45,132",
"Goodwill": "51,584",
"Liabilities, Current": "17,797",
"Liabilities, Non-Current": "0",
"Other Assets": "-51,584",
"Other Compr. Net Income": "1,282",
"Other Expenses": "97,291",
"Other Liabilities": "12,887",
"Other Net Income": "-596",
"Other Revenues": "172,683",
"Property, Plant and Equipment, Net": "22,340",
"Research and Development": "6,825"
},
"output_variables": {
"Liabilities": "30,684",
"Assets": "219,662",
"Expenses": "149,248",
"Revenues": "172,683",
"Stockholders Equity": "188,978",
"Net Income": "22,839",
"Comprehensive Net Income": "23,480",
"BaseVar": "287,078",
"ECR before LimitedLiability": "226%",
"Economic Capital Ratio": "253%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "143,941",
"Assets, Non-Current": "77,726",
"General and Administrative Expense": "143,671",
"Goodwill": "63,878",
"Liabilities, Current": "19,979",
"Liabilities, Non-Current": "0",
"Other Assets": "-63,878",
"Other Compr. Net Income": "-709",
"Other Expenses": "11,450",
"Other Liabilities": "12,567",
"Other Net Income": "100",
"Other Revenues": "184,046",
"Property, Plant and Equipment, Net": "29,933",
"Research and Development": "6,636"
},
"output_variables": {
"Liabilities": "32,546",
"Assets": "251,600",
"Expenses": "161,757",
"Revenues": "184,046",
"Stockholders Equity": "219,054",
"Net Income": "22,389",
"Comprehensive Net Income": "22,034",
"BaseVar": "315,379",
"ECR before LimitedLiability": "227%",
"Economic Capital Ratio": "254%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "168,447",
"Assets, Non-Current": "87,766",
"General and Administrative Expense": "159,041",
"Goodwill": "71,836",
"Liabilities, Current": "17,719",
"Liabilities, Non-Current": "0",
"Other Assets": "-71,836",
"Other Compr. Net Income": "4.0",
"Other Expenses": "14,100",
"Other Liabilities": "14,552",
"Other Net Income": "435",
"Other Revenues": "207,528",
"Property, Plant and Equipment, Net": "34,345",
"Research and Development": "7,781"
},
"output_variables": {
"Liabilities": "32,271",
"Assets": "290,558",
"Expenses": "180,922",
"Revenues": "207,528",
"Stockholders Equity": "258,287",
"Net Income": "27,041",
"Comprehensive Net Income": "27,043",
"BaseVar": "355,859",
"ECR before LimitedLiability": "236%",
"Economic Capital Ratio": "261%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "188,746",
"Assets, Non-Current": "114,606",
"General and Administrative Expense": "195,688",
"Goodwill": "93,420",
"Liabilities, Current": "24,967",
"Liabilities, Non-Current": "0",
"Other Assets": "-93,420",
"Other Compr. Net Income": "1,870",
"Other Expenses": "15,000",
"Other Liabilities": "14,034",
"Other Net Income": "-360",
"Other Revenues": "247,405",
"Property, Plant and Equipment, Net": "41,949",
"Research and Development": "8,326"
},
"output_variables": {
"Liabilities": "39,001",
"Assets": "345,301",
"Expenses": "219,014",
"Revenues": "247,405",
"Stockholders Equity": "306,300",
"Net Income": "28,031",
"Comprehensive Net Income": "28,966",
"BaseVar": "426,476",
"ECR before LimitedLiability": "233%",
"Economic Capital Ratio": "259%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "231,195",
"Assets, Non-Current": "116,513",
"General and Administrative Expense": "220,379",
"Goodwill": "107,493",
"Liabilities, Current": "25,456",
"Liabilities, Non-Current": "0",
"Other Assets": "-107,493",
"Other Compr. Net Income": "-2,863",
"Other Expenses": "18,500",
"Other Liabilities": "15,762",
"Other Net Income": "-1,042",
"Other Revenues": "283,074",
"Property, Plant and Equipment, Net": "44,473",
"Research and Development": "9,577"
},
"output_variables": {
"Liabilities": "41,218",
"Assets": "392,181",
"Expenses": "248,456",
"Revenues": "283,074",
"Stockholders Equity": "350,963",
"Net Income": "33,576",
"Comprehensive Net Income": "32,144",
"BaseVar": "484,417",
"ECR before LimitedLiability": "237%",
"Economic Capital Ratio": "261%"
}
}
},
"top_rated": true,
"trend": 1.0,
"value": 2.610793523502032,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000711377.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000711377.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000711377.svg"
},
{
"company_id": "0000353569",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000353569.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000353569.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000353569_main_keyfigs.svg",
"name": "Quidel CORP DE",
"rank": 4,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000353569.svg",
"report_text": "The relative strengths and weaknesses of Quidel CORP DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Quidel CORP DE compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 120% points.The greatest weakness of Quidel CORP DE is the variable Other Net Income, reducing the Economic Capital Ratio by 3.1% points.
The company's Economic Capital Ratio, given in the ranking table, is 258%, being 122% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000353569_2016_Quidel_CORP_DE.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "29.4",
"Liabilities": "51.4",
"Stockholders Equity": "90.6",
"ECR before LimitedLiability": "158",
"Liabilities, Non-Current": "14.2",
"Other Liabilities": "14.9",
"Assets": "16.4",
"Assets, Non-Current": "-1.26",
"Other Assets": "0.0652",
"Goodwill": "22.7",
"Assets, Current": "-1.50",
"General and Administrative Expense": "6.18",
"Expenses": "25.0",
"Revenues": "17.0",
"Net Income": "34.4",
"Research and Development": "1.43",
"Other Expenses": "17.8",
"Other Revenues": "17.0",
"Comprehensive Net Income": "34.3",
"Other Net Income": "-7.48",
"Economic Capital Ratio": "96.2"
},
"2012": {
"Liabilities, Current": "27.3",
"Liabilities": "59.4",
"Stockholders Equity": "85.9",
"ECR before LimitedLiability": "130",
"Liabilities, Non-Current": "16.1",
"Other Liabilities": "26.1",
"Assets, Current": "-3.68",
"Assets": "10.8",
"Assets, Non-Current": "-1.17",
"Property, Plant and Equipment, Net": "0.935",
"Goodwill": "20.2",
"Other Expenses": "23.2",
"Expenses": "21.2",
"Revenues": "21.5",
"Net Income": "40.4",
"Research and Development": "0.927",
"General and Administrative Expense": "-3.08",
"Other Revenues": "21.5",
"Other Net Income": "-1.27",
"Comprehensive Net Income": "40.5",
"Economic Capital Ratio": "97.6"
},
"2013": {
"Liabilities, Current": "37.1",
"Liabilities": "68.7",
"Stockholders Equity": "91.1",
"ECR before LimitedLiability": "145",
"Other Liabilities": "20.7",
"Liabilities, Non-Current": "23.9",
"Goodwill": "17.0",
"Assets": "9.17",
"Assets, Non-Current": "-1.00",
"Property, Plant and Equipment, Net": "2.16",
"Assets, Current": "-3.64",
"General and Administrative Expense": "25.1",
"Expenses": "17.5",
"Revenues": "28.3",
"Net Income": "41.4",
"Research and Development": "-2.99",
"Other Expenses": "-5.21",
"Other Revenues": "28.3",
"Other Net Income": "-3.51",
"Comprehensive Net Income": "41.4",
"Economic Capital Ratio": "105"
},
"2014": {
"Liabilities, Non-Current": "22.2",
"Liabilities": "69.6",
"Stockholders Equity": "128",
"ECR before LimitedLiability": "172",
"Liabilities, Current": "44.2",
"Other Liabilities": "15.1",
"Assets, Current": "10.4",
"Assets": "21.6",
"Goodwill": "5.85",
"Assets, Non-Current": "-0.662",
"Property, Plant and Equipment, Net": "0.847",
"Other Expenses": "-5.60",
"Expenses": "26.2",
"Revenues": "8.40",
"Net Income": "34.8",
"Research and Development": "1.85",
"General and Administrative Expense": "29.6",
"Other Revenues": "8.40",
"Other Net Income": "0.782",
"Comprehensive Net Income": "34.8",
"Economic Capital Ratio": "123"
},
"2015": {
"Other Liabilities": "23.0",
"Liabilities": "80.8",
"Stockholders Equity": "120",
"ECR before LimitedLiability": "168",
"Liabilities, Current": "47.2",
"Liabilities, Non-Current": "27.4",
"Assets, Current": "8.02",
"Assets": "14.2",
"Other Assets": "-1.43",
"Goodwill": "5.46",
"Property, Plant and Equipment, Net": "1.06",
"Research and Development": "-0.909",
"Expenses": "20.1",
"Revenues": "20.7",
"Net Income": "37.0",
"General and Administrative Expense": "17.6",
"Other Expenses": "3.52",
"Other Revenues": "20.7",
"Comprehensive Net Income": "37.3",
"Other Net Income": "-3.12",
"Economic Capital Ratio": "122"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000353569_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "104,726",
"Assets, Non-Current": "1,239",
"General and Administrative Expense": "111,414",
"Goodwill": "144,843",
"Liabilities, Current": "32,926",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "10,975",
"Other Liabilities": "0",
"Other Net Income": "-2,256",
"Other Revenues": "158,603",
"Property, Plant and Equipment, Net": "28,086",
"Research and Development": "26,325"
},
"output_variables": {
"Liabilities": "32,926",
"Assets": "278,894",
"Expenses": "148,714",
"Revenues": "158,603",
"Stockholders Equity": "245,968",
"Net Income": "7,633",
"Comprehensive Net Income": "7,633",
"BaseVar": "310,696",
"ECR before LimitedLiability": "221%",
"Economic Capital Ratio": "250%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "74,772",
"Assets, Non-Current": "1,817",
"General and Administrative Expense": "112,244",
"Goodwill": "131,354",
"Liabilities, Current": "23,161",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "9,553",
"Other Liabilities": "0",
"Other Net Income": "-1,235",
"Other Revenues": "155,741",
"Property, Plant and Equipment, Net": "34,156",
"Research and Development": "27,716"
},
"output_variables": {
"Liabilities": "23,161",
"Assets": "242,099",
"Expenses": "149,513",
"Revenues": "155,741",
"Stockholders Equity": "218,938",
"Net Income": "4,993",
"Comprehensive Net Income": "4,993",
"BaseVar": "285,874",
"ECR before LimitedLiability": "230%",
"Economic Capital Ratio": "256%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "78,619",
"Assets, Non-Current": "1,784",
"General and Administrative Expense": "60,087",
"Goodwill": "143,025",
"Liabilities, Current": "24,009",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "18",
"Other Expenses": "73,016",
"Other Liabilities": "0",
"Other Net Income": "-731",
"Other Revenues": "175,410",
"Property, Plant and Equipment, Net": "48,057",
"Research and Development": "34,186"
},
"output_variables": {
"Liabilities": "24,009",
"Assets": "271,485",
"Expenses": "167,289",
"Revenues": "175,410",
"Stockholders Equity": "247,476",
"Net Income": "7,390",
"Comprehensive Net Income": "7,399",
"BaseVar": "319,471",
"ECR before LimitedLiability": "234%",
"Economic Capital Ratio": "259%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "275,121",
"Assets, Non-Current": "4,565",
"General and Administrative Expense": "67,344",
"Goodwill": "122,638",
"Liabilities, Current": "36,385",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "-47",
"Other Expenses": "82,657",
"Other Liabilities": "0",
"Other Net Income": "-1,775",
"Other Revenues": "182,615",
"Property, Plant and Equipment, Net": "49,226",
"Research and Development": "37,913"
},
"output_variables": {
"Liabilities": "36,385",
"Assets": "451,550",
"Expenses": "187,914",
"Revenues": "182,615",
"Stockholders Equity": "415,165",
"Net Income": "-7,074",
"Comprehensive Net Income": "-7,098",
"BaseVar": "430,143",
"ECR before LimitedLiability": "230%",
"Economic Capital Ratio": "256%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "240,664",
"Assets, Non-Current": "731",
"General and Administrative Expense": "77,333",
"Goodwill": "112,563",
"Liabilities, Current": "30,830",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "-2.0",
"Other Expenses": "77,326",
"Other Liabilities": "0",
"Other Net Income": "-12,035",
"Other Revenues": "196,129",
"Property, Plant and Equipment, Net": "52,547",
"Research and Development": "35,514"
},
"output_variables": {
"Liabilities": "30,830",
"Assets": "406,505",
"Expenses": "190,173",
"Revenues": "196,129",
"Stockholders Equity": "375,675",
"Net Income": "-6,079",
"Comprehensive Net Income": "-6,080",
"BaseVar": "417,837",
"ECR before LimitedLiability": "233%",
"Economic Capital Ratio": "258%"
}
}
},
"top_rated": true,
"trend": 1.0,
"value": 2.580227398282965,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000353569.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000353569.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000353569.svg"
},
{
"company_id": "0000899923",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000899923.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000899923.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000899923.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000899923_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000899923_main_keyfigs.svg",
"name": "Myriad Genetics INC",
"rank": 5,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000899923.svg",
"report_text": "The relative strengths and weaknesses of Myriad Genetics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Myriad Genetics INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 95% points.The greatest weakness of Myriad Genetics INC is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 25% points.
The company's Economic Capital Ratio, given in the ranking table, is 253%, being 118% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000899923_2016_Myriad_Genetics_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Liabilities": "-1.22",
"Liabilities": "69.0",
"Stockholders Equity": "98.4",
"ECR before LimitedLiability": "125",
"Liabilities, Current": "33.4",
"Liabilities, Non-Current": "45.6",
"Goodwill": "1.45",
"Assets": "-6.03",
"Property, Plant and Equipment, Net": "1.03",
"Assets, Current": "-9.25",
"Assets, Non-Current": "-0.952",
"Other Expenses": "27.3",
"Expenses": "28.0",
"Revenues": "14.8",
"Net Income": "44.5",
"General and Administrative Expense": "-1.98",
"Research and Development": "2.70",
"Other Revenues": "14.8",
"Other Net Income": "3.09",
"Comprehensive Net Income": "44.6",
"Economic Capital Ratio": "127"
},
"2011": {
"Liabilities, Current": "53.8",
"Liabilities": "73.2",
"Stockholders Equity": "106",
"ECR before LimitedLiability": "194",
"Liabilities, Non-Current": "17.8",
"Other Liabilities": "13.0",
"Property, Plant and Equipment, Net": "-0.276",
"Assets": "2.26",
"Assets, Non-Current": "0.356",
"Other Assets": "0.209",
"Assets, Current": "1.57",
"General and Administrative Expense": "13.9",
"Expenses": "33.8",
"Revenues": "32.3",
"Net Income": "57.1",
"Research and Development": "8.82",
"Other Expenses": "12.1",
"Other Revenues": "32.3",
"Comprehensive Net Income": "57.0",
"Other Net Income": "-7.41",
"Economic Capital Ratio": "132"
},
"2012": {
"Liabilities, Current": "40.6",
"Liabilities": "71.1",
"Stockholders Equity": "92.7",
"ECR before LimitedLiability": "156",
"Liabilities, Non-Current": "18.7",
"Other Liabilities": "25.6",
"Assets, Current": "1.44",
"Assets": "2.80",
"Other Assets": "0.671",
"Assets, Non-Current": "0.981",
"Property, Plant and Equipment, Net": "-0.534",
"Other Expenses": "13.6",
"Expenses": "30.8",
"Revenues": "33.4",
"Net Income": "61.8",
"Research and Development": "8.65",
"General and Administrative Expense": "9.42",
"Other Revenues": "33.4",
"Other Net Income": "0.252",
"Comprehensive Net Income": "61.8",
"Economic Capital Ratio": "123"
},
"2013": {
"Liabilities, Current": "45.4",
"Liabilities": "76.5",
"Stockholders Equity": "89.4",
"ECR before LimitedLiability": "165",
"Other Liabilities": "19.5",
"Liabilities, Non-Current": "27.4",
"Goodwill": "-0.348",
"Assets": "2.83",
"Assets, Non-Current": "1.89",
"Property, Plant and Equipment, Net": "-0.650",
"Assets, Current": "1.55",
"General and Administrative Expense": "5.17",
"Expenses": "26.5",
"Revenues": "42.5",
"Net Income": "64.2",
"Research and Development": "5.90",
"Other Expenses": "16.0",
"Other Revenues": "42.5",
"Other Net Income": "-2.50",
"Comprehensive Net Income": "64.1",
"Economic Capital Ratio": "125"
},
"2014": {
"Liabilities, Non-Current": "32.7",
"Liabilities": "94.2",
"Stockholders Equity": "96.2",
"ECR before LimitedLiability": "187",
"Liabilities, Current": "67.1",
"Other Liabilities": "13.5",
"Assets, Current": "-1.70",
"Assets": "3.40",
"Goodwill": "6.64",
"Assets, Non-Current": "1.03",
"Property, Plant and Equipment, Net": "-1.19",
"Other Expenses": "9.45",
"Expenses": "23.0",
"Revenues": "55.3",
"Net Income": "77.9",
"Research and Development": "8.34",
"General and Administrative Expense": "5.68",
"Other Revenues": "55.3",
"Other Net Income": "2.50",
"Comprehensive Net Income": "77.9",
"Economic Capital Ratio": "138"
},
"2015": {
"Other Liabilities": "17.3",
"Liabilities": "95.5",
"Stockholders Equity": "83.7",
"ECR before LimitedLiability": "163",
"Liabilities, Current": "62.6",
"Liabilities, Non-Current": "34.8",
"Assets, Current": "-4.10",
"Assets": "2.29",
"Other Assets": "-2.17",
"Goodwill": "13.5",
"Property, Plant and Equipment, Net": "-1.32",
"Research and Development": "2.10",
"Expenses": "5.30",
"Revenues": "57.3",
"Net Income": "63.4",
"General and Administrative Expense": "-25.5",
"Other Expenses": "26.8",
"Other Revenues": "57.3",
"Comprehensive Net Income": "63.4",
"Other Net Income": "1.38",
"Economic Capital Ratio": "118"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000899923_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "473,976",
"Assets, Non-Current": "85,154",
"General and Administrative Expense": "205,700",
"Goodwill": "2,052",
"Liabilities, Current": "27,466",
"Liabilities, Non-Current": "0",
"Other Assets": "9,404",
"Other Compr. Net Income": "0",
"Other Expenses": "-11,469",
"Other Liabilities": "8,800",
"Other Net Income": "0",
"Other Revenues": "368,407",
"Property, Plant and Equipment, Net": "23,261",
"Research and Development": "21,873"
},
"output_variables": {
"Liabilities": "36,266",
"Assets": "593,847",
"Expenses": "216,104",
"Revenues": "368,407",
"Stockholders Equity": "557,581",
"Net Income": "152,303",
"Comprehensive Net Income": "152,303",
"BaseVar": "607,312",
"ECR before LimitedLiability": "291%",
"Economic Capital Ratio": "304%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "418,261",
"Assets, Non-Current": "70,857",
"General and Administrative Expense": "215,478",
"Goodwill": "72,766",
"Liabilities, Current": "34,387",
"Liabilities, Non-Current": "0",
"Other Assets": "25,863",
"Other Compr. Net Income": "0",
"Other Expenses": "60,018",
"Other Liabilities": "9,648",
"Other Net Income": "0",
"Other Revenues": "403,957",
"Property, Plant and Equipment, Net": "23,080",
"Research and Development": "27,751"
},
"output_variables": {
"Liabilities": "44,035",
"Assets": "610,827",
"Expenses": "303,247",
"Revenues": "403,957",
"Stockholders Equity": "566,792",
"Net Income": "100,710",
"Comprehensive Net Income": "100,710",
"BaseVar": "681,033",
"ECR before LimitedLiability": "268%",
"Economic Capital Ratio": "285%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "422,492",
"Assets, Non-Current": "113,692",
"General and Administrative Expense": "259,835",
"Goodwill": "72,572",
"Liabilities, Current": "44,967",
"Liabilities, Non-Current": "0",
"Other Assets": "57,648",
"Other Compr. Net Income": "-313",
"Other Expenses": "85,596",
"Other Liabilities": "10,008",
"Other Net Income": "4,222",
"Other Revenues": "496,005",
"Property, Plant and Equipment, Net": "24,231",
"Research and Development": "42,645"
},
"output_variables": {
"Liabilities": "54,975",
"Assets": "690,635",
"Expenses": "388,076",
"Revenues": "496,005",
"Stockholders Equity": "635,660",
"Net Income": "112,151",
"Comprehensive Net Income": "111,994",
"BaseVar": "817,113",
"ECR before LimitedLiability": "264%",
"Economic Capital Ratio": "282%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "483,992",
"Assets, Non-Current": "171,748",
"General and Administrative Expense": "316,215",
"Goodwill": "70,180",
"Liabilities, Current": "64,509",
"Liabilities, Non-Current": "0",
"Other Assets": "50,299",
"Other Compr. Net Income": "-262",
"Other Expenses": "101,379",
"Other Liabilities": "10,718",
"Other Net Income": "5,274",
"Other Revenues": "613,165",
"Property, Plant and Equipment, Net": "27,602",
"Research and Development": "53,706"
},
"output_variables": {
"Liabilities": "75,227",
"Assets": "803,821",
"Expenses": "471,300",
"Revenues": "613,165",
"Stockholders Equity": "728,594",
"Net Income": "147,139",
"Comprehensive Net Income": "147,008",
"BaseVar": "984,524",
"ECR before LimitedLiability": "261%",
"Economic Capital Ratio": "279%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "322,400",
"Assets, Non-Current": "89,100",
"General and Administrative Expense": "423,200",
"Goodwill": "374,500",
"Liabilities, Current": "80,600",
"Liabilities, Non-Current": "0",
"Other Assets": "3,200",
"Other Compr. Net Income": "-1,100",
"Other Expenses": "114,700",
"Other Liabilities": "24,200",
"Other Net Income": "3,400",
"Other Revenues": "778,200",
"Property, Plant and Equipment, Net": "34,600",
"Research and Development": "67,500"
},
"output_variables": {
"Liabilities": "104,800",
"Assets": "823,800",
"Expenses": "605,400",
"Revenues": "778,200",
"Stockholders Equity": "719,000",
"Net Income": "176,200",
"Comprehensive Net Income": "175,650",
"BaseVar": "1,158,350",
"ECR before LimitedLiability": "250%",
"Economic Capital Ratio": "271%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "283,600",
"Assets, Non-Current": "45,600",
"General and Administrative Expense": "498,800",
"Goodwill": "369,800",
"Liabilities, Current": "68,700",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "-5,500",
"Other Expenses": "69,300",
"Other Liabilities": "35,400",
"Other Net Income": "700",
"Other Revenues": "723,100",
"Property, Plant and Equipment, Net": "67,200",
"Research and Development": "75,500"
},
"output_variables": {
"Liabilities": "104,100",
"Assets": "766,200",
"Expenses": "643,600",
"Revenues": "723,100",
"Stockholders Equity": "662,100",
"Net Income": "80,200",
"Comprehensive Net Income": "77,450",
"BaseVar": "1,121,600",
"ECR before LimitedLiability": "226%",
"Economic Capital Ratio": "253%"
}
}
},
"top_rated": true,
"trend": -2.0,
"value": 2.5338261198893477,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000899923.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000899923.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000899923.svg"
},
{
"company_id": "0000073290",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000073290.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000073290.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000073290.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000073290_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000073290_main_keyfigs.svg",
"name": "Biomerica INC",
"rank": 6,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000073290.svg",
"report_text": "The relative strengths and weaknesses of Biomerica INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Biomerica INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 101% points.The greatest weakness of Biomerica INC is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 52% points.
The company's Economic Capital Ratio, given in the ranking table, is 249%, being 114% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000073290_2016_Biomerica_INC.pdf",
"shrinked_graph_json": {
"2012": {
"Liabilities, Current": "42.9",
"Liabilities": "81.9",
"Stockholders Equity": "59.8",
"ECR before LimitedLiability": "137",
"Liabilities, Non-Current": "22.0",
"Other Liabilities": "35.3",
"Other Expenses": "36.8",
"Expenses": "7.40",
"Net Income": "63.2",
"Research and Development": "13.7",
"General and Administrative Expense": "-48.4",
"Other Revenues": "55.0",
"Revenues": "55.0",
"Assets, Current": "5.42",
"Other Assets": "0.942",
"Assets, Non-Current": "-1.18",
"Property, Plant and Equipment, Net": "-1.04",
"Goodwill": "-2.57",
"Other Net Income": "1.82",
"Comprehensive Net Income": "63.3",
"Economic Capital Ratio": "104"
},
"2013": {
"Liabilities, Current": "54.1",
"Liabilities": "90.9",
"Stockholders Equity": "73.5",
"ECR before LimitedLiability": "153",
"Other Liabilities": "27.2",
"Liabilities, Non-Current": "31.3",
"Goodwill": "-2.31",
"Assets": "1.05",
"Assets, Non-Current": "-0.902",
"Property, Plant and Equipment, Net": "-0.566",
"Assets, Current": "6.44",
"General and Administrative Expense": "-48.7",
"Expenses": "4.65",
"Revenues": "59.0",
"Net Income": "59.7",
"Research and Development": "8.57",
"Other Expenses": "39.4",
"Other Revenues": "59.0",
"Other Net Income": "-3.92",
"Comprehensive Net Income": "59.5",
"Economic Capital Ratio": "113"
},
"2014": {
"Liabilities, Non-Current": "29.6",
"Liabilities": "94.7",
"Stockholders Equity": "109",
"ECR before LimitedLiability": "168",
"Liabilities, Current": "63.5",
"Other Liabilities": "20.4",
"Assets, Current": "11.8",
"Assets": "8.34",
"Goodwill": "-2.72",
"Other Assets": "3.02",
"Assets, Non-Current": "-1.31",
"Other Expenses": "30.1",
"Expenses": "6.39",
"Revenues": "38.8",
"Net Income": "46.7",
"Research and Development": "6.29",
"General and Administrative Expense": "-32.7",
"Other Revenues": "38.8",
"Other Net Income": "2.25",
"Comprehensive Net Income": "46.8",
"Economic Capital Ratio": "119"
},
"2015": {
"Other Liabilities": "28.5",
"Liabilities": "101",
"Stockholders Equity": "101",
"ECR before LimitedLiability": "160",
"Liabilities, Current": "60.9",
"Liabilities, Non-Current": "33.9",
"Assets, Current": "9.81",
"Assets": "4.76",
"Other Assets": "2.92",
"Goodwill": "-3.21",
"Property, Plant and Equipment, Net": "-1.78",
"Research and Development": "-1.47",
"Expenses": "-4.61",
"Revenues": "46.4",
"Net Income": "43.8",
"General and Administrative Expense": "-52.1",
"Other Expenses": "43.0",
"Other Revenues": "46.4",
"Comprehensive Net Income": "44.2",
"Other Net Income": "1.76",
"Economic Capital Ratio": "114"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000073290_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "4,487",
"Assets, Non-Current": "79",
"General and Administrative Expense": "5,229",
"Goodwill": "195",
"Liabilities, Current": "592",
"Liabilities, Non-Current": "0",
"Other Assets": "226",
"Other Compr. Net Income": "-1.6",
"Other Expenses": "65",
"Other Liabilities": "0",
"Other Net Income": "108",
"Other Revenues": "6,081",
"Property, Plant and Equipment, Net": "585",
"Research and Development": "347"
},
"output_variables": {
"Liabilities": "592",
"Assets": "5,571",
"Expenses": "5,641",
"Revenues": "6,081",
"Stockholders Equity": "4,979",
"Net Income": "548",
"Comprehensive Net Income": "548",
"BaseVar": "8,998",
"ECR before LimitedLiability": "239%",
"Economic Capital Ratio": "263%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "5,253",
"Assets, Non-Current": "71",
"General and Administrative Expense": "5,500",
"Goodwill": "165",
"Liabilities, Current": "560",
"Liabilities, Non-Current": "0",
"Other Assets": "250",
"Other Compr. Net Income": "-3.0",
"Other Expenses": "-12",
"Other Liabilities": "0",
"Other Net Income": "10",
"Other Revenues": "6,473",
"Property, Plant and Equipment, Net": "655",
"Research and Development": "459"
},
"output_variables": {
"Liabilities": "560",
"Assets": "6,395",
"Expenses": "5,946",
"Revenues": "6,473",
"Stockholders Equity": "5,835",
"Net Income": "537",
"Comprehensive Net Income": "535",
"BaseVar": "9,694",
"ECR before LimitedLiability": "245%",
"Economic Capital Ratio": "268%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "4,913",
"Assets, Non-Current": "36",
"General and Administrative Expense": "4,977",
"Goodwill": "382",
"Liabilities, Current": "556",
"Liabilities, Non-Current": "0",
"Other Assets": "524",
"Other Compr. Net Income": "-1.1",
"Other Expenses": "-211",
"Other Liabilities": "0",
"Other Net Income": "20",
"Other Revenues": "5,120",
"Property, Plant and Equipment, Net": "614",
"Research and Development": "590"
},
"output_variables": {
"Liabilities": "556",
"Assets": "6,470",
"Expenses": "5,356",
"Revenues": "5,120",
"Stockholders Equity": "5,914",
"Net Income": "-216",
"Comprehensive Net Income": "-216",
"BaseVar": "8,762",
"ECR before LimitedLiability": "224%",
"Economic Capital Ratio": "252%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "4,392",
"Assets, Non-Current": "57",
"General and Administrative Expense": "4,899",
"Goodwill": "321",
"Liabilities, Current": "524",
"Liabilities, Non-Current": "0",
"Other Assets": "909",
"Other Compr. Net Income": "-2.1",
"Other Expenses": "-315",
"Other Liabilities": "0",
"Other Net Income": "24",
"Other Revenues": "4,962",
"Property, Plant and Equipment, Net": "445",
"Research and Development": "734"
},
"output_variables": {
"Liabilities": "524",
"Assets": "6,124",
"Expenses": "5,318",
"Revenues": "4,962",
"Stockholders Equity": "5,601",
"Net Income": "-331",
"Comprehensive Net Income": "-332",
"BaseVar": "8,477",
"ECR before LimitedLiability": "221%",
"Economic Capital Ratio": "249%"
}
}
},
"top_rated": true,
"trend": 0.0,
"value": 2.494513492999882,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000073290.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000073290.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000073290.svg"
},
{
"company_id": "0001054905",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001054905.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001054905.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001054905.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001054905_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001054905_main_keyfigs.svg",
"name": "Innospec INC",
"rank": 7,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001054905.svg",
"report_text": "The relative strengths and weaknesses of Innospec INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Innospec INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 81% points.The greatest weakness of Innospec INC is the variable Other Expenses, reducing the Economic Capital Ratio by 39% points.
The company's Economic Capital Ratio, given in the ranking table, is 236%, being 100% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001054905_2016_Innospec_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "29.4",
"Liabilities": "60.0",
"Stockholders Equity": "21.0",
"ECR before LimitedLiability": "128",
"Liabilities, Non-Current": "18.6",
"Other Liabilities": "19.5",
"Property, Plant and Equipment, Net": "-4.79",
"Assets": "-7.47",
"Assets, Non-Current": "-3.61",
"Other Assets": "4.30",
"Goodwill": "6.41",
"Assets, Current": "-8.21",
"Other Revenues": "64.1",
"Revenues": "64.1",
"Net Income": "56.7",
"General and Administrative Expense": "55.2",
"Comprehensive Net Income": "57.8",
"Research and Development": "16.3",
"Other Net Income": "-8.06",
"Other Expenses": "-77.5",
"Economic Capital Ratio": "66.0"
},
"2012": {
"Liabilities, Current": "9.93",
"Liabilities": "53.3",
"Stockholders Equity": "17.3",
"ECR before LimitedLiability": "106",
"Liabilities, Non-Current": "19.1",
"Other Liabilities": "30.8",
"Assets, Current": "-7.25",
"Assets": "-5.35",
"Assets, Non-Current": "-2.98",
"Property, Plant and Equipment, Net": "-3.50",
"Goodwill": "9.79",
"Other Expenses": "-65.4",
"Expenses": "11.3",
"Revenues": "62.6",
"Net Income": "73.3",
"Research and Development": "16.9",
"General and Administrative Expense": "52.3",
"Other Revenues": "62.6",
"Other Net Income": "-1.02",
"Comprehensive Net Income": "73.4",
"Economic Capital Ratio": "74.0"
},
"2013": {
"Liabilities, Current": "23.2",
"Liabilities": "61.1",
"Stockholders Equity": "44.5",
"ECR before LimitedLiability": "121",
"Other Liabilities": "22.0",
"Liabilities, Non-Current": "25.4",
"General and Administrative Expense": "42.2",
"Expenses": "8.02",
"Net Income": "55.3",
"Research and Development": "12.9",
"Other Expenses": "-52.4",
"Other Revenues": "50.3",
"Revenues": "50.3",
"Goodwill": "12.2",
"Assets, Non-Current": "-2.38",
"Property, Plant and Equipment, Net": "-2.49",
"Other Assets": "-0.972",
"Assets, Current": "-3.40",
"Other Net Income": "-2.94",
"Comprehensive Net Income": "55.1",
"Economic Capital Ratio": "80.6"
},
"2014": {
"Liabilities, Non-Current": "26.9",
"Liabilities": "70.9",
"Stockholders Equity": "67.4",
"ECR before LimitedLiability": "145",
"Liabilities, Current": "36.5",
"Other Liabilities": "18.4",
"Assets, Current": "-5.99",
"Assets": "4.50",
"Goodwill": "17.1",
"Other Assets": "2.46",
"Assets, Non-Current": "-2.34",
"Other Expenses": "-54.6",
"Expenses": "13.8",
"Revenues": "43.9",
"Net Income": "59.8",
"Research and Development": "15.0",
"General and Administrative Expense": "48.3",
"Other Revenues": "43.9",
"Comprehensive Net Income": "62.2",
"Other Compr. Net Income": "2.31",
"Economic Capital Ratio": "95.2"
},
"2015": {
"Other Liabilities": "26.6",
"Liabilities": "80.9",
"Stockholders Equity": "66.2",
"ECR before LimitedLiability": "146",
"Liabilities, Current": "37.7",
"Liabilities, Non-Current": "31.7",
"Assets, Current": "-3.82",
"Assets": "1.29",
"Other Assets": "-0.904",
"Goodwill": "13.4",
"Assets, Non-Current": "-1.66",
"Property, Plant and Equipment, Net": "-2.57",
"Research and Development": "10.9",
"Expenses": "6.52",
"Revenues": "55.3",
"Net Income": "62.5",
"General and Administrative Expense": "31.1",
"Other Expenses": "-38.6",
"Other Revenues": "55.3",
"Comprehensive Net Income": "62.6",
"Economic Capital Ratio": "100"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001054905_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "320,300",
"Assets, Non-Current": "600",
"General and Administrative Expense": "155,900",
"Goodwill": "159,200",
"Liabilities, Current": "146,000",
"Liabilities, Non-Current": "0",
"Other Assets": "42,800",
"Other Compr. Net Income": "11,600",
"Other Expenses": "558,200",
"Other Liabilities": "0",
"Other Net Income": "6,900",
"Other Revenues": "774,400",
"Property, Plant and Equipment, Net": "45,900",
"Research and Development": "18,300"
},
"output_variables": {
"Liabilities": "146,000",
"Assets": "568,800",
"Expenses": "732,400",
"Revenues": "774,400",
"Stockholders Equity": "422,800",
"Net Income": "48,900",
"Comprehensive Net Income": "54,700",
"BaseVar": "1,120,050",
"ECR before LimitedLiability": "177%",
"Economic Capital Ratio": "219%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "296,600",
"Assets, Non-Current": "1,400",
"General and Administrative Expense": "117,100",
"Goodwill": "217,600",
"Liabilities, Current": "147,300",
"Liabilities, Non-Current": "0",
"Other Assets": "14,000",
"Other Compr. Net Income": "0",
"Other Expenses": "516,200",
"Other Liabilities": "0",
"Other Net Income": "-1,400",
"Other Revenues": "776,400",
"Property, Plant and Equipment, Net": "49,800",
"Research and Development": "19,600"
},
"output_variables": {
"Liabilities": "147,300",
"Assets": "579,400",
"Expenses": "652,900",
"Revenues": "776,400",
"Stockholders Equity": "432,100",
"Net Income": "122,100",
"Comprehensive Net Income": "122,100",
"BaseVar": "1,078,700",
"ECR before LimitedLiability": "197%",
"Economic Capital Ratio": "232%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "407,400",
"Assets, Non-Current": "1,800",
"General and Administrative Expense": "141,900",
"Goodwill": "314,700",
"Liabilities, Current": "155,600",
"Liabilities, Non-Current": "0",
"Other Assets": "10,400",
"Other Compr. Net Income": "-1,800",
"Other Expenses": "582,400",
"Other Liabilities": "0",
"Other Net Income": "4,500",
"Other Revenues": "818,800",
"Property, Plant and Equipment, Net": "60,400",
"Research and Development": "21,200"
},
"output_variables": {
"Liabilities": "155,600",
"Assets": "794,700",
"Expenses": "745,500",
"Revenues": "818,800",
"Stockholders Equity": "639,100",
"Net Income": "77,800",
"Comprehensive Net Income": "76,900",
"BaseVar": "1,260,450",
"ECR before LimitedLiability": "200%",
"Economic Capital Ratio": "235%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "414,200",
"Assets, Non-Current": "700",
"General and Administrative Expense": "169,200",
"Goodwill": "457,200",
"Liabilities, Current": "222,900",
"Liabilities, Non-Current": "0",
"Other Assets": "47,000",
"Other Compr. Net Income": "40,000",
"Other Expenses": "687,600",
"Other Liabilities": "0",
"Other Net Income": "2,200",
"Other Revenues": "960,900",
"Property, Plant and Equipment, Net": "80,800",
"Research and Development": "22,200"
},
"output_variables": {
"Liabilities": "222,900",
"Assets": "999,900",
"Expenses": "879,000",
"Revenues": "960,900",
"Stockholders Equity": "777,000",
"Net Income": "84,100",
"Comprehensive Net Income": "104,100",
"BaseVar": "1,552,450",
"ECR before LimitedLiability": "191%",
"Economic Capital Ratio": "229%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "458,700",
"Assets, Non-Current": "900",
"General and Administrative Expense": "206,700",
"Goodwill": "436,100",
"Liabilities, Current": "206,100",
"Liabilities, Non-Current": "0",
"Other Assets": "58,300",
"Other Compr. Net Income": "-4,600",
"Other Expenses": "656,800",
"Other Liabilities": "0",
"Other Net Income": "-4,000",
"Other Revenues": "1,012,300",
"Property, Plant and Equipment, Net": "76,000",
"Research and Development": "25,300"
},
"output_variables": {
"Liabilities": "206,100",
"Assets": "1,030,000",
"Expenses": "888,800",
"Revenues": "1,012,300",
"Stockholders Equity": "823,900",
"Net Income": "119,500",
"Comprehensive Net Income": "117,200",
"BaseVar": "1,572,900",
"ECR before LimitedLiability": "202%",
"Economic Capital Ratio": "236%"
}
}
},
"top_rated": true,
"trend": 3.0,
"value": 2.358933919854727,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001054905.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001054905.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001054905.svg"
},
{
"company_id": "0000787253",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000787253.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000787253.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000787253.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000787253_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000787253_main_keyfigs.svg",
"name": "Natural Alternatives International Inc",
"rank": 8,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000787253.svg",
"report_text": "The relative strengths and weaknesses of Natural Alternatives International Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Natural Alternatives International Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 116% points.The greatest weakness of Natural Alternatives International Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 107% points.
The company's Economic Capital Ratio, given in the ranking table, is 234%, being 98% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000787253_2016_Natural_Alternatives_International_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "62.5",
"Liabilities": "88.8",
"Stockholders Equity": "49.0",
"ECR before LimitedLiability": "164",
"Liabilities, Non-Current": "23.3",
"Other Liabilities": "19.7",
"Property, Plant and Equipment, Net": "3.33",
"Assets": "-2.70",
"Assets, Non-Current": "-1.64",
"Other Assets": "1.14",
"Goodwill": "-3.98",
"Assets, Current": "-0.823",
"Other Revenues": "75.4",
"Revenues": "75.4",
"Net Income": "65.3",
"General and Administrative Expense": "65.6",
"Comprehensive Net Income": "65.2",
"Research and Development": "22.0",
"Other Net Income": "-10.7",
"Other Expenses": "-107",
"Economic Capital Ratio": "102"
},
"2012": {
"Liabilities, Current": "45.7",
"Liabilities": "88.2",
"Stockholders Equity": "23.3",
"ECR before LimitedLiability": "120",
"Liabilities, Non-Current": "24.5",
"Other Liabilities": "36.6",
"Assets, Current": "-2.03",
"Assets": "-7.96",
"Other Assets": "1.11",
"Assets, Non-Current": "-2.53",
"Property, Plant and Equipment, Net": "1.14",
"Goodwill": "-6.11",
"Other Expenses": "-126",
"Expenses": "-9.87",
"Revenues": "81.9",
"Net Income": "71.6",
"Research and Development": "25.5",
"General and Administrative Expense": "67.7",
"Other Revenues": "81.9",
"Comprehensive Net Income": "72.3",
"Economic Capital Ratio": "87.9"
},
"2014": {
"Liabilities, Non-Current": "34.7",
"Liabilities": "105",
"Stockholders Equity": "60.1",
"ECR before LimitedLiability": "146",
"Liabilities, Current": "65.3",
"Other Liabilities": "23.0",
"Assets, Current": "3.27",
"Assets": "-6.77",
"Goodwill": "-8.57",
"Other Assets": "1.71",
"Assets, Non-Current": "-2.24",
"Other Expenses": "-119",
"Expenses": "-10.1",
"Revenues": "80.3",
"Net Income": "71.7",
"Research and Development": "23.0",
"General and Administrative Expense": "67.4",
"Other Revenues": "80.3",
"Other Net Income": "2.09",
"Comprehensive Net Income": "71.8",
"Economic Capital Ratio": "96.9"
},
"2015": {
"Other Liabilities": "31.2",
"Liabilities": "116",
"Stockholders Equity": "49.8",
"ECR before LimitedLiability": "144",
"Liabilities, Current": "66.5",
"Liabilities, Non-Current": "40.9",
"Assets, Current": "3.86",
"Assets": "-10.6",
"Other Assets": "-3.08",
"Goodwill": "-8.35",
"Property, Plant and Equipment, Net": "-1.84",
"Research and Development": "18.3",
"Expenses": "-22.4",
"Revenues": "96.6",
"Net Income": "74.8",
"General and Administrative Expense": "50.8",
"Other Expenses": "-107",
"Other Revenues": "96.6",
"Comprehensive Net Income": "75.1",
"Other Net Income": "1.93",
"Economic Capital Ratio": "97.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000787253_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "27,828",
"Assets, Non-Current": "453",
"General and Administrative Expense": "8,304",
"Goodwill": "0",
"Liabilities, Current": "4,947",
"Liabilities, Non-Current": "0",
"Other Assets": "1,452",
"Other Compr. Net Income": "50",
"Other Expenses": "42,517",
"Other Liabilities": "719",
"Other Net Income": "25",
"Other Revenues": "55,882",
"Property, Plant and Equipment, Net": "11,411",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "5,666",
"Assets": "41,144",
"Expenses": "50,821",
"Revenues": "55,882",
"Stockholders Equity": "35,478",
"Net Income": "5,086",
"Comprehensive Net Income": "5,111",
"BaseVar": "76,794",
"ECR before LimitedLiability": "230%",
"Economic Capital Ratio": "256%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "34,519",
"Assets, Non-Current": "471",
"General and Administrative Expense": "9,251",
"Goodwill": "0",
"Liabilities, Current": "6,836",
"Liabilities, Non-Current": "0",
"Other Assets": "1,560",
"Other Compr. Net Income": "464",
"Other Expenses": "59,455",
"Other Liabilities": "493",
"Other Net Income": "42",
"Other Revenues": "72,822",
"Property, Plant and Equipment, Net": "10,647",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "7,329",
"Assets": "47,197",
"Expenses": "68,706",
"Revenues": "72,822",
"Stockholders Equity": "39,868",
"Net Income": "4,158",
"Comprehensive Net Income": "4,390",
"BaseVar": "98,280",
"ECR before LimitedLiability": "216%",
"Economic Capital Ratio": "246%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "40,903",
"Assets, Non-Current": "951",
"General and Administrative Expense": "9,961",
"Goodwill": "0",
"Liabilities, Current": "9,600",
"Liabilities, Non-Current": "0",
"Other Assets": "1,593",
"Other Compr. Net Income": "-39",
"Other Expenses": "61,878",
"Other Liabilities": "220",
"Other Net Income": "-109",
"Other Revenues": "73,942",
"Property, Plant and Equipment, Net": "8,811",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "9,820",
"Assets": "52,258",
"Expenses": "71,839",
"Revenues": "73,942",
"Stockholders Equity": "42,438",
"Net Income": "1,994",
"Comprehensive Net Income": "1,974",
"BaseVar": "104,004",
"ECR before LimitedLiability": "194%",
"Economic Capital Ratio": "230%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "43,600",
"Assets, Non-Current": "920",
"General and Administrative Expense": "10,180",
"Goodwill": "0",
"Liabilities, Current": "9,093",
"Liabilities, Non-Current": "21",
"Other Assets": "1,663",
"Other Compr. Net Income": "-297",
"Other Expenses": "66,130",
"Other Liabilities": "842",
"Other Net Income": "148",
"Other Revenues": "79,508",
"Property, Plant and Equipment, Net": "7,633",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "9,956",
"Assets": "53,816",
"Expenses": "76,310",
"Revenues": "79,508",
"Stockholders Equity": "43,860",
"Net Income": "3,346",
"Comprehensive Net Income": "3,198",
"BaseVar": "110,018",
"ECR before LimitedLiability": "198%",
"Economic Capital Ratio": "234%"
}
}
},
"top_rated": true,
"trend": 1.0,
"value": 2.337397181568518,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000787253.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000787253.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000787253.svg"
},
{
"company_id": "0000907654",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000907654.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000907654.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000907654.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000907654_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000907654_main_keyfigs.svg",
"name": "Oruka Therapeutics Inc",
"rank": 9,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000907654.svg",
"report_text": "The relative strengths and weaknesses of Oruka Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Oruka Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 149% points.The greatest weakness of Oruka Therapeutics Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 29% points.
The company's Economic Capital Ratio, given in the ranking table, is 234%, being 98% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000907654_2016_Oruka_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "0",
"Liabilities": "0",
"ECR before LimitedLiability": "-91.5",
"Liabilities, Non-Current": "0",
"Other Liabilities": "0",
"Property, Plant and Equipment, Net": "0",
"Assets": "-77.5",
"Stockholders Equity": "0",
"Assets, Non-Current": "0",
"Goodwill": "0",
"Assets, Current": "-23.3",
"General and Administrative Expense": "0",
"Expenses": "-50.4",
"Net Income": "-38.9",
"Research and Development": "-0.0791",
"Other Expenses": "0",
"Other Revenues": "0",
"Revenues": "0",
"Comprehensive Net Income": "-39.1",
"Other Net Income": "0",
"Economic Capital Ratio": "-153"
},
"2013": {
"Liabilities, Current": "103",
"Liabilities": "173",
"Stockholders Equity": "105",
"ECR before LimitedLiability": "359",
"Other Liabilities": "51.5",
"Liabilities, Non-Current": "59.5",
"Goodwill": "23.8",
"Assets": "-14.2",
"Assets, Non-Current": "8.49",
"Property, Plant and Equipment, Net": "20.4",
"Assets, Current": "-131",
"General and Administrative Expense": "51.2",
"Expenses": "118",
"Revenues": "-98.7",
"Net Income": "265",
"Research and Development": "-7.38",
"Other Expenses": "75.8",
"Other Revenues": "-98.7",
"Other Net Income": "249",
"Comprehensive Net Income": "265",
"Economic Capital Ratio": "319"
},
"2014": {
"Liabilities, Non-Current": "14.8",
"Liabilities": "50.2",
"Stockholders Equity": "104",
"ECR before LimitedLiability": "97.3",
"Liabilities, Current": "28.4",
"Other Liabilities": "9.86",
"Assets, Current": "119",
"Assets": "97.2",
"Goodwill": "-8.03",
"Assets, Non-Current": "0.826",
"Property, Plant and Equipment, Net": "-6.21",
"Other Expenses": "15.9",
"Expenses": "-6.77",
"Revenues": "-36.8",
"Net Income": "-42.6",
"Research and Development": "-31.9",
"General and Administrative Expense": "10.2",
"Other Revenues": "-36.8",
"Other Net Income": "1.07",
"Comprehensive Net Income": "-42.5",
"Economic Capital Ratio": "47.9"
},
"2015": {
"Other Liabilities": "13.9",
"Liabilities": "55.9",
"Stockholders Equity": "149",
"ECR before LimitedLiability": "144",
"Liabilities, Current": "32.5",
"Liabilities, Non-Current": "16.8",
"Assets, Current": "145",
"Assets": "63.8",
"Other Assets": "-1.67",
"Goodwill": "-3.43",
"Property, Plant and Equipment, Net": "-2.84",
"Research and Development": "-17.1",
"Expenses": "14.4",
"Revenues": "-29.1",
"Net Income": "-12.9",
"General and Administrative Expense": "12.7",
"Other Expenses": "18.1",
"Other Revenues": "-29.1",
"Comprehensive Net Income": "-12.7",
"Other Net Income": "0.597",
"Economic Capital Ratio": "97.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000907654_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "6,212",
"Assets, Non-Current": "224",
"General and Administrative Expense": "39,356",
"Goodwill": "0",
"Liabilities, Current": "754",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "12,041",
"Other Liabilities": "16",
"Other Net Income": "27,282",
"Other Revenues": "2,026",
"Property, Plant and Equipment, Net": "66",
"Research and Development": "41,585"
},
"output_variables": {
"Liabilities": "770",
"Assets": "6,502",
"Expenses": "92,982",
"Revenues": "2,026",
"Stockholders Equity": "5,732",
"Net Income": "-63,674",
"Comprehensive Net Income": "-63,674",
"BaseVar": "64,781",
"ECR before LimitedLiability": "-1,535%",
"Economic Capital Ratio": "0.0000000000000000000015%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "16,925",
"Assets, Non-Current": "130",
"General and Administrative Expense": "4,012",
"Goodwill": "0",
"Liabilities, Current": "1,502",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "-2,277",
"Other Liabilities": "1.0",
"Other Net Income": "27,282",
"Other Revenues": "5.0",
"Property, Plant and Equipment, Net": "29",
"Research and Development": "2,928"
},
"output_variables": {
"Liabilities": "1,503",
"Assets": "17,084",
"Expenses": "4,663",
"Revenues": "5.0",
"Stockholders Equity": "15,581",
"Net Income": "22,624",
"Comprehensive Net Income": "22,624",
"BaseVar": "25,268",
"ECR before LimitedLiability": "473%",
"Economic Capital Ratio": "474%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "15,488",
"Assets, Non-Current": "608",
"General and Administrative Expense": "4,068",
"Goodwill": "0",
"Liabilities, Current": "1,388",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "3.0",
"Other Liabilities": "3.0",
"Other Net Income": "0",
"Other Revenues": "7.0",
"Property, Plant and Equipment, Net": "36",
"Research and Development": "5,625"
},
"output_variables": {
"Liabilities": "1,391",
"Assets": "16,132",
"Expenses": "9,696",
"Revenues": "7.0",
"Stockholders Equity": "14,741",
"Net Income": "-9,689",
"Comprehensive Net Income": "-9,689",
"BaseVar": "13,613",
"ECR before LimitedLiability": "120%",
"Economic Capital Ratio": "181%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "38,916",
"Assets, Non-Current": "630",
"General and Administrative Expense": "4,392",
"Goodwill": "0",
"Liabilities, Current": "1,504",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "4.0",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "14",
"Property, Plant and Equipment, Net": "28",
"Research and Development": "7,063"
},
"output_variables": {
"Liabilities": "1,504",
"Assets": "39,574",
"Expenses": "11,459",
"Revenues": "14",
"Stockholders Equity": "38,070",
"Net Income": "-11,445",
"Comprehensive Net Income": "-11,445",
"BaseVar": "26,276",
"ECR before LimitedLiability": "198%",
"Economic Capital Ratio": "234%"
}
}
},
"top_rated": true,
"trend": 7.0,
"value": 2.3355911503349795,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000907654.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000907654.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000907654.svg"
},
{
"company_id": "0000037785",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000037785.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000037785.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000037785.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000037785_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000037785_main_keyfigs.svg",
"name": "FMC CORP",
"rank": 10,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000037785.svg",
"report_text": "The relative strengths and weaknesses of FMC CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of FMC CORP compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 73% points.The greatest weakness of FMC CORP is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 9.5% points.
The company's Economic Capital Ratio, given in the ranking table, is 223%, being 88% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000037785_2016_FMC_CORP.pdf",
"shrinked_graph_json": {
"2009": {
"Liabilities, Non-Current": "1.10",
"Liabilities": "-12.3",
"Stockholders Equity": "20.1",
"ECR before LimitedLiability": "9.42",
"Liabilities, Current": "-15.4",
"Other Liabilities": "1.64",
"Property, Plant and Equipment, Net": "6.68",
"Assets": "10.3",
"Other Assets": "4.39",
"Assets, Current": "-1.53",
"Goodwill": "0.287",
"General and Administrative Expense": "-28.3",
"Expenses": "12.9",
"Revenues": "-12.5",
"Comprehensive Net Income": "-0.188",
"Other Expenses": "39.8",
"Research and Development": "-0.0822",
"Other Revenues": "-12.5",
"Other Net Income": "-0.721",
"Other Compr. Net Income": "-0.157",
"Economic Capital Ratio": "8.70"
},
"2010": {
"Other Liabilities": "4.05",
"Liabilities": "23.4",
"Stockholders Equity": "10.1",
"ECR before LimitedLiability": "29.8",
"Liabilities, Current": "-21.9",
"Liabilities, Non-Current": "36.5",
"Other Expenses": "15.1",
"Expenses": "-3.63",
"Net Income": "14.6",
"General and Administrative Expense": "-24.5",
"Research and Development": "5.36",
"Other Revenues": "14.0",
"Revenues": "14.0",
"Goodwill": "-7.02",
"Property, Plant and Equipment, Net": "5.42",
"Assets, Current": "-4.49",
"Assets, Non-Current": "-2.70",
"Other Assets": "8.69",
"Other Net Income": "4.20",
"Comprehensive Net Income": "14.0",
"Economic Capital Ratio": "31.8"
},
"2011": {
"Liabilities, Current": "12.1",
"Liabilities": "38.3",
"Assets": "6.77",
"Stockholders Equity": "44.3",
"ECR before LimitedLiability": "130",
"Liabilities, Non-Current": "14.6",
"Other Liabilities": "15.3",
"Property, Plant and Equipment, Net": "7.10",
"Other Assets": "4.07",
"Assets, Current": "-3.03",
"General and Administrative Expense": "-12.1",
"Expenses": "20.0",
"Revenues": "34.4",
"Net Income": "46.8",
"Research and Development": "12.0",
"Other Expenses": "19.8",
"Other Revenues": "34.4",
"Comprehensive Net Income": "45.3",
"Other Net Income": "-8.00",
"Other Compr. Net Income": "-1.42",
"Economic Capital Ratio": "67.9"
},
"2012": {
"Liabilities, Current": "-7.79",
"Liabilities": "29.0",
"Stockholders Equity": "36.6",
"ECR before LimitedLiability": "92.7",
"Liabilities, Non-Current": "14.0",
"Other Liabilities": "23.0",
"Assets, Current": "-2.45",
"Assets": "6.71",
"Other Assets": "2.78",
"Property, Plant and Equipment, Net": "7.17",
"Goodwill": "-1.11",
"Other Expenses": "22.5",
"Expenses": "21.3",
"Revenues": "28.7",
"Net Income": "49.1",
"Research and Development": "12.8",
"General and Administrative Expense": "-14.3",
"Other Revenues": "28.7",
"Other Net Income": "-1.30",
"Comprehensive Net Income": "48.7",
"Economic Capital Ratio": "60.2"
},
"2013": {
"Liabilities, Current": "-25.8",
"Liabilities": "9.70",
"Assets": "8.11",
"Stockholders Equity": "21.7",
"ECR before LimitedLiability": "76.7",
"Other Liabilities": "14.8",
"Liabilities, Non-Current": "17.2",
"Goodwill": "-1.19",
"Property, Plant and Equipment, Net": "8.49",
"Assets, Current": "1.89",
"General and Administrative Expense": "-8.10",
"Expenses": "24.7",
"Revenues": "21.8",
"Net Income": "41.9",
"Research and Development": "9.95",
"Other Expenses": "22.8",
"Other Revenues": "21.8",
"Other Net Income": "-5.58",
"Comprehensive Net Income": "43.9",
"Other Compr. Net Income": "1.68",
"Economic Capital Ratio": "36.5"
},
"2014": {
"Liabilities, Non-Current": "20.0",
"Liabilities": "31.7",
"Stockholders Equity": "48.3",
"ECR before LimitedLiability": "108",
"Liabilities, Current": "-0.642",
"Other Liabilities": "13.5",
"Assets, Current": "2.63",
"Assets": "12.9",
"Goodwill": "-2.79",
"Other Assets": "2.87",
"Property, Plant and Equipment, Net": "9.21",
"Other Expenses": "17.0",
"Expenses": "24.0",
"Revenues": "24.5",
"Net Income": "50.4",
"Research and Development": "12.0",
"General and Administrative Expense": "-5.11",
"Other Revenues": "24.5",
"Comprehensive Net Income": "48.5",
"Other Compr. Net Income": "-1.64",
"Economic Capital Ratio": "58.5"
},
"2015": {
"Other Liabilities": "19.8",
"Liabilities": "50.9",
"Stockholders Equity": "72.7",
"ECR before LimitedLiability": "133",
"Liabilities, Current": "13.3",
"Liabilities, Non-Current": "23.8",
"Assets, Current": "2.04",
"Assets": "14.1",
"Goodwill": "6.74",
"Assets, Non-Current": "1.84",
"Property, Plant and Equipment, Net": "2.65",
"Research and Development": "7.85",
"Expenses": "19.6",
"Revenues": "14.5",
"Net Income": "46.5",
"General and Administrative Expense": "-9.50",
"Other Expenses": "21.0",
"Other Revenues": "14.5",
"Comprehensive Net Income": "46.0",
"Other Net Income": "12.5",
"Economic Capital Ratio": "87.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000037785_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "1,487,700",
"Assets, Non-Current": "211,400",
"General and Administrative Expense": "2,265,900",
"Goodwill": "209,500",
"Liabilities, Current": "709,200",
"Liabilities, Non-Current": "0",
"Other Assets": "263,100",
"Other Compr. Net Income": "-13,400",
"Other Expenses": "213,000",
"Other Liabilities": "0",
"Other Net Income": "-15,700",
"Other Revenues": "2,826,200",
"Property, Plant and Equipment, Net": "964,500",
"Research and Development": "92,800"
},
"output_variables": {
"Liabilities": "709,200",
"Assets": "3,136,200",
"Expenses": "2,571,700",
"Revenues": "2,826,200",
"Stockholders Equity": "2,427,000",
"Net Income": "238,800",
"Comprehensive Net Income": "232,100",
"BaseVar": "4,636,200",
"ECR before LimitedLiability": "185%",
"Economic Capital Ratio": "225%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "1,646,200",
"Assets, Non-Current": "223,700",
"General and Administrative Expense": "2,476,800",
"Goodwill": "194,400",
"Liabilities, Current": "963,400",
"Liabilities, Non-Current": "0",
"Other Assets": "337,100",
"Other Compr. Net Income": "-44,900",
"Other Expenses": "323,400",
"Other Liabilities": "0",
"Other Net Income": "36,500",
"Other Revenues": "3,116,300",
"Property, Plant and Equipment, Net": "918,500",
"Research and Development": "100,500"
},
"output_variables": {
"Liabilities": "963,400",
"Assets": "3,319,900",
"Expenses": "2,900,700",
"Revenues": "3,116,300",
"Stockholders Equity": "2,356,500",
"Net Income": "252,100",
"Comprehensive Net Income": "229,650",
"BaseVar": "5,190,850",
"ECR before LimitedLiability": "161%",
"Economic Capital Ratio": "209%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "1,869,400",
"Assets, Non-Current": "198,900",
"General and Administrative Expense": "2,653,000",
"Goodwill": "413,200",
"Liabilities, Current": "919,900",
"Liabilities, Non-Current": "0",
"Other Assets": "275,200",
"Other Compr. Net Income": "-94,600",
"Other Expenses": "208,400",
"Other Liabilities": "0",
"Other Net Income": "-29,100",
"Other Revenues": "3,377,900",
"Property, Plant and Equipment, Net": "986,800",
"Research and Development": "105,200"
},
"output_variables": {
"Liabilities": "919,900",
"Assets": "3,743,500",
"Expenses": "2,966,600",
"Revenues": "3,377,900",
"Stockholders Equity": "2,823,600",
"Net Income": "382,200",
"Comprehensive Net Income": "334,900",
"BaseVar": "5,565,800",
"ECR before LimitedLiability": "180%",
"Economic Capital Ratio": "221%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "2,181,800",
"Assets, Non-Current": "312,500",
"General and Administrative Expense": "2,934,200",
"Goodwill": "510,100",
"Liabilities, Current": "1,135,400",
"Liabilities, Non-Current": "0",
"Other Assets": "233,300",
"Other Compr. Net Income": "-38,400",
"Other Expenses": "230,200",
"Other Liabilities": "0",
"Other Net Income": "-30,400",
"Other Revenues": "3,748,300",
"Property, Plant and Equipment, Net": "1,136,200",
"Research and Development": "117,800"
},
"output_variables": {
"Liabilities": "1,135,400",
"Assets": "4,373,900",
"Expenses": "3,282,200",
"Revenues": "3,748,300",
"Stockholders Equity": "3,238,500",
"Net Income": "435,700",
"Comprehensive Net Income": "416,500",
"BaseVar": "6,304,300",
"ECR before LimitedLiability": "176%",
"Economic Capital Ratio": "219%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "2,945,000",
"Assets, Non-Current": "288,800",
"General and Administrative Expense": "3,050,200",
"Goodwill": "661,700",
"Liabilities, Current": "1,986,700",
"Liabilities, Non-Current": "0",
"Other Assets": "91,400",
"Other Compr. Net Income": "192,900",
"Other Expenses": "238,900",
"Other Liabilities": "0",
"Other Net Income": "-160,000",
"Other Revenues": "3,874,800",
"Property, Plant and Equipment, Net": "1,248,300",
"Research and Development": "117,700"
},
"output_variables": {
"Liabilities": "1,986,700",
"Assets": "5,235,200",
"Expenses": "3,406,800",
"Revenues": "3,874,800",
"Stockholders Equity": "3,248,500",
"Net Income": "308,000",
"Comprehensive Net Income": "404,450",
"BaseVar": "7,428,200",
"ECR before LimitedLiability": "134%",
"Economic Capital Ratio": "191%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "2,934,400",
"Assets, Non-Current": "298,100",
"General and Administrative Expense": "3,283,900",
"Goodwill": "599,400",
"Liabilities, Current": "1,910,400",
"Liabilities, Non-Current": "0",
"Other Assets": "200,100",
"Other Compr. Net Income": "-188,500",
"Other Expenses": "213,300",
"Other Liabilities": "0",
"Other Net Income": "-90,100",
"Other Revenues": "4,037,700",
"Property, Plant and Equipment, Net": "1,308,500",
"Research and Development": "128,300"
},
"output_variables": {
"Liabilities": "1,910,400",
"Assets": "5,340,500",
"Expenses": "3,625,500",
"Revenues": "4,037,700",
"Stockholders Equity": "3,430,100",
"Net Income": "322,100",
"Comprehensive Net Income": "227,850",
"BaseVar": "7,596,350",
"ECR before LimitedLiability": "136%",
"Economic Capital Ratio": "192%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "2,971,900",
"Assets, Non-Current": "437,600",
"General and Administrative Expense": "2,939,000",
"Goodwill": "1,613,100",
"Liabilities, Current": "1,453,300",
"Liabilities, Non-Current": "0",
"Other Assets": "286,900",
"Other Compr. Net Income": "-91,000",
"Other Expenses": "372,800",
"Other Liabilities": "0",
"Other Net Income": "677,500",
"Other Revenues": "3,276,500",
"Property, Plant and Equipment, Net": "1,016,400",
"Research and Development": "143,700"
},
"output_variables": {
"Liabilities": "1,453,300",
"Assets": "6,325,900",
"Expenses": "3,455,500",
"Revenues": "3,276,500",
"Stockholders Equity": "4,872,600",
"Net Income": "498,500",
"Comprehensive Net Income": "453,000",
"BaseVar": "7,639,850",
"ECR before LimitedLiability": "183%",
"Economic Capital Ratio": "223%"
}
}
},
"top_rated": true,
"trend": 5.0,
"value": 2.2338977337645,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000037785.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000037785.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000037785.svg"
},
{
"company_id": "0001050007",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001050007.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001050007.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001050007_main_keyfigs.svg",
"name": "Nutraceutical International CORP",
"rank": 11,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001050007.svg",
"report_text": "The relative strengths and weaknesses of Nutraceutical International CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Nutraceutical International CORP compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 73% points.The greatest weakness of Nutraceutical International CORP is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 43% points.
The company's Economic Capital Ratio, given in the ranking table, is 219%, being 84% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001050007_2016_Nutraceutical_International_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "43.0",
"Liabilities": "36.2",
"Stockholders Equity": "25.2",
"ECR before LimitedLiability": "117",
"Liabilities, Non-Current": "14.8",
"Other Liabilities": "-27.0",
"General and Administrative Expense": "-26.3",
"Expenses": "11.9",
"Net Income": "49.4",
"Research and Development": "16.3",
"Other Expenses": "21.4",
"Other Revenues": "44.8",
"Revenues": "44.8",
"Property, Plant and Equipment, Net": "19.0",
"Assets, Non-Current": "-3.01",
"Other Assets": "2.65",
"Goodwill": "1.34",
"Assets, Current": "-13.4",
"Comprehensive Net Income": "49.4",
"Other Net Income": "-7.67",
"Economic Capital Ratio": "54.9"
},
"2012": {
"Liabilities, Current": "30.9",
"Liabilities": "33.1",
"Stockholders Equity": "19.1",
"ECR before LimitedLiability": "83.4",
"Liabilities, Non-Current": "15.1",
"Other Liabilities": "-14.0",
"Assets, Current": "-12.9",
"Assets": "-1.66",
"Other Assets": "1.74",
"Assets, Non-Current": "-3.30",
"Property, Plant and Equipment, Net": "17.5",
"Goodwill": "1.43",
"Other Expenses": "24.8",
"Expenses": "12.2",
"Revenues": "41.0",
"Net Income": "53.5",
"Research and Development": "17.6",
"General and Administrative Expense": "-30.9",
"Other Revenues": "41.0",
"Comprehensive Net Income": "53.6",
"Economic Capital Ratio": "50.9"
},
"2013": {
"Liabilities, Current": "38.4",
"Liabilities": "44.3",
"Stockholders Equity": "24.4",
"ECR before LimitedLiability": "98.0",
"Other Liabilities": "-18.5",
"Liabilities, Non-Current": "22.8",
"Assets": "-2.85",
"Assets, Non-Current": "-3.06",
"Property, Plant and Equipment, Net": "17.1",
"Other Assets": "-0.733",
"Assets, Current": "-11.4",
"General and Administrative Expense": "-35.8",
"Expenses": "7.55",
"Revenues": "49.2",
"Net Income": "53.7",
"Research and Development": "15.3",
"Other Expenses": "26.8",
"Other Revenues": "49.2",
"Other Net Income": "-3.40",
"Comprehensive Net Income": "53.6",
"Economic Capital Ratio": "57.9"
},
"2014": {
"Liabilities, Non-Current": "23.8",
"Liabilities": "55.1",
"Stockholders Equity": "50.6",
"ECR before LimitedLiability": "122",
"Liabilities, Current": "55.4",
"Other Liabilities": "-29.6",
"Assets, Current": "-9.77",
"Assets": "3.37",
"Goodwill": "2.19",
"Assets, Non-Current": "-2.83",
"Property, Plant and Equipment, Net": "16.5",
"Other Expenses": "18.0",
"Expenses": "12.1",
"Revenues": "43.4",
"Net Income": "58.6",
"Research and Development": "16.7",
"General and Administrative Expense": "-22.9",
"Other Revenues": "43.4",
"Other Net Income": "1.66",
"Comprehensive Net Income": "58.7",
"Economic Capital Ratio": "72.9"
},
"2015": {
"Other Liabilities": "-8.48",
"Liabilities": "73.5",
"Stockholders Equity": "54.2",
"ECR before LimitedLiability": "129",
"Liabilities, Current": "56.2",
"Liabilities, Non-Current": "29.8",
"Research and Development": "13.4",
"Expenses": "2.23",
"Net Income": "58.2",
"General and Administrative Expense": "-42.7",
"Other Expenses": "29.0",
"Other Revenues": "54.6",
"Revenues": "54.6",
"Assets, Current": "-7.67",
"Other Assets": "-2.95",
"Goodwill": "1.15",
"Assets, Non-Current": "-1.83",
"Property, Plant and Equipment, Net": "13.7",
"Comprehensive Net Income": "58.6",
"Other Net Income": "1.17",
"Economic Capital Ratio": "83.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001050007_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "62,069",
"Assets, Non-Current": "1,781",
"General and Administrative Expense": "161,107",
"Goodwill": "28,546",
"Liabilities, Current": "19,737",
"Liabilities, Non-Current": "253",
"Other Assets": "7,175",
"Other Compr. Net Income": "0",
"Other Expenses": "11,245",
"Other Liabilities": "32,000",
"Other Net Income": "0",
"Other Revenues": "188,070",
"Property, Plant and Equipment, Net": "72,094",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "51,990",
"Assets": "171,665",
"Expenses": "172,352",
"Revenues": "188,070",
"Stockholders Equity": "119,675",
"Net Income": "15,718",
"Comprehensive Net Income": "15,718",
"BaseVar": "292,038",
"ECR before LimitedLiability": "161%",
"Economic Capital Ratio": "208%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "68,268",
"Assets, Non-Current": "1,617",
"General and Administrative Expense": "171,838",
"Goodwill": "34,626",
"Liabilities, Current": "20,670",
"Liabilities, Non-Current": "192",
"Other Assets": "5,953",
"Other Compr. Net Income": "0",
"Other Expenses": "12,762",
"Other Liabilities": "34,000",
"Other Net Income": "0",
"Other Revenues": "200,367",
"Property, Plant and Equipment, Net": "75,454",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "54,862",
"Assets": "185,918",
"Expenses": "184,600",
"Revenues": "200,367",
"Stockholders Equity": "131,056",
"Net Income": "15,767",
"Comprehensive Net Income": "15,767",
"BaseVar": "312,874",
"ECR before LimitedLiability": "162%",
"Economic Capital Ratio": "209%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "75,048",
"Assets, Non-Current": "1,313",
"General and Administrative Expense": "177,931",
"Goodwill": "34,901",
"Liabilities, Current": "21,796",
"Liabilities, Non-Current": "138",
"Other Assets": "4,834",
"Other Compr. Net Income": "-137",
"Other Expenses": "13,458",
"Other Liabilities": "32,500",
"Other Net Income": "0",
"Other Revenues": "208,397",
"Property, Plant and Equipment, Net": "76,214",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "54,434",
"Assets": "192,310",
"Expenses": "191,389",
"Revenues": "208,397",
"Stockholders Equity": "137,876",
"Net Income": "17,008",
"Comprehensive Net Income": "16,940",
"BaseVar": "323,334",
"ECR before LimitedLiability": "167%",
"Economic Capital Ratio": "212%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "83,850",
"Assets, Non-Current": "1,203",
"General and Administrative Expense": "185,043",
"Goodwill": "45,587",
"Liabilities, Current": "21,709",
"Liabilities, Non-Current": "456",
"Other Assets": "4,894",
"Other Compr. Net Income": "-122",
"Other Expenses": "13,542",
"Other Liabilities": "43,000",
"Other Net Income": "0",
"Other Revenues": "214,474",
"Property, Plant and Equipment, Net": "79,244",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "65,165",
"Assets": "214,778",
"Expenses": "198,585",
"Revenues": "214,474",
"Stockholders Equity": "149,613",
"Net Income": "15,889",
"Comprehensive Net Income": "15,828",
"BaseVar": "346,562",
"ECR before LimitedLiability": "158%",
"Economic Capital Ratio": "206%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "86,215",
"Assets, Non-Current": "1,668",
"General and Administrative Expense": "187,511",
"Goodwill": "41,989",
"Liabilities, Current": "20,528",
"Liabilities, Non-Current": "174",
"Other Assets": "4,932",
"Other Compr. Net Income": "-458",
"Other Expenses": "13,697",
"Other Liabilities": "31,500",
"Other Net Income": "0",
"Other Revenues": "216,479",
"Property, Plant and Equipment, Net": "77,645",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "52,202",
"Assets": "212,449",
"Expenses": "201,208",
"Revenues": "216,479",
"Stockholders Equity": "160,247",
"Net Income": "15,271",
"Comprehensive Net Income": "15,042",
"BaseVar": "341,398",
"ECR before LimitedLiability": "177%",
"Economic Capital Ratio": "219%"
}
}
},
"top_rated": true,
"trend": 2.0,
"value": 2.193691870081748,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001050007.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001050007.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001050007.svg"
},
{
"company_id": "0000896264",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000896264.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000896264.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000896264.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000896264_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000896264_main_keyfigs.svg",
"name": "Usana Health Sciences INC",
"rank": 12,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000896264.svg",
"report_text": "The relative strengths and weaknesses of Usana Health Sciences INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Usana Health Sciences INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 136% points.The greatest weakness of Usana Health Sciences INC is the variable Other Expenses, reducing the Economic Capital Ratio by 107% points.
The company's Economic Capital Ratio, given in the ranking table, is 219%, being 83% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000896264_2016_Usana_Health_Sciences_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "67.6",
"Liabilities": "107",
"Stockholders Equity": "-19.3",
"ECR before LimitedLiability": "143",
"Liabilities, Non-Current": "28.7",
"Other Liabilities": "30.0",
"Property, Plant and Equipment, Net": "-0.726",
"Assets": "-19.1",
"Assets, Non-Current": "-3.29",
"Other Assets": "2.14",
"Assets, Current": "-18.2",
"General and Administrative Expense": "65.1",
"Expenses": "-30.3",
"Revenues": "150",
"Net Income": "95.7",
"Research and Development": "29.6",
"Other Expenses": "-152",
"Other Revenues": "150",
"Comprehensive Net Income": "95.6",
"Other Net Income": "-14.5",
"Economic Capital Ratio": "81.2"
},
"2012": {
"Liabilities, Current": "43.0",
"Liabilities": "98.2",
"Stockholders Equity": "-40.4",
"ECR before LimitedLiability": "108",
"Liabilities, Non-Current": "28.9",
"Other Liabilities": "45.8",
"Assets, Current": "-17.5",
"Assets": "-20.6",
"Assets, Non-Current": "-3.61",
"Property, Plant and Equipment, Net": "-1.72",
"Goodwill": "-2.28",
"Other Expenses": "-136",
"Expenses": "-26.7",
"Revenues": "146",
"Net Income": "111",
"Research and Development": "32.0",
"General and Administrative Expense": "54.8",
"Other Revenues": "146",
"Other Net Income": "-1.09",
"Comprehensive Net Income": "111",
"Economic Capital Ratio": "75.5"
},
"2013": {
"Liabilities, Current": "41.0",
"Liabilities": "90.3",
"Stockholders Equity": "-9.00",
"ECR before LimitedLiability": "117",
"Other Liabilities": "30.8",
"Liabilities, Non-Current": "35.4",
"Goodwill": "-3.54",
"Assets": "-16.9",
"Assets, Non-Current": "-2.34",
"Property, Plant and Equipment, Net": "-2.23",
"Assets, Current": "-10.9",
"General and Administrative Expense": "44.0",
"Expenses": "-18.0",
"Revenues": "119",
"Net Income": "91.4",
"Research and Development": "23.2",
"Other Expenses": "-98.7",
"Other Revenues": "119",
"Other Net Income": "-5.32",
"Comprehensive Net Income": "91.0",
"Economic Capital Ratio": "76.6"
},
"2015": {
"Other Liabilities": "39.5",
"Liabilities": "128",
"Stockholders Equity": "2.12",
"ECR before LimitedLiability": "129",
"Liabilities, Current": "65.0",
"Liabilities, Non-Current": "46.9",
"Assets, Current": "-17.0",
"Assets": "-24.9",
"Other Assets": "-5.78",
"Goodwill": "-6.26",
"Property, Plant and Equipment, Net": "-2.45",
"Research and Development": "22.2",
"Expenses": "-36.7",
"Revenues": "136",
"Net Income": "116",
"General and Administrative Expense": "35.7",
"Other Expenses": "-107",
"Other Revenues": "136",
"Comprehensive Net Income": "117",
"Other Net Income": "1.81",
"Economic Capital Ratio": "83.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000896264_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "106,059",
"Assets, Non-Current": "6,273",
"General and Administrative Expense": "137,063",
"Goodwill": "60,377",
"Liabilities, Current": "59,696",
"Liabilities, Non-Current": "0",
"Other Assets": "11,033",
"Other Compr. Net Income": "0",
"Other Expenses": "394,346",
"Other Liabilities": "0",
"Other Net Income": "222",
"Other Revenues": "581,939",
"Property, Plant and Equipment, Net": "60,754",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "59,696",
"Assets": "244,496",
"Expenses": "531,409",
"Revenues": "581,939",
"Stockholders Equity": "184,800",
"Net Income": "50,752",
"Comprehensive Net Income": "50,752",
"BaseVar": "708,881",
"ECR before LimitedLiability": "200%",
"Economic Capital Ratio": "235%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "132,545",
"Assets, Non-Current": "7,128",
"General and Administrative Expense": "154,237",
"Goodwill": "59,975",
"Liabilities, Current": "70,844",
"Liabilities, Non-Current": "0",
"Other Assets": "5,956",
"Other Compr. Net Income": "1,097",
"Other Expenses": "428,303",
"Other Liabilities": "0",
"Other Net Income": "247",
"Other Revenues": "648,726",
"Property, Plant and Equipment, Net": "61,751",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "70,844",
"Assets": "267,355",
"Expenses": "582,540",
"Revenues": "648,726",
"Stockholders Equity": "196,511",
"Net Income": "66,433",
"Comprehensive Net Income": "66,982",
"BaseVar": "785,404",
"ECR before LimitedLiability": "199%",
"Economic Capital Ratio": "234%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "229,045",
"Assets, Non-Current": "14,154",
"General and Administrative Expense": "166,208",
"Goodwill": "60,572",
"Liabilities, Current": "95,871",
"Liabilities, Non-Current": "0",
"Other Assets": "5,519",
"Other Compr. Net Income": "-1,142",
"Other Expenses": "472,812",
"Other Liabilities": "0",
"Other Net Income": "-131",
"Other Revenues": "718,175",
"Property, Plant and Equipment, Net": "59,180",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "95,871",
"Assets": "368,470",
"Expenses": "639,020",
"Revenues": "718,175",
"Stockholders Equity": "272,599",
"Net Income": "79,024",
"Comprehensive Net Income": "78,453",
"BaseVar": "911,404",
"ECR before LimitedLiability": "195%",
"Economic Capital Ratio": "231%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "190,927",
"Assets, Non-Current": "23,667",
"General and Administrative Expense": "184,531",
"Goodwill": "58,893",
"Liabilities, Current": "108,705",
"Liabilities, Non-Current": "0",
"Other Assets": "5,933",
"Other Compr. Net Income": "-3,662",
"Other Expenses": "528,855",
"Other Liabilities": "0",
"Other Net Income": "-449",
"Other Revenues": "790,471",
"Property, Plant and Equipment, Net": "71,164",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "108,705",
"Assets": "350,584",
"Expenses": "713,386",
"Revenues": "790,471",
"Stockholders Equity": "241,879",
"Net Income": "76,636",
"Comprehensive Net Income": "74,805",
"BaseVar": "983,628",
"ECR before LimitedLiability": "177%",
"Economic Capital Ratio": "219%"
}
}
},
"top_rated": true,
"trend": null,
"value": 2.1910042288641236,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000896264.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000896264.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000896264.svg"
},
{
"company_id": "0000811641",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000811641.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000811641.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000811641.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000811641_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000811641_main_keyfigs.svg",
"name": "Immucell CORP DE",
"rank": 13,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000811641.svg",
"report_text": "The relative strengths and weaknesses of Immucell CORP DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Immucell CORP DE compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 61% points.The greatest weakness of Immucell CORP DE is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 27% points.
The company's Economic Capital Ratio, given in the ranking table, is 214%, being 78% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000811641_2016_Immucell_CORP_DE.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "35.7",
"Liabilities": "30.0",
"Stockholders Equity": "78.7",
"ECR before LimitedLiability": "133",
"Liabilities, Non-Current": "11.4",
"Other Liabilities": "-21.1",
"Property, Plant and Equipment, Net": "7.45",
"Assets": "26.7",
"Assets, Non-Current": "-1.95",
"Other Assets": "6.85",
"Goodwill": "-4.32",
"Assets, Current": "15.6",
"General and Administrative Expense": "30.8",
"Expenses": "23.8",
"Revenues": "5.42",
"Net Income": "23.1",
"Research and Development": "-6.31",
"Other Revenues": "5.42",
"Comprehensive Net Income": "23.1",
"Other Net Income": "-6.15",
"Economic Capital Ratio": "70.7"
},
"2012": {
"Liabilities, Current": "26.9",
"Liabilities": "30.9",
"Stockholders Equity": "75.1",
"ECR before LimitedLiability": "107",
"Liabilities, Non-Current": "12.2",
"Other Liabilities": "-7.99",
"Assets, Current": "15.0",
"Assets": "21.8",
"Other Assets": "5.55",
"Assets, Non-Current": "-1.68",
"Property, Plant and Equipment, Net": "5.68",
"Goodwill": "-4.29",
"Other Expenses": "-3.33",
"Expenses": "25.9",
"Revenues": "6.62",
"Net Income": "31.9",
"Research and Development": "3.13",
"General and Administrative Expense": "26.1",
"Other Revenues": "6.62",
"Comprehensive Net Income": "31.9",
"Economic Capital Ratio": "74.4"
},
"2013": {
"Liabilities, Current": "36.6",
"Liabilities": "47.1",
"Stockholders Equity": "80.5",
"ECR before LimitedLiability": "126",
"Other Liabilities": "-6.91",
"Liabilities, Non-Current": "19.7",
"Goodwill": "-4.23",
"Assets": "16.4",
"Assets, Non-Current": "-1.64",
"Property, Plant and Equipment, Net": "6.13",
"Other Assets": "3.48",
"Assets, Current": "12.4",
"General and Administrative Expense": "25.6",
"Expenses": "20.4",
"Revenues": "17.0",
"Net Income": "34.3",
"Other Expenses": "-4.65",
"Other Revenues": "17.0",
"Other Net Income": "-2.68",
"Comprehensive Net Income": "34.2",
"Economic Capital Ratio": "85.4"
},
"2014": {
"Liabilities, Non-Current": "6.58",
"Liabilities": "67.0",
"Stockholders Equity": "92.2",
"ECR before LimitedLiability": "147",
"Liabilities, Current": "50.9",
"Other Liabilities": "16.2",
"Assets, Current": "1.73",
"Assets": "14.8",
"Goodwill": "-5.84",
"Other Assets": "8.55",
"Assets, Non-Current": "-1.91",
"Property, Plant and Equipment, Net": "13.8",
"Other Expenses": "-10.9",
"Expenses": "14.3",
"Revenues": "26.4",
"Net Income": "41.8",
"Research and Development": "-7.90",
"General and Administrative Expense": "32.2",
"Other Revenues": "26.4",
"Comprehensive Net Income": "41.9",
"Economic Capital Ratio": "97.7"
},
"2015": {
"Other Liabilities": "19.8",
"Liabilities": "46.8",
"Stockholders Equity": "60.7",
"ECR before LimitedLiability": "124",
"Liabilities, Current": "48.9",
"Liabilities, Non-Current": "-27.0",
"Assets, Current": "4.49",
"Assets": "11.1",
"Goodwill": "-6.99",
"Assets, Non-Current": "-1.71",
"Property, Plant and Equipment, Net": "18.9",
"Research and Development": "1.79",
"Expenses": "16.9",
"Revenues": "29.9",
"Net Income": "48.4",
"General and Administrative Expense": "21.6",
"Other Expenses": "-6.51",
"Other Revenues": "29.9",
"Comprehensive Net Income": "48.7",
"Other Net Income": "0.915",
"Economic Capital Ratio": "78.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000811641_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "7,151",
"Assets, Non-Current": "19",
"General and Administrative Expense": "1,726",
"Goodwill": "0",
"Liabilities, Current": "635",
"Liabilities, Non-Current": "0",
"Other Assets": "1,306",
"Other Compr. Net Income": "0",
"Other Expenses": "2,010",
"Other Liabilities": "1,336",
"Other Net Income": "-64",
"Other Revenues": "5,111",
"Property, Plant and Equipment, Net": "2,515",
"Research and Development": "1,720"
},
"output_variables": {
"Liabilities": "1,971",
"Assets": "10,991",
"Expenses": "5,457",
"Revenues": "5,111",
"Stockholders Equity": "9,020",
"Net Income": "-410",
"Comprehensive Net Income": "-410",
"BaseVar": "11,797",
"ECR before LimitedLiability": "184%",
"Economic Capital Ratio": "224%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "7,363",
"Assets, Non-Current": "64",
"General and Administrative Expense": "1,892",
"Goodwill": "0",
"Liabilities, Current": "666",
"Liabilities, Non-Current": "0",
"Other Assets": "1,246",
"Other Compr. Net Income": "0",
"Other Expenses": "2,491",
"Other Liabilities": "1,170",
"Other Net Income": "0",
"Other Revenues": "5,390",
"Property, Plant and Equipment, Net": "2,358",
"Research and Development": "918"
},
"output_variables": {
"Liabilities": "1,836",
"Assets": "11,030",
"Expenses": "5,300",
"Revenues": "5,390",
"Stockholders Equity": "9,195",
"Net Income": "90",
"Comprehensive Net Income": "90",
"BaseVar": "11,778",
"ECR before LimitedLiability": "197%",
"Economic Capital Ratio": "233%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "7,268",
"Assets, Non-Current": "14",
"General and Administrative Expense": "1,926",
"Goodwill": "0",
"Liabilities, Current": "636",
"Liabilities, Non-Current": "0",
"Other Assets": "1,155",
"Other Compr. Net Income": "0",
"Other Expenses": "2,810",
"Other Liabilities": "929",
"Other Net Income": "0",
"Other Revenues": "6,007",
"Property, Plant and Equipment, Net": "2,525",
"Research and Development": "1,154"
},
"output_variables": {
"Liabilities": "1,565",
"Assets": "10,961",
"Expenses": "5,890",
"Revenues": "6,007",
"Stockholders Equity": "9,396",
"Net Income": "117",
"Comprehensive Net Income": "117",
"BaseVar": "12,211",
"ECR before LimitedLiability": "207%",
"Economic Capital Ratio": "240%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "5,469",
"Assets, Non-Current": "19",
"General and Administrative Expense": "2,476",
"Goodwill": "0",
"Liabilities, Current": "1,009",
"Liabilities, Non-Current": "785",
"Other Assets": "1,726",
"Other Compr. Net Income": "-3.5",
"Other Expenses": "3,109",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "7,597",
"Property, Plant and Equipment, Net": "3,838",
"Research and Development": "2,179"
},
"output_variables": {
"Liabilities": "1,793",
"Assets": "11,052",
"Expenses": "7,764",
"Revenues": "7,597",
"Stockholders Equity": "9,258",
"Net Income": "-167",
"Comprehensive Net Income": "-169",
"BaseVar": "14,105",
"ECR before LimitedLiability": "195%",
"Economic Capital Ratio": "231%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "7,873",
"Assets, Non-Current": "50",
"General and Administrative Expense": "2,893",
"Goodwill": "0",
"Liabilities, Current": "818",
"Liabilities, Non-Current": "3,169",
"Other Assets": "959",
"Other Compr. Net Income": "-27",
"Other Expenses": "4,887",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "10,229",
"Property, Plant and Equipment, Net": "5,719",
"Research and Development": "1,235"
},
"output_variables": {
"Liabilities": "3,987",
"Assets": "14,601",
"Expenses": "9,015",
"Revenues": "10,229",
"Stockholders Equity": "10,614",
"Net Income": "1,213",
"Comprehensive Net Income": "1,200",
"BaseVar": "18,929",
"ECR before LimitedLiability": "169%",
"Economic Capital Ratio": "214%"
}
}
},
"top_rated": false,
"trend": -5.0,
"value": 2.141062690224189,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000811641.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000811641.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000811641.svg"
},
{
"company_id": "0001038133",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001038133.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001038133.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001038133.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001038133_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001038133_main_keyfigs.svg",
"name": "Heska CORP",
"rank": 14,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001038133.svg",
"report_text": "The relative strengths and weaknesses of Heska CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Heska CORP compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 63% points.The greatest weakness of Heska CORP is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 39% points.
The company's Economic Capital Ratio, given in the ranking table, is 210%, being 74% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001038133_2016_Heska_CORP.pdf",
"shrinked_graph_json": {
"2015": {
"Other Liabilities": "1.40",
"Liabilities": "63.3",
"Stockholders Equity": "50.0",
"ECR before LimitedLiability": "120",
"Liabilities, Current": "39.4",
"Liabilities, Non-Current": "27.6",
"Research and Development": "11.1",
"Expenses": "4.31",
"Net Income": "53.9",
"General and Administrative Expense": "-39.4",
"Other Expenses": "31.3",
"Other Revenues": "47.9",
"Revenues": "47.9",
"Assets, Current": "-9.24",
"Other Assets": "28.9",
"Goodwill": "-8.75",
"Assets, Non-Current": "-0.859",
"Property, Plant and Equipment, Net": "0.755",
"Comprehensive Net Income": "54.1",
"Other Net Income": "1.10",
"Economic Capital Ratio": "73.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001038133_strength_weakness.svg",
"table_records": {
"2015": {
"input_variables": {
"Assets, Current": "41,262",
"Assets, Non-Current": "3,072",
"General and Administrative Expense": "94,382",
"Goodwill": "0",
"Liabilities, Current": "18,803",
"Liabilities, Non-Current": "69",
"Other Assets": "48,365",
"Other Compr. Net Income": "-376",
"Other Expenses": "3,038",
"Other Liabilities": "11,572",
"Other Net Income": "0",
"Other Revenues": "104,597",
"Property, Plant and Equipment, Net": "17,020",
"Research and Development": "1,658"
},
"output_variables": {
"Liabilities": "30,444",
"Assets": "109,719",
"Expenses": "99,078",
"Revenues": "104,597",
"Stockholders Equity": "79,275",
"Net Income": "5,519",
"Comprehensive Net Income": "5,331",
"BaseVar": "172,107",
"ECR before LimitedLiability": "163%",
"Economic Capital Ratio": "210%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.096140497096126,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001038133.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001038133.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001038133.svg"
},
{
"company_id": "0000768408",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000768408.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000768408.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000768408.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000768408_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000768408_main_keyfigs.svg",
"name": "Cyanotech CORP",
"rank": 15,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000768408.svg",
"report_text": "The relative strengths and weaknesses of Cyanotech CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cyanotech CORP compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 68% points.The greatest weakness of Cyanotech CORP is the variable Other Expenses, reducing the Economic Capital Ratio by 27% points.
The company's Economic Capital Ratio, given in the ranking table, is 199%, being 63% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000768408_2016_Cyanotech_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "44.2",
"Liabilities": "64.9",
"Stockholders Equity": "41.4",
"ECR before LimitedLiability": "146",
"Liabilities, Non-Current": "9.21",
"Other Liabilities": "19.9",
"General and Administrative Expense": "39.9",
"Expenses": "8.05",
"Net Income": "58.1",
"Research and Development": "16.6",
"Other Expenses": "-54.2",
"Other Revenues": "59.5",
"Revenues": "59.5",
"Property, Plant and Equipment, Net": "7.85",
"Assets, Non-Current": "-1.81",
"Other Assets": "1.74",
"Goodwill": "-5.37",
"Assets, Current": "-1.96",
"Comprehensive Net Income": "58.0",
"Other Net Income": "-9.70",
"Economic Capital Ratio": "84.2"
},
"2012": {
"Liabilities, Current": "27.7",
"Liabilities": "65.1",
"Stockholders Equity": "30.6",
"ECR before LimitedLiability": "119",
"Liabilities, Non-Current": "15.4",
"Other Liabilities": "32.9",
"Assets, Current": "-2.73",
"Assets": "-3.23",
"Other Assets": "2.44",
"Assets, Non-Current": "-1.64",
"Property, Plant and Equipment, Net": "5.43",
"Goodwill": "-5.30",
"Other Expenses": "-52.3",
"Expenses": "10.3",
"Revenues": "63.6",
"Net Income": "72.5",
"Research and Development": "19.4",
"General and Administrative Expense": "37.4",
"Other Revenues": "63.6",
"Comprehensive Net Income": "72.6",
"Economic Capital Ratio": "87.0"
},
"2013": {
"Liabilities, Current": "36.1",
"Liabilities": "35.1",
"Stockholders Equity": "29.5",
"ECR before LimitedLiability": "102",
"Other Liabilities": "18.2",
"Liabilities, Non-Current": "-22.9",
"Goodwill": "-7.31",
"Assets": "1.96",
"Property, Plant and Equipment, Net": "10.5",
"Other Assets": "12.4",
"Assets, Current": "-7.17",
"General and Administrative Expense": "25.2",
"Expenses": "16.7",
"Revenues": "41.5",
"Net Income": "55.5",
"Research and Development": "13.0",
"Other Expenses": "-22.2",
"Other Revenues": "41.5",
"Other Net Income": "-3.50",
"Comprehensive Net Income": "55.4",
"Economic Capital Ratio": "61.8"
},
"2014": {
"Liabilities, Non-Current": "-12.0",
"Liabilities": "51.7",
"Stockholders Equity": "50.3",
"ECR before LimitedLiability": "111",
"Liabilities, Current": "47.8",
"Other Liabilities": "15.6",
"Assets, Current": "-9.36",
"Assets": "4.25",
"Goodwill": "-10.3",
"Other Assets": "4.38",
"Assets, Non-Current": "-1.65",
"Property, Plant and Equipment, Net": "33.6",
"Other Expenses": "-33.6",
"Expenses": "8.85",
"Revenues": "37.9",
"Net Income": "49.3",
"Research and Development": "15.1",
"General and Administrative Expense": "27.8",
"Other Revenues": "37.9",
"Comprehensive Net Income": "49.4",
"Economic Capital Ratio": "61.7"
},
"2015": {
"Other Liabilities": "24.3",
"Liabilities": "68.2",
"Stockholders Equity": "39.3",
"ECR before LimitedLiability": "109",
"Liabilities, Current": "50.4",
"Liabilities, Non-Current": "-3.00",
"Assets, Current": "-13.1",
"Assets": "-6.51",
"Other Assets": "1.58",
"Goodwill": "-10.8",
"Assets, Non-Current": "-1.31",
"Property, Plant and Equipment, Net": "27.8",
"Research and Development": "12.2",
"Expenses": "-3.97",
"Revenues": "57.9",
"Net Income": "54.2",
"General and Administrative Expense": "11.1",
"Other Expenses": "-27.4",
"Other Revenues": "57.9",
"Comprehensive Net Income": "54.7",
"Economic Capital Ratio": "62.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000768408_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "8,481",
"Assets, Non-Current": "287",
"General and Administrative Expense": "4,808",
"Goodwill": "0",
"Liabilities, Current": "2,196",
"Liabilities, Non-Current": "553",
"Other Assets": "535",
"Other Compr. Net Income": "0",
"Other Expenses": "9,941",
"Other Liabilities": "0",
"Other Net Income": "-66",
"Other Revenues": "16,827",
"Property, Plant and Equipment, Net": "4,557",
"Research and Development": "282"
},
"output_variables": {
"Liabilities": "2,749",
"Assets": "13,860",
"Expenses": "15,031",
"Revenues": "16,827",
"Stockholders Equity": "11,111",
"Net Income": "1,730",
"Comprehensive Net Income": "1,730",
"BaseVar": "24,266",
"ECR before LimitedLiability": "204%",
"Economic Capital Ratio": "238%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "11,419",
"Assets, Non-Current": "478",
"General and Administrative Expense": "6,494",
"Goodwill": "0",
"Liabilities, Current": "3,361",
"Liabilities, Non-Current": "400",
"Other Assets": "1,307",
"Other Compr. Net Income": "0",
"Other Expenses": "14,135",
"Other Liabilities": "12",
"Other Net Income": "-50",
"Other Revenues": "24,631",
"Property, Plant and Equipment, Net": "5,834",
"Research and Development": "320"
},
"output_variables": {
"Liabilities": "3,773",
"Assets": "19,038",
"Expenses": "20,949",
"Revenues": "24,631",
"Stockholders Equity": "15,265",
"Net Income": "3,632",
"Comprehensive Net Income": "3,632",
"BaseVar": "34,220",
"ECR before LimitedLiability": "215%",
"Economic Capital Ratio": "245%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "12,191",
"Assets, Non-Current": "772",
"General and Administrative Expense": "8,355",
"Goodwill": "0",
"Liabilities, Current": "2,885",
"Liabilities, Non-Current": "5,454",
"Other Assets": "6,789",
"Other Compr. Net Income": "0",
"Other Expenses": "14,648",
"Other Liabilities": "21",
"Other Net Income": "-111",
"Other Revenues": "27,581",
"Property, Plant and Equipment, Net": "8,835",
"Research and Development": "258"
},
"output_variables": {
"Liabilities": "8,360",
"Assets": "28,587",
"Expenses": "23,261",
"Revenues": "27,581",
"Stockholders Equity": "20,227",
"Net Income": "4,209",
"Comprehensive Net Income": "4,209",
"BaseVar": "43,950",
"ECR before LimitedLiability": "173%",
"Economic Capital Ratio": "216%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "12,584",
"Assets, Non-Current": "902",
"General and Administrative Expense": "10,884",
"Goodwill": "0",
"Liabilities, Current": "4,155",
"Liabilities, Non-Current": "5,263",
"Other Assets": "1,737",
"Other Compr. Net Income": "0",
"Other Expenses": "17,127",
"Other Liabilities": "8.0",
"Other Net Income": "-118",
"Other Revenues": "28,178",
"Property, Plant and Equipment, Net": "14,754",
"Research and Development": "469"
},
"output_variables": {
"Liabilities": "9,426",
"Assets": "29,977",
"Expenses": "28,480",
"Revenues": "28,178",
"Stockholders Equity": "20,551",
"Net Income": "-420",
"Comprehensive Net Income": "-420",
"BaseVar": "48,090",
"ECR before LimitedLiability": "141%",
"Economic Capital Ratio": "195%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "11,794",
"Assets, Non-Current": "846",
"General and Administrative Expense": "13,531",
"Goodwill": "0",
"Liabilities, Current": "4,315",
"Liabilities, Non-Current": "5,109",
"Other Assets": "3,521",
"Other Compr. Net Income": "0",
"Other Expenses": "19,692",
"Other Liabilities": "8.0",
"Other Net Income": "-93",
"Other Revenues": "33,809",
"Property, Plant and Equipment, Net": "14,754",
"Research and Development": "517"
},
"output_variables": {
"Liabilities": "9,432",
"Assets": "30,915",
"Expenses": "33,740",
"Revenues": "33,809",
"Stockholders Equity": "21,483",
"Net Income": "-24",
"Comprehensive Net Income": "-24",
"BaseVar": "53,994",
"ECR before LimitedLiability": "146%",
"Economic Capital Ratio": "199%"
}
}
},
"top_rated": false,
"trend": -1.0,
"value": 1.9854946097737725,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000768408.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000768408.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000768408.svg"
},
{
"company_id": "0000744218",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000744218.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000744218.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000744218.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000744218_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000744218_main_keyfigs.svg",
"name": "Celldex Therapeutics Inc",
"rank": 16,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000744218.svg",
"report_text": "The relative strengths and weaknesses of Celldex Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Celldex Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 111% points.The greatest weakness of Celldex Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 27% points.
The company's Economic Capital Ratio, given in the ranking table, is 195%, being 59% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000744218_2016_Celldex_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "9.86",
"Liabilities": "-3.63",
"Stockholders Equity": "67.0",
"ECR before LimitedLiability": "60.1",
"Liabilities, Non-Current": "-3.93",
"Other Liabilities": "-9.89",
"Property, Plant and Equipment, Net": "0.343",
"Assets": "67.5",
"Assets, Non-Current": "-3.70",
"Goodwill": "40.9",
"Assets, Current": "26.4",
"General and Administrative Expense": "37.3",
"Expenses": "10.4",
"Revenues": "-30.9",
"Net Income": "-25.8",
"Research and Development": "-26.0",
"Other Expenses": "3.29",
"Other Revenues": "-30.9",
"Comprehensive Net Income": "-25.9",
"Other Net Income": "-4.47",
"Economic Capital Ratio": "-1.92"
},
"2012": {
"Liabilities, Current": "1.74",
"Liabilities": "4.57",
"Stockholders Equity": "78.6",
"ECR before LimitedLiability": "37.3",
"Liabilities, Non-Current": "-2.06",
"Other Liabilities": "4.88",
"Assets, Current": "49.6",
"Assets": "78.6",
"Assets, Non-Current": "-3.55",
"Property, Plant and Equipment, Net": "-3.08",
"Goodwill": "21.4",
"Other Expenses": "9.36",
"Expenses": "8.36",
"Revenues": "-32.0",
"Net Income": "-24.8",
"Research and Development": "-30.8",
"General and Administrative Expense": "33.5",
"Other Revenues": "-32.0",
"Other Net Income": "-0.401",
"Comprehensive Net Income": "-25.1",
"Economic Capital Ratio": "4.79"
},
"2013": {
"Liabilities, Current": "17.3",
"Liabilities": "31.9",
"Stockholders Equity": "133",
"ECR before LimitedLiability": "114",
"Other Liabilities": "10.4",
"Liabilities, Non-Current": "6.72",
"Goodwill": "1.26",
"Assets": "65.4",
"Assets, Non-Current": "-1.30",
"Property, Plant and Equipment, Net": "-1.50",
"Assets, Current": "79.0",
"General and Administrative Expense": "23.7",
"Expenses": "22.1",
"Revenues": "-30.5",
"Net Income": "-8.50",
"Research and Development": "-17.4",
"Other Expenses": "15.1",
"Other Revenues": "-30.5",
"Other Net Income": "-1.65",
"Comprehensive Net Income": "-8.59",
"Economic Capital Ratio": "73.7"
},
"2014": {
"Liabilities, Non-Current": "3.49",
"Liabilities": "35.9",
"Stockholders Equity": "99.6",
"ECR before LimitedLiability": "96.9",
"Liabilities, Current": "24.3",
"Other Liabilities": "9.38",
"Assets, Current": "96.6",
"Assets": "96.4",
"Goodwill": "3.01",
"Assets, Non-Current": "-1.97",
"Property, Plant and Equipment, Net": "-2.60",
"Other Expenses": "14.6",
"Expenses": "4.42",
"Revenues": "-33.2",
"Net Income": "-27.9",
"Research and Development": "-38.6",
"General and Administrative Expense": "30.8",
"Other Revenues": "-33.2",
"Comprehensive Net Income": "-26.9",
"Other Compr. Net Income": "1.06",
"Economic Capital Ratio": "47.5"
},
"2015": {
"Other Liabilities": "12.8",
"Liabilities": "36.3",
"Stockholders Equity": "111",
"ECR before LimitedLiability": "105",
"Liabilities, Current": "21.4",
"Liabilities, Non-Current": "3.92",
"Assets, Current": "110",
"Assets": "78.5",
"Other Assets": "-3.01",
"Assets, Non-Current": "-1.32",
"Property, Plant and Equipment, Net": "-2.77",
"Research and Development": "-27.3",
"Expenses": "8.22",
"Revenues": "-26.9",
"Net Income": "-18.0",
"General and Administrative Expense": "16.9",
"Other Expenses": "18.9",
"Other Revenues": "-26.9",
"Comprehensive Net Income": "-17.5",
"Other Net Income": "0.613",
"Economic Capital Ratio": "58.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000744218_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "54,684",
"Assets, Non-Current": "329",
"General and Administrative Expense": "9,243",
"Goodwill": "33,888",
"Liabilities, Current": "14,298",
"Liabilities, Non-Current": "5,966",
"Other Assets": "0",
"Other Compr. Net Income": "-99",
"Other Expenses": "12,778",
"Other Liabilities": "9,008",
"Other Net Income": "396",
"Other Revenues": "9,265",
"Property, Plant and Equipment, Net": "9,093",
"Research and Development": "32,439"
},
"output_variables": {
"Liabilities": "29,272",
"Assets": "97,994",
"Expenses": "54,460",
"Revenues": "9,265",
"Stockholders Equity": "68,722",
"Net Income": "-44,799",
"Comprehensive Net Income": "-44,848",
"BaseVar": "95,743",
"ECR before LimitedLiability": "77%",
"Economic Capital Ratio": "152%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "85,114",
"Assets, Non-Current": "424",
"General and Administrative Expense": "10,016",
"Goodwill": "32,798",
"Liabilities, Current": "17,685",
"Liabilities, Non-Current": "6,336",
"Other Assets": "0",
"Other Compr. Net Income": "-953",
"Other Expenses": "11,865",
"Other Liabilities": "5,746",
"Other Net Income": "0",
"Other Revenues": "11,202",
"Property, Plant and Equipment, Net": "7,205",
"Research and Development": "47,398"
},
"output_variables": {
"Liabilities": "29,767",
"Assets": "125,541",
"Expenses": "69,279",
"Revenues": "11,202",
"Stockholders Equity": "95,774",
"Net Income": "-58,077",
"Comprehensive Net Income": "-58,554",
"BaseVar": "118,371",
"ECR before LimitedLiability": "94%",
"Economic Capital Ratio": "163%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "305,189",
"Assets, Non-Current": "148",
"General and Administrative Expense": "14,805",
"Goodwill": "31,785",
"Liabilities, Current": "20,350",
"Liabilities, Non-Current": "6,950",
"Other Assets": "0",
"Other Compr. Net Income": "-185",
"Other Expenses": "3,347",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "4,111",
"Property, Plant and Equipment, Net": "9,973",
"Research and Development": "67,401"
},
"output_variables": {
"Liabilities": "27,300",
"Assets": "347,095",
"Expenses": "85,553",
"Revenues": "4,111",
"Stockholders Equity": "319,795",
"Net Income": "-81,442",
"Comprehensive Net Income": "-81,534",
"BaseVar": "232,122",
"ECR before LimitedLiability": "190%",
"Economic Capital Ratio": "228%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "204,985",
"Assets, Non-Current": "1,722",
"General and Administrative Expense": "20,622",
"Goodwill": "30,772",
"Liabilities, Current": "24,491",
"Liabilities, Non-Current": "11,863",
"Other Assets": "0",
"Other Compr. Net Income": "4,272",
"Other Expenses": "1,013",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "3,586",
"Property, Plant and Equipment, Net": "10,535",
"Research and Development": "104,381"
},
"output_variables": {
"Liabilities": "36,354",
"Assets": "248,014",
"Expenses": "126,016",
"Revenues": "3,586",
"Stockholders Equity": "211,660",
"Net Income": "-122,430",
"Comprehensive Net Income": "-120,294",
"BaseVar": "209,121",
"ECR before LimitedLiability": "119%",
"Economic Capital Ratio": "181%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "294,936",
"Assets, Non-Current": "1,428",
"General and Administrative Expense": "33,837",
"Goodwill": "29,759",
"Liabilities, Current": "30,240",
"Liabilities, Non-Current": "17,239",
"Other Assets": "0",
"Other Compr. Net Income": "2,061",
"Other Expenses": "1,013",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "5,480",
"Property, Plant and Equipment, Net": "11,461",
"Research and Development": "100,171"
},
"output_variables": {
"Liabilities": "47,479",
"Assets": "337,584",
"Expenses": "135,021",
"Revenues": "5,480",
"Stockholders Equity": "290,105",
"Net Income": "-129,541",
"Comprehensive Net Income": "-128,510",
"BaseVar": "263,812",
"ECR before LimitedLiability": "140%",
"Economic Capital Ratio": "195%"
}
}
},
"top_rated": false,
"trend": 1.0,
"value": 1.94537397258884,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000744218.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000744218.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000744218.svg"
},
{
"company_id": "0000722830",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000722830.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000722830.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000722830.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000722830_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000722830_main_keyfigs.svg",
"name": "Immunomedics INC",
"rank": 17,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000722830.svg",
"report_text": "The relative strengths and weaknesses of Immunomedics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Immunomedics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 118% points.The greatest weakness of Immunomedics INC is the variable Research and Development, reducing the Economic Capital Ratio by 39% points.
The company's Economic Capital Ratio, given in the ranking table, is 192%, being 56% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000722830_2016_Immunomedics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "23.4",
"Liabilities": "46.6",
"Stockholders Equity": "78.3",
"ECR before LimitedLiability": "91.2",
"Liabilities, Non-Current": "12.7",
"Other Liabilities": "13.3",
"Property, Plant and Equipment, Net": "-1.99",
"Assets": "22.4",
"Assets, Non-Current": "-4.24",
"Other Assets": "1.72",
"Goodwill": "-9.02",
"Assets, Current": "52.4",
"General and Administrative Expense": "38.0",
"Expenses": "-11.1",
"Net Income": "-15.9",
"Other Net Income": "-5.26",
"Research and Development": "-71.3",
"Other Expenses": "24.3",
"Comprehensive Net Income": "-15.6",
"Other Revenues": "0.420",
"Economic Capital Ratio": "29.2"
},
"2012": {
"Liabilities, Current": "21.2",
"Liabilities": "56.5",
"Stockholders Equity": "60.6",
"ECR before LimitedLiability": "114",
"Liabilities, Non-Current": "16.7",
"Other Liabilities": "27.1",
"Assets, Current": "22.6",
"Assets": "6.17",
"Assets, Non-Current": "-2.24",
"Property, Plant and Equipment, Net": "-2.57",
"Goodwill": "-4.98",
"Other Expenses": "29.0",
"Expenses": "12.6",
"Revenues": "32.5",
"Net Income": "44.0",
"Research and Development": "-66.7",
"General and Administrative Expense": "41.8",
"Other Revenues": "32.5",
"Other Net Income": "-0.600",
"Comprehensive Net Income": "43.8",
"Economic Capital Ratio": "81.5"
},
"2013": {
"Liabilities, Current": "18.6",
"Liabilities": "48.3",
"Stockholders Equity": "79.8",
"ECR before LimitedLiability": "96.7",
"Other Liabilities": "16.0",
"Liabilities, Non-Current": "18.6",
"Goodwill": "-7.01",
"Assets": "20.0",
"Assets, Non-Current": "-2.77",
"Property, Plant and Equipment, Net": "-3.64",
"Assets, Current": "56.1",
"General and Administrative Expense": "32.0",
"Expenses": "1.77",
"Revenues": "-40.2",
"Net Income": "7.10",
"Research and Development": "-60.1",
"Other Expenses": "26.2",
"Other Revenues": "-40.2",
"Other Net Income": "44.6",
"Comprehensive Net Income": "7.24",
"Economic Capital Ratio": "56.6"
},
"2014": {
"Liabilities, Non-Current": "19.0",
"Liabilities": "57.9",
"Stockholders Equity": "72.6",
"ECR before LimitedLiability": "63.9",
"Liabilities, Current": "29.4",
"Other Liabilities": "12.6",
"Assets, Current": "82.8",
"Assets": "63.5",
"Goodwill": "-14.4",
"Assets, Non-Current": "-4.92",
"Property, Plant and Equipment, Net": "-7.14",
"Other Expenses": "19.0",
"Expenses": "-25.0",
"Revenues": "-27.2",
"Net Income": "-49.1",
"Research and Development": "-70.3",
"General and Administrative Expense": "36.2",
"Other Revenues": "-27.2",
"Other Net Income": "1.54",
"Comprehensive Net Income": "-48.8",
"Economic Capital Ratio": "14.5"
},
"2015": {
"Other Liabilities": "14.0",
"Liabilities": "47.0",
"Stockholders Equity": "109",
"ECR before LimitedLiability": "102",
"Liabilities, Current": "19.5",
"Liabilities, Non-Current": "16.9",
"Assets, Current": "118",
"Assets": "73.1",
"Other Assets": "-3.40",
"Goodwill": "-6.95",
"Assets, Non-Current": "-1.83",
"Property, Plant and Equipment, Net": "-4.29",
"Other Revenues": "-25.1",
"Revenues": "-25.1",
"Net Income": "-24.9",
"Other Expenses": "18.6",
"Comprehensive Net Income": "-24.8",
"Research and Development": "-39.2",
"General and Administrative Expense": "20.6",
"Other Net Income": "0.676",
"Economic Capital Ratio": "56.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000722830_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "30,258",
"Assets, Non-Current": "30",
"General and Administrative Expense": "7,944",
"Goodwill": "0",
"Liabilities, Current": "5,548",
"Liabilities, Non-Current": "0",
"Other Assets": "581",
"Other Compr. Net Income": "227",
"Other Expenses": "529",
"Other Liabilities": "0",
"Other Net Income": "480",
"Other Revenues": "18,117",
"Property, Plant and Equipment, Net": "3,456",
"Research and Development": "25,369"
},
"output_variables": {
"Liabilities": "5,548",
"Assets": "34,325",
"Expenses": "33,842",
"Revenues": "18,117",
"Stockholders Equity": "28,776",
"Net Income": "-15,244",
"Comprehensive Net Income": "-15,131",
"BaseVar": "46,270",
"ECR before LimitedLiability": "122%",
"Economic Capital Ratio": "183%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "35,479",
"Assets, Non-Current": "30",
"General and Administrative Expense": "6,609",
"Goodwill": "0",
"Liabilities, Current": "5,595",
"Liabilities, Non-Current": "0",
"Other Assets": "598",
"Other Compr. Net Income": "-201",
"Other Expenses": "637",
"Other Liabilities": "0",
"Other Net Income": "13",
"Other Revenues": "32,753",
"Property, Plant and Equipment, Net": "2,528",
"Research and Development": "24,824"
},
"output_variables": {
"Liabilities": "5,595",
"Assets": "38,635",
"Expenses": "32,069",
"Revenues": "32,753",
"Stockholders Equity": "33,040",
"Net Income": "696",
"Comprehensive Net Income": "596",
"BaseVar": "54,633",
"ECR before LimitedLiability": "207%",
"Economic Capital Ratio": "240%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "45,216",
"Assets, Non-Current": "30",
"General and Administrative Expense": "6,981",
"Goodwill": "0",
"Liabilities, Current": "6,731",
"Liabilities, Non-Current": "0",
"Other Assets": "595",
"Other Compr. Net Income": "186",
"Other Expenses": "437",
"Other Liabilities": "0",
"Other Net Income": "19,340",
"Other Revenues": "4,973",
"Property, Plant and Equipment, Net": "2,087",
"Research and Development": "28,381"
},
"output_variables": {
"Liabilities": "6,731",
"Assets": "47,927",
"Expenses": "35,799",
"Revenues": "4,973",
"Stockholders Equity": "41,196",
"Net Income": "-11,486",
"Comprehensive Net Income": "-11,393",
"BaseVar": "57,478",
"ECR before LimitedLiability": "165%",
"Economic Capital Ratio": "211%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "45,385",
"Assets, Non-Current": "30",
"General and Administrative Expense": "9,414",
"Goodwill": "0",
"Liabilities, Current": "7,127",
"Liabilities, Non-Current": "0",
"Other Assets": "176",
"Other Compr. Net Income": "205",
"Other Expenses": "1,536",
"Other Liabilities": "0",
"Other Net Income": "0.94",
"Other Revenues": "9,098",
"Property, Plant and Equipment, Net": "1,895",
"Research and Development": "33,680"
},
"output_variables": {
"Liabilities": "7,127",
"Assets": "47,486",
"Expenses": "44,630",
"Revenues": "9,098",
"Stockholders Equity": "40,360",
"Net Income": "-35,531",
"Comprehensive Net Income": "-35,428",
"BaseVar": "54,273",
"ECR before LimitedLiability": "73%",
"Economic Capital Ratio": "148%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "103,487",
"Assets, Non-Current": "30",
"General and Administrative Expense": "9,872",
"Goodwill": "0",
"Liabilities, Current": "12,080",
"Liabilities, Non-Current": "0",
"Other Assets": "21",
"Other Compr. Net Income": "-301",
"Other Expenses": "2,414",
"Other Liabilities": "0",
"Other Net Income": "-1.2",
"Other Revenues": "5,899",
"Property, Plant and Equipment, Net": "2,242",
"Research and Development": "41,736"
},
"output_variables": {
"Liabilities": "12,080",
"Assets": "105,780",
"Expenses": "54,022",
"Revenues": "5,899",
"Stockholders Equity": "93,700",
"Net Income": "-48,124",
"Comprehensive Net Income": "-48,275",
"BaseVar": "89,041",
"ECR before LimitedLiability": "136%",
"Economic Capital Ratio": "192%"
}
}
},
"top_rated": false,
"trend": 4.0,
"value": 1.9204968951650403,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000722830.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000722830.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000722830.svg"
},
{
"company_id": "0001056358",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001056358.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001056358.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001056358.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001056358_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001056358_main_keyfigs.svg",
"name": "Mannatech INC",
"rank": 18,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001056358.svg",
"report_text": "The relative strengths and weaknesses of Mannatech INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Mannatech INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 113% points.The greatest weakness of Mannatech INC is the variable Other Expenses, reducing the Economic Capital Ratio by 74% points.
The company's Economic Capital Ratio, given in the ranking table, is 181%, being 45% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001056358_2016_Mannatech_INC.pdf",
"shrinked_graph_json": {
"2009": {
"Liabilities, Non-Current": "-3.85",
"Liabilities": "-9.05",
"Stockholders Equity": "-140",
"ECR before LimitedLiability": "-70.0",
"Other Liabilities": "-5.76",
"Property, Plant and Equipment, Net": "-17.3",
"Assets": "-58.1",
"Other Assets": "9.04",
"Assets, Current": "-42.8",
"Assets, Non-Current": "-13.3",
"Goodwill": "-14.0",
"General and Administrative Expense": "3.92",
"Expenses": "-62.6",
"Revenues": "34.1",
"Net Income": "-34.3",
"Other Expenses": "-72.3",
"Research and Development": "7.47",
"Other Revenues": "34.1",
"Comprehensive Net Income": "-34.2",
"Other Net Income": "1.13",
"Economic Capital Ratio": "-70.7"
},
"2010": {
"Liabilities": "65.1",
"Stockholders Equity": "-124",
"ECR before LimitedLiability": "-29.4",
"Liabilities, Current": "11.6",
"Liabilities, Non-Current": "59.2",
"Goodwill": "-32.3",
"Assets": "-66.0",
"Property, Plant and Equipment, Net": "-17.8",
"Assets, Current": "-42.4",
"Assets, Non-Current": "-19.2",
"Other Assets": "15.5",
"Other Expenses": "-110",
"Expenses": "-90.9",
"Revenues": "69.9",
"Net Income": "2.46",
"General and Administrative Expense": "0.961",
"Research and Development": "20.1",
"Other Revenues": "69.9",
"Other Net Income": "7.69",
"Comprehensive Net Income": "2.63",
"Economic Capital Ratio": "-27.4"
},
"2011": {
"Liabilities, Current": "21.5",
"Liabilities": "26.5",
"Stockholders Equity": "-120",
"ECR before LimitedLiability": "12.3",
"Liabilities, Non-Current": "15.7",
"Other Liabilities": "19.3",
"Property, Plant and Equipment, Net": "-28.7",
"Assets": "-95.4",
"Assets, Non-Current": "-15.7",
"Goodwill": "-40.1",
"Assets, Current": "-73.9",
"General and Administrative Expense": "19.8",
"Expenses": "-80.7",
"Revenues": "66.1",
"Net Income": "25.7",
"Research and Development": "21.0",
"Other Expenses": "-141",
"Other Revenues": "66.1",
"Comprehensive Net Income": "25.8",
"Other Net Income": "-23.1",
"Economic Capital Ratio": "-49.7"
},
"2012": {
"Liabilities, Current": "31.4",
"Liabilities": "63.0",
"Stockholders Equity": "-131",
"ECR before LimitedLiability": "19.9",
"Liabilities, Non-Current": "23.7",
"Other Liabilities": "47.8",
"Assets, Current": "-53.5",
"Assets": "-73.2",
"Other Assets": "8.93",
"Assets, Non-Current": "-10.5",
"Property, Plant and Equipment, Net": "-24.7",
"Goodwill": "-31.3",
"Other Expenses": "-119",
"Expenses": "-64.4",
"Revenues": "99.2",
"Net Income": "69.9",
"Research and Development": "49.9",
"General and Administrative Expense": "15.8",
"Other Revenues": "99.2",
"Comprehensive Net Income": "69.9",
"Economic Capital Ratio": "-12.6"
},
"2013": {
"Liabilities, Current": "28.6",
"Liabilities": "69.1",
"Stockholders Equity": "-101",
"ECR before LimitedLiability": "38.7",
"Other Liabilities": "33.1",
"Liabilities, Non-Current": "34.3",
"Goodwill": "-27.6",
"Assets": "-63.4",
"Assets, Non-Current": "-7.35",
"Property, Plant and Equipment, Net": "-20.9",
"Assets, Current": "-41.2",
"General and Administrative Expense": "12.7",
"Expenses": "-49.9",
"Revenues": "98.1",
"Net Income": "73.4",
"Research and Development": "35.2",
"Other Expenses": "-90.9",
"Other Revenues": "98.1",
"Other Net Income": "-10.2",
"Comprehensive Net Income": "73.4",
"Economic Capital Ratio": "-1.46"
},
"2014": {
"Liabilities, Non-Current": "37.3",
"Liabilities": "82.2",
"Stockholders Equity": "-34.5",
"ECR before LimitedLiability": "81.1",
"Liabilities, Current": "60.6",
"Other Liabilities": "26.3",
"Assets, Current": "-31.3",
"Assets": "-49.0",
"Goodwill": "-24.3",
"Other Assets": "22.4",
"Assets, Non-Current": "-5.37",
"Property, Plant and Equipment, Net": "-20.0",
"Other Expenses": "-92.9",
"Expenses": "-34.1",
"Revenues": "99.1",
"Net Income": "85.9",
"Research and Development": "36.0",
"General and Administrative Expense": "28.8",
"Other Revenues": "99.1",
"Comprehensive Net Income": "86.0",
"Economic Capital Ratio": "31.6"
},
"2015": {
"Other Liabilities": "35.8",
"Liabilities": "98.1",
"Stockholders Equity": "-29.5",
"ECR before LimitedLiability": "91.3",
"Liabilities, Current": "64.6",
"Liabilities, Non-Current": "43.2",
"Assets, Current": "-24.4",
"Assets": "-44.4",
"Other Assets": "3.61",
"Goodwill": "-20.6",
"Property, Plant and Equipment, Net": "-17.7",
"Research and Development": "25.2",
"Expenses": "-45.3",
"Revenues": "113",
"Net Income": "97.9",
"General and Administrative Expense": "3.64",
"Other Expenses": "-74.5",
"Other Revenues": "113",
"Comprehensive Net Income": "98.1",
"Other Net Income": "-3.27",
"Economic Capital Ratio": "45.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001056358_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "64,485",
"Assets, Non-Current": "2,503",
"General and Administrative Expense": "116,810",
"Goodwill": "0",
"Liabilities, Current": "42,679",
"Liabilities, Non-Current": "3,348",
"Other Assets": "8,170",
"Other Compr. Net Income": "0",
"Other Expenses": "191,782",
"Other Liabilities": "4,991",
"Other Net Income": "1,519",
"Other Revenues": "289,705",
"Property, Plant and Equipment, Net": "27,144",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "51,018",
"Assets": "102,302",
"Expenses": "308,592",
"Revenues": "289,705",
"Stockholders Equity": "51,284",
"Net Income": "-17,368",
"Comprehensive Net Income": "-17,368",
"BaseVar": "376,568",
"ECR before LimitedLiability": "69%",
"Economic Capital Ratio": "145%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "55,215",
"Assets, Non-Current": "3,054",
"General and Administrative Expense": "95,411",
"Goodwill": "0",
"Liabilities, Current": "32,240",
"Liabilities, Non-Current": "4,996",
"Other Assets": "4,705",
"Other Compr. Net Income": "0",
"Other Expenses": "143,734",
"Other Liabilities": "3,107",
"Other Net Income": "441",
"Other Revenues": "228,088",
"Property, Plant and Equipment, Net": "18,449",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "40,343",
"Assets": "81,423",
"Expenses": "239,145",
"Revenues": "228,088",
"Stockholders Equity": "41,080",
"Net Income": "-10,616",
"Comprehensive Net Income": "-10,616",
"BaseVar": "294,720",
"ECR before LimitedLiability": "75%",
"Economic Capital Ratio": "150%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "41,731",
"Assets, Non-Current": "2,815",
"General and Administrative Expense": "86,118",
"Goodwill": "0",
"Liabilities, Current": "29,876",
"Liabilities, Non-Current": "5,382",
"Other Assets": "4,158",
"Other Compr. Net Income": "881",
"Other Expenses": "134,241",
"Other Liabilities": "1,359",
"Other Net Income": "-989",
"Other Revenues": "200,689",
"Property, Plant and Equipment, Net": "9,566",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "36,617",
"Assets": "58,270",
"Expenses": "220,359",
"Revenues": "200,689",
"Stockholders Equity": "21,653",
"Net Income": "-20,659",
"Comprehensive Net Income": "-20,218",
"BaseVar": "258,902",
"ECR before LimitedLiability": "20%",
"Economic Capital Ratio": "104%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "35,302",
"Assets, Non-Current": "3,187",
"General and Administrative Expense": "71,817",
"Goodwill": "0",
"Liabilities, Current": "24,221",
"Liabilities, Non-Current": "2,178",
"Other Assets": "4,246",
"Other Compr. Net Income": "-250",
"Other Expenses": "103,698",
"Other Liabilities": "940",
"Other Net Income": "680",
"Other Revenues": "173,447",
"Property, Plant and Equipment, Net": "4,825",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "27,339",
"Assets": "47,560",
"Expenses": "175,515",
"Revenues": "173,447",
"Stockholders Equity": "20,221",
"Net Income": "-1,388",
"Comprehensive Net Income": "-1,513",
"BaseVar": "212,396",
"ECR before LimitedLiability": "70%",
"Economic Capital Ratio": "146%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "43,674",
"Assets, Non-Current": "3,591",
"General and Administrative Expense": "69,855",
"Goodwill": "0",
"Liabilities, Current": "30,058",
"Liabilities, Non-Current": "2,101",
"Other Assets": "5,557",
"Other Compr. Net Income": "-66",
"Other Expenses": "102,447",
"Other Liabilities": "450",
"Other Net Income": "-1,947",
"Other Revenues": "177,423",
"Property, Plant and Equipment, Net": "3,239",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "32,609",
"Assets": "56,061",
"Expenses": "172,302",
"Revenues": "177,423",
"Stockholders Equity": "23,452",
"Net Income": "3,174",
"Comprehensive Net Income": "3,141",
"BaseVar": "220,204",
"ECR before LimitedLiability": "80%",
"Economic Capital Ratio": "153%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "49,363",
"Assets, Non-Current": "3,567",
"General and Administrative Expense": "74,543",
"Goodwill": "0",
"Liabilities, Current": "33,008",
"Liabilities, Non-Current": "2,136",
"Other Assets": "14,468",
"Other Compr. Net Income": "634",
"Other Expenses": "106,121",
"Other Liabilities": "878",
"Other Net Income": "-2,921",
"Other Revenues": "190,081",
"Property, Plant and Equipment, Net": "0",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "36,022",
"Assets": "67,398",
"Expenses": "180,664",
"Revenues": "190,081",
"Stockholders Equity": "31,376",
"Net Income": "6,496",
"Comprehensive Net Income": "6,813",
"BaseVar": "238,860",
"ECR before LimitedLiability": "96%",
"Economic Capital Ratio": "165%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "49,885",
"Assets, Non-Current": "3,759",
"General and Administrative Expense": "68,560",
"Goodwill": "0",
"Liabilities, Current": "26,379",
"Liabilities, Non-Current": "1,994",
"Other Assets": "14,998",
"Other Compr. Net Income": "795",
"Other Expenses": "101,923",
"Other Liabilities": "1,705",
"Other Net Income": "-3,945",
"Other Revenues": "180,267",
"Property, Plant and Equipment, Net": "0",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "30,078",
"Assets": "68,642",
"Expenses": "170,483",
"Revenues": "180,267",
"Stockholders Equity": "38,564",
"Net Income": "5,839",
"Comprehensive Net Income": "6,236",
"BaseVar": "227,105",
"ECR before LimitedLiability": "120%",
"Economic Capital Ratio": "181%"
}
}
},
"top_rated": false,
"trend": 0.0,
"value": 1.8123105436676885,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001056358.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001056358.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001056358.svg"
},
{
"company_id": "0001324736",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001324736.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001324736.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001324736_main_keyfigs.svg",
"name": "Hero Technologies Inc",
"rank": 19,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001324736.svg",
"report_text": "The relative strengths and weaknesses of Hero Technologies Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Hero Technologies Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 160% points.The greatest weakness of Hero Technologies Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 41% points.
The company's Economic Capital Ratio, given in the ranking table, is 176%, being 40% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001324736_2016_Hero_Technologies_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Liabilities, Current": "11.7",
"Liabilities": "-30.9",
"Stockholders Equity": "61.5",
"ECR before LimitedLiability": "70.3",
"Other Liabilities": "-60.6",
"Liabilities, Non-Current": "8.89",
"Goodwill": "-5.02",
"Assets": "78.9",
"Assets, Non-Current": "-1.96",
"Property, Plant and Equipment, Net": "-4.31",
"Other Assets": "167",
"Assets, Current": "-16.2",
"General and Administrative Expense": "25.4",
"Expenses": "42.4",
"Revenues": "-25.3",
"Net Income": "14.7",
"Research and Development": "6.23",
"Other Expenses": "9.09",
"Other Revenues": "-25.3",
"Comprehensive Net Income": "14.7",
"Economic Capital Ratio": "30.2"
},
"2015": {
"Other Liabilities": "-40.9",
"Liabilities": "-15.0",
"Stockholders Equity": "72.1",
"ECR before LimitedLiability": "86.1",
"Liabilities, Current": "9.31",
"Liabilities, Non-Current": "11.9",
"Assets, Current": "-17.3",
"Assets": "83.3",
"Other Assets": "160",
"Goodwill": "-6.09",
"Property, Plant and Equipment, Net": "-5.10",
"Research and Development": "5.81",
"Expenses": "48.1",
"Revenues": "-22.8",
"Net Income": "11.1",
"General and Administrative Expense": "23.9",
"Other Expenses": "15.6",
"Other Revenues": "-22.8",
"Comprehensive Net Income": "11.3",
"Other Net Income": "-9.64",
"Economic Capital Ratio": "40.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001324736_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "33",
"Assets, Non-Current": "0",
"General and Administrative Expense": "0",
"Goodwill": "0",
"Liabilities, Current": "1,177",
"Liabilities, Non-Current": "0",
"Other Assets": "17,186",
"Other Compr. Net Income": "6.5",
"Other Expenses": "829",
"Other Liabilities": "4,992",
"Other Net Income": "286",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "0",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "6,170",
"Assets": "17,219",
"Expenses": "829",
"Revenues": "0",
"Stockholders Equity": "11,049",
"Net Income": "-542",
"Comprehensive Net Income": "-539",
"BaseVar": "12,255",
"ECR before LimitedLiability": "125%",
"Economic Capital Ratio": "185%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "27",
"Assets, Non-Current": "0",
"General and Administrative Expense": "0",
"Goodwill": "0",
"Liabilities, Current": "2,043",
"Liabilities, Non-Current": "0",
"Other Assets": "16,360",
"Other Compr. Net Income": "3.7",
"Other Expenses": "38",
"Other Liabilities": "3,939",
"Other Net Income": "-1,683",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "0",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "5,982",
"Assets": "16,387",
"Expenses": "38",
"Revenues": "0",
"Stockholders Equity": "10,405",
"Net Income": "-1,721",
"Comprehensive Net Income": "-1,719",
"BaseVar": "12,047",
"ECR before LimitedLiability": "112%",
"Economic Capital Ratio": "176%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.760990718344464,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001324736.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001324736.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001324736.svg"
},
{
"company_id": "0000009326",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000009326.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000009326.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000009326.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000009326_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000009326_main_keyfigs.svg",
"name": "Balchem CORP",
"rank": 20,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000009326.svg",
"report_text": "The relative strengths and weaknesses of Balchem CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Balchem CORP compared to the market average is the variable Goodwill, increasing the Economic Capital Ratio by 55% points.The greatest weakness of Balchem CORP is the variable Other Liabilities, reducing the Economic Capital Ratio by 62% points.
The company's Economic Capital Ratio, given in the ranking table, is 173%, being 37% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000009326_2016_Balchem_CORP.pdf",
"shrinked_graph_json": {
"2012": {
"Liabilities, Current": "39.3",
"Liabilities": "70.0",
"Stockholders Equity": "61.8",
"ECR before LimitedLiability": "134",
"Liabilities, Non-Current": "19.9",
"Other Liabilities": "24.1",
"Assets, Current": "3.11",
"Assets": "2.38",
"Assets, Non-Current": "-1.45",
"Property, Plant and Equipment, Net": "0.767",
"Goodwill": "0.209",
"Other Expenses": "27.0",
"Expenses": "15.7",
"Revenues": "48.0",
"Net Income": "61.6",
"Research and Development": "18.3",
"General and Administrative Expense": "-32.2",
"Other Revenues": "48.0",
"Other Net Income": "-0.697",
"Comprehensive Net Income": "61.7",
"Economic Capital Ratio": "102"
},
"2013": {
"Liabilities, Current": "44.6",
"Liabilities": "74.2",
"Stockholders Equity": "71.5",
"ECR before LimitedLiability": "146",
"Other Liabilities": "16.4",
"Liabilities, Non-Current": "27.4",
"Goodwill": "-0.644",
"Assets": "3.47",
"Assets, Non-Current": "-1.24",
"Other Assets": "-0.777",
"Assets, Current": "6.39",
"General and Administrative Expense": "-30.5",
"Expenses": "14.5",
"Revenues": "47.8",
"Net Income": "57.8",
"Research and Development": "14.8",
"Other Expenses": "27.9",
"Other Revenues": "47.8",
"Other Net Income": "-3.56",
"Comprehensive Net Income": "57.9",
"Economic Capital Ratio": "106"
},
"2014": {
"Liabilities, Non-Current": "16.9",
"Liabilities": "-5.56",
"Stockholders Equity": "21.9",
"ECR before LimitedLiability": "75.4",
"Liabilities, Current": "36.8",
"Other Liabilities": "-76.0",
"Assets, Current": "-20.0",
"Assets": "20.3",
"Goodwill": "70.7",
"Assets, Non-Current": "-3.54",
"Property, Plant and Equipment, Net": "3.19",
"Other Expenses": "16.5",
"Expenses": "32.0",
"Revenues": "13.1",
"Net Income": "48.9",
"Research and Development": "12.9",
"General and Administrative Expense": "1.39",
"Other Revenues": "13.1",
"Other Net Income": "1.31",
"Comprehensive Net Income": "48.7",
"Economic Capital Ratio": "26.0"
},
"2015": {
"Other Liabilities": "-61.5",
"Liabilities": "8.99",
"Stockholders Equity": "27.7",
"ECR before LimitedLiability": "82.6",
"Liabilities, Current": "37.0",
"Liabilities, Non-Current": "19.7",
"Assets, Current": "-16.3",
"Assets": "13.8",
"Other Assets": "-5.07",
"Goodwill": "55.2",
"Assets, Non-Current": "-2.35",
"Property, Plant and Equipment, Net": "4.85",
"Research and Development": "9.27",
"Expenses": "23.7",
"Revenues": "19.7",
"Net Income": "46.6",
"General and Administrative Expense": "-8.86",
"Other Expenses": "23.5",
"Other Revenues": "19.7",
"Comprehensive Net Income": "46.8",
"Economic Capital Ratio": "36.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000009326_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "211,909",
"Assets, Non-Current": "538",
"General and Administrative Expense": "247,194",
"Goodwill": "47,373",
"Liabilities, Current": "30,234",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "179",
"Other Expenses": "19,849",
"Other Liabilities": "9,299",
"Other Net Income": "77",
"Other Revenues": "310,393",
"Property, Plant and Equipment, Net": "52,725",
"Research and Development": "3,422"
},
"output_variables": {
"Liabilities": "39,533",
"Assets": "312,545",
"Expenses": "270,465",
"Revenues": "310,393",
"Stockholders Equity": "273,012",
"Net Income": "40,005",
"Comprehensive Net Income": "40,094",
"BaseVar": "466,596",
"ECR before LimitedLiability": "235%",
"Economic Capital Ratio": "260%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "277,774",
"Assets, Non-Current": "541",
"General and Administrative Expense": "267,949",
"Goodwill": "43,641",
"Liabilities, Current": "35,753",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "957",
"Other Expenses": "20,968",
"Other Liabilities": "9,761",
"Other Net Income": "240",
"Other Revenues": "337,173",
"Property, Plant and Equipment, Net": "54,916",
"Research and Development": "3,622"
},
"output_variables": {
"Liabilities": "45,514",
"Assets": "376,872",
"Expenses": "292,539",
"Revenues": "337,173",
"Stockholders Equity": "331,358",
"Net Income": "44,874",
"Comprehensive Net Income": "45,352",
"BaseVar": "526,648",
"ECR before LimitedLiability": "236%",
"Economic Capital Ratio": "261%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "181,302",
"Assets, Non-Current": "4,341",
"General and Administrative Expense": "454,430",
"Goodwill": "544,040",
"Liabilities, Current": "95,522",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "-2,849",
"Other Expenses": "29,371",
"Other Liabilities": "373,851",
"Other Net Income": "54",
"Other Revenues": "541,383",
"Property, Plant and Equipment, Net": "131,588",
"Research and Development": "4,810"
},
"output_variables": {
"Liabilities": "469,373",
"Assets": "861,271",
"Expenses": "488,611",
"Revenues": "541,383",
"Stockholders Equity": "391,898",
"Net Income": "52,826",
"Comprehensive Net Income": "51,402",
"BaseVar": "1,181,770",
"ECR before LimitedLiability": "88%",
"Economic Capital Ratio": "160%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "198,829",
"Assets, Non-Current": "5,062",
"General and Administrative Expense": "452,546",
"Goodwill": "518,817",
"Liabilities, Current": "81,120",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "-2,463",
"Other Expenses": "33,934",
"Other Liabilities": "336,398",
"Other Net Income": "-300",
"Other Revenues": "552,492",
"Property, Plant and Equipment, Net": "158,515",
"Research and Development": "5,990"
},
"output_variables": {
"Liabilities": "417,518",
"Assets": "881,223",
"Expenses": "492,470",
"Revenues": "552,492",
"Stockholders Equity": "463,705",
"Net Income": "59,722",
"Comprehensive Net Income": "58,490",
"BaseVar": "1,173,233",
"ECR before LimitedLiability": "107%",
"Economic Capital Ratio": "173%"
}
}
},
"top_rated": false,
"trend": -1.0,
"value": 1.725055483073024,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000009326.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000009326.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000009326.svg"
},
{
"company_id": "0001374328",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001374328.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001374328.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001374328.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001374328_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001374328_main_keyfigs.svg",
"name": "Fitlife Brands INC",
"rank": 21,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001374328.svg",
"report_text": "The relative strengths and weaknesses of Fitlife Brands INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Fitlife Brands INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 50% points.The greatest weakness of Fitlife Brands INC is the variable Other Expenses, reducing the Economic Capital Ratio by 29% points.
The company's Economic Capital Ratio, given in the ranking table, is 169%, being 33% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001374328_2016_Fitlife_Brands_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "53.4",
"Liabilities": "95.2",
"Stockholders Equity": "-40.7",
"ECR before LimitedLiability": "108",
"Liabilities, Non-Current": "25.7",
"Other Liabilities": "27.0",
"Property, Plant and Equipment, Net": "-14.6",
"Assets": "-33.5",
"Assets, Non-Current": "-6.95",
"Goodwill": "2.56",
"Assets, Current": "-23.4",
"General and Administrative Expense": "53.1",
"Expenses": "-37.8",
"Revenues": "118",
"Net Income": "86.8",
"Research and Development": "30.1",
"Other Expenses": "-133",
"Other Revenues": "118",
"Comprehensive Net Income": "86.7",
"Other Net Income": "-11.4",
"Economic Capital Ratio": "45.6"
},
"2012": {
"Liabilities, Current": "46.1",
"Liabilities": "100",
"Stockholders Equity": "-33.4",
"ECR before LimitedLiability": "113",
"Liabilities, Non-Current": "29.3",
"Other Liabilities": "46.3",
"Assets, Current": "-8.09",
"Assets": "-18.3",
"Assets, Non-Current": "-4.12",
"Property, Plant and Equipment, Net": "-8.41",
"Goodwill": "-3.90",
"Other Expenses": "-134",
"Expenses": "-26.0",
"Revenues": "142",
"Net Income": "109",
"Research and Development": "31.9",
"General and Administrative Expense": "53.0",
"Other Revenues": "142",
"Other Net Income": "-1.19",
"Comprehensive Net Income": "109",
"Economic Capital Ratio": "80.5"
},
"2013": {
"Liabilities, Current": "39.7",
"Liabilities": "58.8",
"Stockholders Equity": "-47.1",
"ECR before LimitedLiability": "64.9",
"Other Liabilities": "26.2",
"Liabilities, Non-Current": "-5.15",
"Goodwill": "-11.0",
"Assets": "-35.1",
"Assets, Non-Current": "-7.12",
"Property, Plant and Equipment, Net": "-14.7",
"Assets, Current": "-11.0",
"General and Administrative Expense": "37.3",
"Expenses": "-18.4",
"Revenues": "96.8",
"Net Income": "93.1",
"Research and Development": "23.4",
"Other Expenses": "-76.7",
"Other Revenues": "96.8",
"Other Net Income": "-4.97",
"Comprehensive Net Income": "92.9",
"Economic Capital Ratio": "24.8"
},
"2014": {
"Liabilities, Non-Current": "10.1",
"Liabilities": "102",
"Stockholders Equity": "16.6",
"ECR before LimitedLiability": "126",
"Liabilities, Current": "76.5",
"Other Liabilities": "24.9",
"Assets, Current": "-1.12",
"Assets": "-20.0",
"Goodwill": "-8.50",
"Assets, Non-Current": "-4.51",
"Property, Plant and Equipment, Net": "-10.2",
"Other Expenses": "-102",
"Expenses": "-14.1",
"Revenues": "121",
"Net Income": "104",
"Research and Development": "25.9",
"General and Administrative Expense": "51.9",
"Other Revenues": "121",
"Other Net Income": "2.57",
"Comprehensive Net Income": "105",
"Economic Capital Ratio": "76.9"
},
"2015": {
"Other Liabilities": "22.1",
"Liabilities": "46.0",
"Stockholders Equity": "21.1",
"ECR before LimitedLiability": "79.3",
"Liabilities, Current": "8.24",
"Liabilities, Non-Current": "17.9",
"Assets, Current": "-6.68",
"Assets": "-9.20",
"Other Assets": "-3.37",
"Goodwill": "20.5",
"Assets, Non-Current": "-3.91",
"Property, Plant and Equipment, Net": "-11.0",
"Research and Development": "13.9",
"Expenses": "-2.00",
"Revenues": "49.7",
"Net Income": "48.7",
"General and Administrative Expense": "15.1",
"Other Expenses": "-29.2",
"Other Revenues": "49.7",
"Comprehensive Net Income": "49.2",
"Economic Capital Ratio": "33.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001374328_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "3,296",
"Assets, Non-Current": "0",
"General and Administrative Expense": "3,675",
"Goodwill": "1,477",
"Liabilities, Current": "1,616",
"Liabilities, Non-Current": "0",
"Other Assets": "6.8",
"Other Compr. Net Income": "0",
"Other Expenses": "8,207",
"Other Liabilities": "0",
"Other Net Income": "118",
"Other Revenues": "12,092",
"Property, Plant and Equipment, Net": "43",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "1,616",
"Assets": "4,823",
"Expenses": "11,883",
"Revenues": "12,092",
"Stockholders Equity": "3,206",
"Net Income": "327",
"Comprehensive Net Income": "327",
"BaseVar": "15,266",
"ECR before LimitedLiability": "147%",
"Economic Capital Ratio": "199%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "6,397",
"Assets, Non-Current": "0",
"General and Administrative Expense": "4,400",
"Goodwill": "1,257",
"Liabilities, Current": "1,870",
"Liabilities, Non-Current": "0",
"Other Assets": "3.0",
"Other Compr. Net Income": "0",
"Other Expenses": "11,812",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "18,093",
"Property, Plant and Equipment, Net": "19",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "1,870",
"Assets": "7,676",
"Expenses": "16,212",
"Revenues": "18,093",
"Stockholders Equity": "5,805",
"Net Income": "1,881",
"Comprehensive Net Income": "1,881",
"BaseVar": "21,925",
"ECR before LimitedLiability": "206%",
"Economic Capital Ratio": "239%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "8,134",
"Assets, Non-Current": "0",
"General and Administrative Expense": "5,516",
"Goodwill": "1,037",
"Liabilities, Current": "2,475",
"Liabilities, Non-Current": "1,947",
"Other Assets": "53",
"Other Compr. Net Income": "0",
"Other Expenses": "12,781",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "19,684",
"Property, Plant and Equipment, Net": "6.0",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "4,422",
"Assets": "9,230",
"Expenses": "18,296",
"Revenues": "19,684",
"Stockholders Equity": "4,809",
"Net Income": "1,388",
"Comprehensive Net Income": "1,388",
"BaseVar": "25,816",
"ECR before LimitedLiability": "117%",
"Economic Capital Ratio": "179%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "9,060",
"Assets, Non-Current": "0",
"General and Administrative Expense": "5,015",
"Goodwill": "1,037",
"Liabilities, Current": "1,950",
"Liabilities, Non-Current": "1,440",
"Other Assets": "3.0",
"Other Compr. Net Income": "0",
"Other Expenses": "13,094",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "19,960",
"Property, Plant and Equipment, Net": "3.1",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "3,390",
"Assets": "10,104",
"Expenses": "18,108",
"Revenues": "19,960",
"Stockholders Equity": "6,714",
"Net Income": "1,852",
"Comprehensive Net Income": "1,852",
"BaseVar": "25,781",
"ECR before LimitedLiability": "164%",
"Economic Capital Ratio": "210%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "9,536",
"Assets, Non-Current": "0",
"General and Administrative Expense": "7,068",
"Goodwill": "6,930",
"Liabilities, Current": "6,533",
"Liabilities, Non-Current": "914",
"Other Assets": "866",
"Other Compr. Net Income": "0",
"Other Expenses": "11,953",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "17,931",
"Property, Plant and Equipment, Net": "227",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "7,448",
"Assets": "17,558",
"Expenses": "19,021",
"Revenues": "17,931",
"Stockholders Equity": "10,111",
"Net Income": "-1,090",
"Comprehensive Net Income": "-1,090",
"BaseVar": "30,979",
"ECR before LimitedLiability": "102%",
"Economic Capital Ratio": "169%"
}
}
},
"top_rated": false,
"trend": -9.0,
"value": 1.6920966519363807,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001374328.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001374328.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001374328.svg"
},
{
"company_id": "0001028215",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001028215.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001028215.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001028215.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001028215_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001028215_main_keyfigs.svg",
"name": "KMG Chemicals INC",
"rank": 22,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001028215.svg",
"report_text": "The relative strengths and weaknesses of KMG Chemicals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of KMG Chemicals INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 73% points.The greatest weakness of KMG Chemicals INC is the variable Other Expenses, reducing the Economic Capital Ratio by 62% points.
The company's Economic Capital Ratio, given in the ranking table, is 166%, being 30% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001028215_2016_KMG_Chemicals_INC.pdf",
"shrinked_graph_json": {
"2012": {
"Liabilities, Current": "34.3",
"Liabilities": "46.3",
"Stockholders Equity": "-17.3",
"ECR before LimitedLiability": "67.9",
"Liabilities, Non-Current": "-10.8",
"Other Liabilities": "23.3",
"Assets, Current": "-20.8",
"Assets": "-19.9",
"Assets, Non-Current": "-4.66",
"Property, Plant and Equipment, Net": "14.9",
"Goodwill": "-6.47",
"Other Expenses": "-100",
"Expenses": "-2.11",
"Revenues": "76.4",
"Net Income": "70.4",
"Research and Development": "23.1",
"General and Administrative Expense": "75.8",
"Other Revenues": "76.4",
"Other Net Income": "-2.46",
"Comprehensive Net Income": "69.4",
"Economic Capital Ratio": "35.4"
},
"2013": {
"Liabilities, Current": "23.9",
"Liabilities": "-2.79",
"Stockholders Equity": "-15.5",
"ECR before LimitedLiability": "42.0",
"Other Liabilities": "9.06",
"Liabilities, Non-Current": "-40.2",
"Goodwill": "-2.31",
"Assets": "-8.80",
"Assets, Non-Current": "-4.42",
"Property, Plant and Equipment, Net": "23.6",
"Other Assets": "-2.84",
"Assets, Current": "-16.2",
"General and Administrative Expense": "54.0",
"Expenses": "15.7",
"Revenues": "36.7",
"Net Income": "50.4",
"Research and Development": "15.2",
"Other Expenses": "-44.3",
"Other Revenues": "36.7",
"Other Net Income": "-3.97",
"Comprehensive Net Income": "50.7",
"Economic Capital Ratio": "1.82"
},
"2014": {
"Liabilities, Non-Current": "-15.3",
"Liabilities": "46.7",
"Stockholders Equity": "2.25",
"ECR before LimitedLiability": "74.2",
"Liabilities, Current": "49.4",
"Other Liabilities": "11.5",
"Assets, Current": "-23.7",
"Assets": "-20.0",
"Goodwill": "-6.23",
"Other Assets": "1.05",
"Assets, Non-Current": "-4.91",
"Property, Plant and Equipment, Net": "19.3",
"Other Expenses": "-81.8",
"Expenses": "1.03",
"Revenues": "69.6",
"Net Income": "71.9",
"Research and Development": "22.3",
"General and Administrative Expense": "73.7",
"Other Revenues": "69.6",
"Comprehensive Net Income": "72.9",
"Economic Capital Ratio": "24.7"
},
"2015": {
"Other Liabilities": "15.9",
"Liabilities": "52.5",
"ECR before LimitedLiability": "76.0",
"Liabilities, Current": "45.8",
"Liabilities, Non-Current": "-8.78",
"Assets, Current": "-22.2",
"Assets": "-21.1",
"Other Assets": "-7.85",
"Assets, Non-Current": "-2.99",
"Property, Plant and Equipment, Net": "13.7",
"Research and Development": "15.8",
"Expenses": "-3.08",
"Net Income": "71.8",
"General and Administrative Expense": "52.2",
"Other Expenses": "-62.1",
"Other Revenues": "73.0",
"Revenues": "73.0",
"Other Compr. Net Income": "-1.54",
"Comprehensive Net Income": "69.7",
"Other Net Income": "2.23",
"Economic Capital Ratio": "30.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001028215_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "75,661",
"Assets, Non-Current": "3,116",
"General and Administrative Expense": "24,858",
"Goodwill": "18,758",
"Liabilities, Current": "28,677",
"Liabilities, Non-Current": "25,200",
"Other Assets": "2,129",
"Other Compr. Net Income": "-3,106",
"Other Expenses": "231,159",
"Other Liabilities": "7,046",
"Other Net Income": "-2,858",
"Other Revenues": "272,700",
"Property, Plant and Equipment, Net": "68,026",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "60,923",
"Assets": "167,690",
"Expenses": "256,017",
"Revenues": "272,700",
"Stockholders Equity": "106,767",
"Net Income": "13,825",
"Comprehensive Net Income": "12,272",
"BaseVar": "381,647",
"ECR before LimitedLiability": "139%",
"Economic Capital Ratio": "194%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "118,836",
"Assets, Non-Current": "4,232",
"General and Administrative Expense": "28,978",
"Goodwill": "40,190",
"Liabilities, Current": "45,843",
"Liabilities, Non-Current": "87,470",
"Other Assets": "2,069",
"Other Compr. Net Income": "1,835",
"Other Expenses": "222,868",
"Other Liabilities": "11,462",
"Other Net Income": "-2,117",
"Other Revenues": "263,311",
"Property, Plant and Equipment, Net": "96,688",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "144,775",
"Assets": "262,015",
"Expenses": "251,846",
"Revenues": "263,311",
"Stockholders Equity": "117,240",
"Net Income": "9,348",
"Comprehensive Net Income": "10,266",
"BaseVar": "462,950",
"ECR before LimitedLiability": "84%",
"Economic Capital Ratio": "156%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "111,653",
"Assets, Non-Current": "4,365",
"General and Administrative Expense": "38,421",
"Goodwill": "40,948",
"Liabilities, Current": "58,251",
"Liabilities, Non-Current": "62,520",
"Other Assets": "1,442",
"Other Compr. Net Income": "3,149",
"Other Expenses": "312,288",
"Other Liabilities": "9,881",
"Other Net Income": "-3,685",
"Other Revenues": "353,406",
"Property, Plant and Equipment, Net": "92,450",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "130,652",
"Assets": "250,858",
"Expenses": "350,709",
"Revenues": "353,406",
"Stockholders Equity": "120,206",
"Net Income": "-988",
"Comprehensive Net Income": "586",
"BaseVar": "546,230",
"ECR before LimitedLiability": "87%",
"Economic Capital Ratio": "158%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "96,845",
"Assets, Non-Current": "4,826",
"General and Administrative Expense": "37,461",
"Goodwill": "58,968",
"Liabilities, Current": "50,434",
"Liabilities, Non-Current": "55,429",
"Other Assets": "1,131",
"Other Compr. Net Income": "-10,312",
"Other Expenses": "273,194",
"Other Liabilities": "13,075",
"Other Net Income": "2,295",
"Other Revenues": "320,498",
"Property, Plant and Equipment, Net": "80,589",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "118,938",
"Assets": "242,359",
"Expenses": "310,655",
"Revenues": "320,498",
"Stockholders Equity": "123,421",
"Net Income": "12,138",
"Comprehensive Net Income": "6,982",
"BaseVar": "502,528",
"ECR before LimitedLiability": "97%",
"Economic Capital Ratio": "166%"
}
}
},
"top_rated": false,
"trend": -2.0,
"value": 1.6598806063866092,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001028215.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001028215.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001028215.svg"
},
{
"company_id": "0000949858",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000949858.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000949858.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000949858.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000949858_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000949858_main_keyfigs.svg",
"name": "Achieve LIFE Sciences INC",
"rank": 23,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000949858.svg",
"report_text": "The relative strengths and weaknesses of Achieve LIFE Sciences INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Achieve LIFE Sciences INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 78% points.The greatest weakness of Achieve LIFE Sciences INC is the variable Other Revenues, reducing the Economic Capital Ratio by 37% points.
The company's Economic Capital Ratio, given in the ranking table, is 159%, being 23% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000949858_2016_Achieve_LIFE_Sciences_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "-43.8",
"Liabilities": "-43.7",
"Stockholders Equity": "19.4",
"ECR before LimitedLiability": "40.7",
"Liabilities, Non-Current": "7.76",
"Other Liabilities": "-7.86",
"Property, Plant and Equipment, Net": "-10.3",
"Assets": "48.0",
"Assets, Non-Current": "-3.79",
"Goodwill": "-9.74",
"Assets, Current": "59.2",
"General and Administrative Expense": "39.1",
"Expenses": "34.1",
"Revenues": "-40.2",
"Net Income": "2.87",
"Research and Development": "-21.6",
"Other Expenses": "19.2",
"Other Revenues": "-40.2",
"Comprehensive Net Income": "2.83",
"Other Net Income": "15.9",
"Economic Capital Ratio": "-21.3"
},
"2012": {
"Liabilities, Current": "4.96",
"Liabilities": "19.5",
"Stockholders Equity": "77.5",
"ECR before LimitedLiability": "70.3",
"Liabilities, Non-Current": "9.90",
"Other Liabilities": "5.33",
"Assets, Current": "97.0",
"Assets": "40.6",
"Assets, Non-Current": "-2.01",
"Property, Plant and Equipment, Net": "-6.18",
"Goodwill": "-6.64",
"Other Expenses": "23.7",
"Expenses": "13.2",
"Revenues": "-47.0",
"Net Income": "0.352",
"Research and Development": "-42.8",
"General and Administrative Expense": "32.9",
"Other Revenues": "-47.0",
"Other Net Income": "34.2",
"Comprehensive Net Income": "0.405",
"Economic Capital Ratio": "37.8"
},
"2013": {
"Liabilities": "26.7",
"Stockholders Equity": "30.0",
"ECR before LimitedLiability": "17.0",
"Other Liabilities": "4.51",
"Liabilities, Non-Current": "19.7",
"Goodwill": "-18.4",
"Assets": "3.95",
"Assets, Non-Current": "-5.18",
"Property, Plant and Equipment, Net": "-15.3",
"Other Assets": "-3.95",
"Assets, Current": "49.4",
"General and Administrative Expense": "46.8",
"Expenses": "-21.6",
"Revenues": "-61.1",
"Net Income": "-21.3",
"Research and Development": "-89.9",
"Other Expenses": "40.9",
"Other Revenues": "-61.1",
"Other Net Income": "48.9",
"Comprehensive Net Income": "-21.4",
"Economic Capital Ratio": "-23.2"
},
"2014": {
"Liabilities, Non-Current": "20.4",
"Liabilities": "28.2",
"Stockholders Equity": "47.1",
"ECR before LimitedLiability": "47.6",
"Liabilities, Current": "-5.45",
"Other Liabilities": "13.5",
"Assets, Current": "53.1",
"Assets": "21.1",
"Goodwill": "-17.9",
"Assets, Non-Current": "-5.69",
"Property, Plant and Equipment, Net": "-14.0",
"Other Expenses": "27.9",
"Expenses": "-6.25",
"Revenues": "-54.8",
"Net Income": "-3.20",
"Research and Development": "-68.4",
"General and Administrative Expense": "47.1",
"Other Revenues": "-54.8",
"Other Net Income": "48.5",
"Comprehensive Net Income": "-3.13",
"Economic Capital Ratio": "-1.85"
},
"2015": {
"Other Liabilities": "15.3",
"Liabilities": "19.4",
"Stockholders Equity": "60.3",
"ECR before LimitedLiability": "68.8",
"Liabilities, Current": "-15.6",
"Liabilities, Non-Current": "18.9",
"Assets, Current": "78.2",
"Assets": "34.1",
"Other Assets": "-5.24",
"Goodwill": "-11.4",
"Property, Plant and Equipment, Net": "-8.72",
"Research and Development": "-34.3",
"Expenses": "7.53",
"Revenues": "-37.4",
"Net Income": "5.56",
"General and Administrative Expense": "18.1",
"Other Expenses": "27.8",
"Other Revenues": "-37.4",
"Comprehensive Net Income": "5.87",
"Other Net Income": "41.2",
"Economic Capital Ratio": "23.0"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000949858_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "67,326",
"Assets, Non-Current": "509",
"General and Administrative Expense": "6,230",
"Goodwill": "0",
"Liabilities, Current": "30,786",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "6,339",
"Other Net Income": "13,110",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "180",
"Research and Development": "21,553"
},
"output_variables": {
"Liabilities": "37,125",
"Assets": "68,015",
"Expenses": "27,783",
"Revenues": "0",
"Stockholders Equity": "30,890",
"Net Income": "-14,673",
"Comprehensive Net Income": "-14,673",
"BaseVar": "73,016",
"ECR before LimitedLiability": "53%",
"Economic Capital Ratio": "132%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "80,179",
"Assets, Non-Current": "1,152",
"General and Administrative Expense": "7,791",
"Goodwill": "0",
"Liabilities, Current": "11,556",
"Liabilities, Non-Current": "0",
"Other Assets": "314",
"Other Compr. Net Income": "1.0",
"Other Expenses": "-1,657",
"Other Liabilities": "4,253",
"Other Net Income": "24,984",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "371",
"Research and Development": "39,948"
},
"output_variables": {
"Liabilities": "15,809",
"Assets": "82,016",
"Expenses": "46,082",
"Revenues": "0",
"Stockholders Equity": "66,207",
"Net Income": "-21,098",
"Comprehensive Net Income": "-21,098",
"BaseVar": "84,446",
"ECR before LimitedLiability": "142%",
"Economic Capital Ratio": "196%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "53,867",
"Assets, Non-Current": "1,111",
"General and Administrative Expense": "9,892",
"Goodwill": "0",
"Liabilities, Current": "14,934",
"Liabilities, Non-Current": "0",
"Other Assets": "314",
"Other Compr. Net Income": "6.0",
"Other Expenses": "0",
"Other Liabilities": "3,544",
"Other Net Income": "33,360",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "397",
"Research and Development": "55,317"
},
"output_variables": {
"Liabilities": "18,478",
"Assets": "55,689",
"Expenses": "65,209",
"Revenues": "0",
"Stockholders Equity": "37,211",
"Net Income": "-31,849",
"Comprehensive Net Income": "-31,846",
"BaseVar": "86,371",
"ECR before LimitedLiability": "52%",
"Economic Capital Ratio": "131%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "55,761",
"Assets, Non-Current": "273",
"General and Administrative Expense": "10,625",
"Goodwill": "0",
"Liabilities, Current": "22,218",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "-21",
"Other Expenses": "-267",
"Other Liabilities": "14",
"Other Net Income": "30,342",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "257",
"Research and Development": "46,224"
},
"output_variables": {
"Liabilities": "22,232",
"Assets": "56,291",
"Expenses": "56,582",
"Revenues": "0",
"Stockholders Equity": "34,059",
"Net Income": "-26,240",
"Comprehensive Net Income": "-26,250",
"BaseVar": "82,734",
"ECR before LimitedLiability": "52%",
"Economic Capital Ratio": "132%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "57,298",
"Assets, Non-Current": "37",
"General and Administrative Expense": "11,805",
"Goodwill": "0",
"Liabilities, Current": "20,664",
"Liabilities, Non-Current": "0",
"Other Assets": "272",
"Other Compr. Net Income": "10",
"Other Expenses": "0",
"Other Liabilities": "105",
"Other Net Income": "20,112",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "602",
"Research and Development": "25,108"
},
"output_variables": {
"Liabilities": "20,769",
"Assets": "58,209",
"Expenses": "36,913",
"Revenues": "0",
"Stockholders Equity": "37,440",
"Net Income": "-16,801",
"Comprehensive Net Income": "-16,796",
"BaseVar": "68,006",
"ECR before LimitedLiability": "87%",
"Economic Capital Ratio": "159%"
}
}
},
"top_rated": false,
"trend": 2.0,
"value": 1.587855193765952,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000949858.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000949858.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000949858.svg"
},
{
"company_id": "0001562733",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001562733.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001562733.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001562733_main_keyfigs.svg",
"name": "Synergy CHC Corp",
"rank": 24,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001562733.svg",
"report_text": "The relative strengths and weaknesses of Synergy CHC Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Synergy CHC Corp compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 57% points.The greatest weakness of Synergy CHC Corp is the variable Liabilities, Current, reducing the Economic Capital Ratio by 32% points.
The company's Economic Capital Ratio, given in the ranking table, is 141%, being 5.1% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001562733_2016_Synergy_CHC_Corp.pdf",
"shrinked_graph_json": {
"2014": {
"Liabilities, Non-Current": "0",
"Liabilities": "0",
"ECR before LimitedLiability": "-84.1",
"Liabilities, Current": "0",
"Other Liabilities": "0",
"Assets, Current": "-0.849",
"Assets": "-17.0",
"Goodwill": "0",
"Other Assets": "0",
"Assets, Non-Current": "0",
"Property, Plant and Equipment, Net": "0",
"Other Expenses": "0",
"Expenses": "-0.620",
"Net Income": "-11.6",
"Research and Development": "0",
"General and Administrative Expense": "-6.22",
"Other Revenues": "0",
"Revenues": "0",
"Stockholders Equity": "0",
"Comprehensive Net Income": "-11.6",
"Economic Capital Ratio": "-134"
},
"2015": {
"Other Liabilities": "15.6",
"Liabilities": "-30.4",
"Stockholders Equity": "-19.1",
"ECR before LimitedLiability": "51.0",
"Liabilities, Current": "-32.4",
"Liabilities, Non-Current": "-14.5",
"Assets, Current": "-15.9",
"Assets": "2.79",
"Other Assets": "-5.63",
"Goodwill": "56.6",
"Assets, Non-Current": "-3.71",
"Property, Plant and Equipment, Net": "-11.4",
"Research and Development": "10.7",
"Expenses": "42.2",
"Revenues": "0.884",
"Net Income": "57.0",
"General and Administrative Expense": "19.9",
"Other Expenses": "9.14",
"Other Revenues": "0.884",
"Comprehensive Net Income": "57.1",
"Other Net Income": "26.9",
"Economic Capital Ratio": "5.14"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001562733_strength_weakness.svg",
"table_records": {
"2014": {
"input_variables": {
"Assets, Current": "55",
"Assets, Non-Current": "0",
"General and Administrative Expense": "967",
"Goodwill": "0",
"Liabilities, Current": "181",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "2.0",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "9.2",
"Property, Plant and Equipment, Net": "0",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "181",
"Assets": "55",
"Expenses": "969",
"Revenues": "9.2",
"Stockholders Equity": "-126",
"Net Income": "-960",
"Comprehensive Net Income": "-960",
"BaseVar": "607",
"ECR before LimitedLiability": "-958%",
"Economic Capital Ratio": "0.00000012%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "9,337",
"Assets, Non-Current": "0",
"General and Administrative Expense": "7,054",
"Goodwill": "17,412",
"Liabilities, Current": "15,503",
"Liabilities, Non-Current": "6,217",
"Other Assets": "379",
"Other Compr. Net Income": "0",
"Other Expenses": "5,916",
"Other Liabilities": "0",
"Other Net Income": "7,633",
"Other Revenues": "13,456",
"Property, Plant and Equipment, Net": "12",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "21,720",
"Assets": "27,139",
"Expenses": "12,970",
"Revenues": "13,456",
"Stockholders Equity": "5,420",
"Net Income": "8,119",
"Comprehensive Net Income": "8,119",
"BaseVar": "41,459",
"ECR before LimitedLiability": "64%",
"Economic Capital Ratio": "141%"
}
}
},
"top_rated": false,
"trend": 24.0,
"value": 1.4097379750860468,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001562733.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001562733.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001562733.svg"
},
{
"company_id": "0001578932",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001578932.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001578932.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001578932.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001578932_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001578932_main_keyfigs.svg",
"name": "OCI Partners LP",
"rank": 25,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001578932.svg",
"report_text": "The relative strengths and weaknesses of OCI Partners LP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of OCI Partners LP compared to the market average is the variable Property, Plant and Equipment, Net, increasing the Economic Capital Ratio by 83% points.The greatest weakness of OCI Partners LP is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 90% points.
The company's Economic Capital Ratio, given in the ranking table, is 139%, being 3.2% points above the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001578932_2016_OCI_Partners_LP.pdf",
"shrinked_graph_json": {
"2013": {
"Liabilities, Current": "23.8",
"Liabilities": "-51.1",
"Stockholders Equity": "-25.1",
"ECR before LimitedLiability": "30.3",
"Other Liabilities": "12.0",
"Liabilities, Non-Current": "-109",
"Goodwill": "-12.0",
"Assets": "8.54",
"Assets, Non-Current": "-3.84",
"Property, Plant and Equipment, Net": "60.2",
"Other Assets": "-2.93",
"Assets, Current": "-12.7",
"General and Administrative Expense": "45.4",
"Expenses": "46.3",
"Revenues": "16.1",
"Net Income": "60.1",
"Research and Development": "11.6",
"Other Expenses": "-10.3",
"Other Revenues": "16.1",
"Comprehensive Net Income": "60.1",
"Economic Capital Ratio": "-9.85"
},
"2014": {
"Liabilities, Non-Current": "-88.5",
"Liabilities": "-33.9",
"Stockholders Equity": "-1.48",
"ECR before LimitedLiability": "57.9",
"Liabilities, Current": "28.9",
"Other Liabilities": "10.2",
"Assets, Current": "-24.1",
"Assets": "22.1",
"Goodwill": "-12.6",
"Assets, Non-Current": "-2.78",
"Property, Plant and Equipment, Net": "67.5",
"Other Expenses": "-16.0",
"Expenses": "46.7",
"Revenues": "9.75",
"Net Income": "57.4",
"Research and Development": "13.1",
"General and Administrative Expense": "51.6",
"Other Revenues": "9.75",
"Other Net Income": "1.39",
"Comprehensive Net Income": "57.4",
"Economic Capital Ratio": "8.50"
},
"2015": {
"Other Liabilities": "13.5",
"Liabilities": "-32.2",
"Stockholders Equity": "3.67",
"ECR before LimitedLiability": "49.1",
"Liabilities, Current": "28.6",
"Liabilities, Non-Current": "-90.0",
"Assets, Current": "-27.7",
"Assets": "27.2",
"Other Assets": "-5.99",
"Goodwill": "-12.1",
"Assets, Non-Current": "-3.12",
"Property, Plant and Equipment, Net": "83.3",
"Research and Development": "9.24",
"Expenses": "39.8",
"Revenues": "3.06",
"Net Income": "44.4",
"General and Administrative Expense": "36.3",
"Other Expenses": "-5.99",
"Other Revenues": "3.06",
"Comprehensive Net Income": "44.8",
"Economic Capital Ratio": "3.24"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001578932_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "236,238",
"Assets, Non-Current": "7,135",
"General and Administrative Expense": "26,774",
"Goodwill": "0",
"Liabilities, Current": "61,358",
"Liabilities, Non-Current": "391,634",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "245,304",
"Other Liabilities": "17",
"Other Net Income": "-1,535",
"Other Revenues": "427,964",
"Property, Plant and Equipment, Net": "361,007",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "453,009",
"Assets": "604,380",
"Expenses": "272,078",
"Revenues": "427,964",
"Stockholders Equity": "151,371",
"Net Income": "154,351",
"Comprehensive Net Income": "154,351",
"BaseVar": "879,483",
"ECR before LimitedLiability": "68%",
"Economic Capital Ratio": "145%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "117,530",
"Assets, Non-Current": "11,552",
"General and Administrative Expense": "22,356",
"Goodwill": "0",
"Liabilities, Current": "97,499",
"Liabilities, Non-Current": "388,777",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "261,917",
"Other Liabilities": "0",
"Other Net Income": "941",
"Other Revenues": "402,780",
"Property, Plant and Equipment, Net": "545,258",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "486,276",
"Assets": "674,340",
"Expenses": "284,273",
"Revenues": "402,780",
"Stockholders Equity": "188,064",
"Net Income": "119,448",
"Comprehensive Net Income": "119,448",
"BaseVar": "924,305",
"ECR before LimitedLiability": "65%",
"Economic Capital Ratio": "142%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "57,723",
"Assets, Non-Current": "1,188",
"General and Administrative Expense": "21,232",
"Goodwill": "0",
"Liabilities, Current": "74,228",
"Liabilities, Non-Current": "422,519",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "236,313",
"Other Liabilities": "0",
"Other Net Income": "123",
"Other Revenues": "309,443",
"Property, Plant and Equipment, Net": "674,699",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "496,747",
"Assets": "733,610",
"Expenses": "257,545",
"Revenues": "309,443",
"Stockholders Equity": "236,863",
"Net Income": "52,021",
"Comprehensive Net Income": "52,021",
"BaseVar": "898,734",
"ECR before LimitedLiability": "61%",
"Economic Capital Ratio": "139%"
}
}
},
"top_rated": false,
"trend": -3.0,
"value": 1.3907417657783316,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001578932.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001578932.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001578932.svg"
},
{
"company_id": "0001569737",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001569737.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001569737.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001569737_main_keyfigs.svg",
"name": "Jishanye Inc",
"rank": 26,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001569737.svg",
"report_text": "The relative strengths and weaknesses of Jishanye Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Jishanye Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 62% points.The greatest weakness of Jishanye Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 53% points.
The company's Economic Capital Ratio, given in the ranking table, is 132%, being 3.3% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001569737_2016_Jishanye_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Liabilities, Current": "5.29",
"Liabilities": "3.98",
"Stockholders Equity": "-66.1",
"ECR before LimitedLiability": "-108",
"Liabilities, Non-Current": "-0.436",
"Goodwill": "-8.43",
"Assets": "-46.9",
"Assets, Non-Current": "-2.75",
"Property, Plant and Equipment, Net": "2.60",
"Other Assets": "-1.58",
"Assets, Current": "-33.7",
"General and Administrative Expense": "-20.1",
"Expenses": "-9.65",
"Revenues": "-7.01",
"Net Income": "-23.7",
"Research and Development": "1.66",
"Other Expenses": "2.16",
"Other Revenues": "-7.01",
"Other Net Income": "-0.501",
"Comprehensive Net Income": "-23.7",
"Economic Capital Ratio": "-148"
},
"2014": {
"Liabilities, Non-Current": "-0.387",
"Liabilities": "5.33",
"Stockholders Equity": "-73.5",
"ECR before LimitedLiability": "-78.3",
"Liabilities, Current": "5.77",
"Other Liabilities": "-0.258",
"Assets, Current": "-21.3",
"Assets": "-41.6",
"Goodwill": "-6.22",
"Other Assets": "0.123",
"Assets, Non-Current": "-1.70",
"Property, Plant and Equipment, Net": "-4.66",
"Other Expenses": "1.88",
"Expenses": "-0.670",
"Revenues": "-5.49",
"Net Income": "-6.49",
"Research and Development": "1.36",
"General and Administrative Expense": "-5.82",
"Other Revenues": "-5.49",
"Comprehensive Net Income": "-6.48",
"Economic Capital Ratio": "-128"
},
"2015": {
"Other Liabilities": "13.1",
"Liabilities": "-19.2",
"Stockholders Equity": "32.4",
"ECR before LimitedLiability": "42.5",
"Liabilities, Current": "-52.6",
"Liabilities, Non-Current": "15.8",
"Assets, Current": "62.3",
"Assets": "47.9",
"Other Assets": "-5.21",
"Goodwill": "-12.5",
"Assets, Non-Current": "-3.38",
"Property, Plant and Equipment, Net": "-10.5",
"Research and Development": "9.17",
"Expenses": "24.8",
"Revenues": "-15.5",
"Net Income": "8.77",
"General and Administrative Expense": "-9.33",
"Other Expenses": "25.5",
"Other Revenues": "-15.5",
"Comprehensive Net Income": "9.05",
"Economic Capital Ratio": "-3.34"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001569737_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "12",
"Assets, Non-Current": "0",
"General and Administrative Expense": "179",
"Goodwill": "0",
"Liabilities, Current": "152",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "16",
"Other Liabilities": "0",
"Other Net Income": "-0.73",
"Other Revenues": "25",
"Property, Plant and Equipment, Net": "27",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "152",
"Assets": "39",
"Expenses": "195",
"Revenues": "25",
"Stockholders Equity": "-113",
"Net Income": "-171",
"Comprehensive Net Income": "-171",
"BaseVar": "206",
"ECR before LimitedLiability": "-340%",
"Economic Capital Ratio": "6.5%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "15",
"Assets, Non-Current": "0",
"General and Administrative Expense": "162",
"Goodwill": "0",
"Liabilities, Current": "274",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-1.4",
"Other Revenues": "18",
"Property, Plant and Equipment, Net": "0",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "274",
"Assets": "15",
"Expenses": "162",
"Revenues": "18",
"Stockholders Equity": "-259",
"Net Income": "-146",
"Comprehensive Net Income": "-146",
"BaseVar": "235",
"ECR before LimitedLiability": "-347%",
"Economic Capital Ratio": "5.9%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "1,058",
"Assets, Non-Current": "0",
"General and Administrative Expense": "457",
"Goodwill": "0",
"Liabilities, Current": "569",
"Liabilities, Non-Current": "0",
"Other Assets": "9.7",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "4.5",
"Other Revenues": "204",
"Property, Plant and Equipment, Net": "0",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "569",
"Assets": "1,067",
"Expenses": "457",
"Revenues": "204",
"Stockholders Equity": "498",
"Net Income": "-249",
"Comprehensive Net Income": "-249",
"BaseVar": "1,151",
"ECR before LimitedLiability": "53%",
"Economic Capital Ratio": "132%"
}
}
},
"top_rated": false,
"trend": 18.0,
"value": 1.3249385527716644,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001569737.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001569737.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001569737.svg"
},
{
"company_id": "0000926617",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000926617.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000926617.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000926617.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000926617_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000926617_main_keyfigs.svg",
"name": "Aspira Women s Health Inc",
"rank": 27,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000926617.svg",
"report_text": "The relative strengths and weaknesses of Aspira Women s Health Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Aspira Women s Health Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 69% points.The greatest weakness of Aspira Women s Health Inc is the variable Net Income, reducing the Economic Capital Ratio by 73% points.
The company's Economic Capital Ratio, given in the ranking table, is 122%, being 14% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000926617_2016_Aspira_Women_s_Health_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "-27.4",
"Liabilities": "-16.5",
"Stockholders Equity": "1.22",
"Liabilities, Non-Current": "0.717",
"Other Liabilities": "0.0331",
"Property, Plant and Equipment, Net": "-0.750",
"Assets": "10.6",
"Assets, Non-Current": "-0.512",
"Goodwill": "-0.750",
"Assets, Current": "38.8",
"General and Administrative Expense": "-0.698",
"Expenses": "-0.271",
"Revenues": "-30.5",
"Net Income": "-40.2",
"Research and Development": "-0.703",
"Other Expenses": "3.05",
"Other Revenues": "-30.5",
"ECR before LimitedLiability": "-7.59",
"Comprehensive Net Income": "-40.3",
"Other Net Income": "-0.448",
"Economic Capital Ratio": "-69.6"
},
"2012": {
"Assets, Current": "16.6",
"Assets": "-0.140",
"Other Liabilities": "0.301",
"Stockholders Equity": "-0.140",
"Assets, Non-Current": "-2.31",
"Property, Plant and Equipment, Net": "-14.0",
"Goodwill": "-17.1",
"Other Expenses": "4.58",
"Expenses": "-21.6",
"Revenues": "-44.6",
"Net Income": "-41.3",
"Research and Development": "-1.11",
"General and Administrative Expense": "-46.7",
"Other Revenues": "-44.6",
"ECR before LimitedLiability": "-41.5",
"Liabilities, Current": "-9.91",
"Liabilities, Non-Current": "0.785",
"Other Net Income": "3.96",
"Comprehensive Net Income": "-40.2",
"Other Compr. Net Income": "0.0563",
"Economic Capital Ratio": "-74.0"
},
"2013": {
"Liabilities, Current": "7.06",
"Liabilities": "26.4",
"Stockholders Equity": "113",
"ECR before LimitedLiability": "94.4",
"Other Liabilities": "8.35",
"Liabilities, Non-Current": "12.6",
"Goodwill": "-4.97",
"Assets": "62.6",
"Assets, Non-Current": "-1.95",
"Property, Plant and Equipment, Net": "-3.52",
"Assets, Current": "125",
"General and Administrative Expense": "-1.21",
"Expenses": "15.3",
"Revenues": "-24.5",
"Net Income": "-10.5",
"Research and Development": "-1.71",
"Other Expenses": "18.2",
"Other Revenues": "-24.5",
"Other Net Income": "-1.65",
"Comprehensive Net Income": "-10.5",
"Economic Capital Ratio": "54.3"
},
"2014": {
"Liabilities, Non-Current": "17.8",
"Liabilities": "43.3",
"Stockholders Equity": "55.7",
"ECR before LimitedLiability": "45.4",
"Liabilities, Current": "15.5",
"Other Liabilities": "11.9",
"Assets, Current": "82.0",
"Assets": "48.5",
"Goodwill": "-16.2",
"Assets, Non-Current": "-5.60",
"Property, Plant and Equipment, Net": "-10.3",
"Other Expenses": "16.2",
"Expenses": "-24.0",
"Revenues": "-36.7",
"Net Income": "-56.4",
"Research and Development": "-10.7",
"General and Administrative Expense": "-28.1",
"Other Revenues": "-36.7",
"Other Net Income": "1.56",
"Comprehensive Net Income": "-56.3",
"Economic Capital Ratio": "-4.05"
},
"2015": {
"Other Liabilities": "17.7",
"Liabilities": "38.3",
"Stockholders Equity": "51.8",
"ECR before LimitedLiability": "32.1",
"Liabilities, Current": "24.9",
"Liabilities, Non-Current": "22.2",
"Assets, Current": "69.1",
"Assets": "39.1",
"Other Assets": "-8.79",
"Goodwill": "-18.6",
"Assets, Non-Current": "-5.20",
"Property, Plant and Equipment, Net": "-5.31",
"Research and Development": "-12.7",
"Expenses": "-43.9",
"Revenues": "-35.3",
"Net Income": "-72.6",
"General and Administrative Expense": "-48.9",
"Other Expenses": "20.1",
"Other Revenues": "-35.3",
"Comprehensive Net Income": "-72.3",
"Economic Capital Ratio": "-13.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000926617_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "22,893",
"Assets, Non-Current": "2.0",
"General and Administrative Expense": "14,177",
"Goodwill": "0",
"Liabilities, Current": "11,476",
"Liabilities, Non-Current": "52",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "114",
"Other Liabilities": "1,224",
"Other Net Income": "-35",
"Other Revenues": "1,923",
"Property, Plant and Equipment, Net": "216",
"Research and Development": "5,387"
},
"output_variables": {
"Liabilities": "12,752",
"Assets": "23,111",
"Expenses": "19,678",
"Revenues": "1,923",
"Stockholders Equity": "10,359",
"Net Income": "-17,790",
"Comprehensive Net Income": "-17,790",
"BaseVar": "28,750",
"ECR before LimitedLiability": "-20%",
"Economic Capital Ratio": "84%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "8,492",
"Assets, Non-Current": "0",
"General and Administrative Expense": "9,292",
"Goodwill": "0",
"Liabilities, Current": "3,197",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "153",
"Other Expenses": "118",
"Other Liabilities": "770",
"Other Net Income": "2,386",
"Other Revenues": "2,094",
"Property, Plant and Equipment, Net": "142",
"Research and Development": "2,216"
},
"output_variables": {
"Liabilities": "3,967",
"Assets": "8,634",
"Expenses": "11,626",
"Revenues": "2,094",
"Stockholders Equity": "4,667",
"Net Income": "-7,146",
"Comprehensive Net Income": "-7,070",
"BaseVar": "14,430",
"ECR before LimitedLiability": "-11%",
"Economic Capital Ratio": "84%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "30,249",
"Assets, Non-Current": "0",
"General and Administrative Expense": "8,834",
"Goodwill": "0",
"Liabilities, Current": "3,558",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "316",
"Other Net Income": "44",
"Other Revenues": "2,566",
"Property, Plant and Equipment, Net": "391",
"Research and Development": "2,595"
},
"output_variables": {
"Liabilities": "3,874",
"Assets": "30,640",
"Expenses": "11,429",
"Revenues": "2,566",
"Stockholders Equity": "26,766",
"Net Income": "-8,819",
"Comprehensive Net Income": "-8,819",
"BaseVar": "24,276",
"ECR before LimitedLiability": "161%",
"Economic Capital Ratio": "209%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "23,666",
"Assets, Non-Current": "0",
"General and Administrative Expense": "15,835",
"Goodwill": "0",
"Liabilities, Current": "4,919",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "1,230",
"Other Liabilities": "0",
"Other Net Income": "2.0",
"Other Revenues": "2,521",
"Property, Plant and Equipment, Net": "508",
"Research and Development": "4,667"
},
"output_variables": {
"Liabilities": "4,919",
"Assets": "24,174",
"Expenses": "21,732",
"Revenues": "2,521",
"Stockholders Equity": "19,255",
"Net Income": "-19,209",
"Comprehensive Net Income": "-19,209",
"BaseVar": "26,674",
"ECR before LimitedLiability": "49%",
"Economic Capital Ratio": "129%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "19,366",
"Assets, Non-Current": "0",
"General and Administrative Expense": "15,366",
"Goodwill": "0",
"Liabilities, Current": "3,351",
"Liabilities, Non-Current": "0",
"Other Assets": "90",
"Other Compr. Net Income": "0",
"Other Expenses": "2,309",
"Other Liabilities": "63",
"Other Net Income": "134",
"Other Revenues": "2,177",
"Property, Plant and Equipment, Net": "1,504",
"Research and Development": "3,751"
},
"output_variables": {
"Liabilities": "3,414",
"Assets": "20,960",
"Expenses": "21,426",
"Revenues": "2,177",
"Stockholders Equity": "17,546",
"Net Income": "-19,115",
"Comprehensive Net Income": "-19,115",
"BaseVar": "24,056",
"ECR before LimitedLiability": "40%",
"Economic Capital Ratio": "122%"
}
}
},
"top_rated": false,
"trend": -1.0,
"value": 1.2201024631243058,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000926617.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000926617.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000926617.svg"
},
{
"company_id": "0000074303",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000074303.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000074303.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000074303.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000074303_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000074303_main_keyfigs.svg",
"name": "OLIN Corp",
"rank": 28,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000074303.svg",
"report_text": "The relative strengths and weaknesses of OLIN Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of OLIN Corp compared to the market average is the variable Property, Plant and Equipment, Net, increasing the Economic Capital Ratio by 37% points.The greatest weakness of OLIN Corp is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 68% points.
The company's Economic Capital Ratio, given in the ranking table, is 121%, being 14% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000074303_2016_OLIN_Corp.pdf",
"shrinked_graph_json": {
"2010": {
"Liabilities": "-32.8",
"Stockholders Equity": "-28.9",
"ECR before LimitedLiability": "-30.5",
"Liabilities, Current": "1.73",
"Liabilities, Non-Current": "-36.2",
"Goodwill": "-4.33",
"Assets": "-4.43",
"Property, Plant and Equipment, Net": "15.0",
"Assets, Current": "-12.7",
"Assets, Non-Current": "-7.23",
"Other Assets": "9.43",
"Other Expenses": "21.0",
"Expenses": "8.06",
"Revenues": "-3.03",
"Net Income": "9.56",
"General and Administrative Expense": "-19.2",
"Research and Development": "8.02",
"Other Revenues": "-3.03",
"Other Net Income": "4.53",
"Comprehensive Net Income": "9.63",
"Economic Capital Ratio": "-28.5"
},
"2011": {
"Liabilities, Current": "25.7",
"Liabilities": "-22.1",
"Stockholders Equity": "-11.3",
"ECR before LimitedLiability": "63.0",
"Liabilities, Non-Current": "-61.5",
"Other Liabilities": "5.23",
"Property, Plant and Equipment, Net": "22.8",
"Assets": "3.43",
"Assets, Non-Current": "-2.36",
"Other Assets": "2.89",
"Goodwill": "11.7",
"Assets, Current": "-21.4",
"General and Administrative Expense": "-4.85",
"Expenses": "28.8",
"Revenues": "16.3",
"Net Income": "47.9",
"Research and Development": "14.7",
"Other Expenses": "18.4",
"Other Revenues": "16.3",
"Comprehensive Net Income": "47.8",
"Economic Capital Ratio": "0.966"
},
"2012": {
"Liabilities, Current": "15.1",
"Liabilities": "-34.4",
"Stockholders Equity": "-22.1",
"ECR before LimitedLiability": "16.0",
"Liabilities, Non-Current": "-69.6",
"Other Liabilities": "12.2",
"Assets, Current": "-26.2",
"Assets": "2.32",
"Assets, Non-Current": "1.50",
"Property, Plant and Equipment, Net": "27.3",
"Goodwill": "12.7",
"Other Expenses": "25.4",
"Expenses": "33.0",
"Revenues": "14.0",
"Net Income": "48.4",
"Research and Development": "16.2",
"General and Administrative Expense": "-8.75",
"Other Revenues": "14.0",
"Comprehensive Net Income": "46.8",
"Other Compr. Net Income": "-1.24",
"Economic Capital Ratio": "-16.5"
},
"2013": {
"Liabilities, Current": "25.1",
"Liabilities": "-16.8",
"Stockholders Equity": "-18.2",
"ECR before LimitedLiability": "35.3",
"Other Liabilities": "8.23",
"Liabilities, Non-Current": "-57.4",
"Goodwill": "9.75",
"Assets": "-4.23",
"Property, Plant and Equipment, Net": "23.4",
"Other Assets": "-2.99",
"Assets, Current": "-24.2",
"General and Administrative Expense": "-18.6",
"Expenses": "22.4",
"Revenues": "28.7",
"Net Income": "50.6",
"Research and Development": "14.3",
"Other Expenses": "28.6",
"Other Revenues": "28.7",
"Other Net Income": "-2.96",
"Comprehensive Net Income": "50.6",
"Economic Capital Ratio": "-4.82"
},
"2014": {
"Liabilities, Non-Current": "-58.3",
"Liabilities": "-1.31",
"Stockholders Equity": "3.36",
"ECR before LimitedLiability": "56.9",
"Liabilities, Current": "41.5",
"Other Liabilities": "6.72",
"Assets, Current": "-23.7",
"Assets": "3.47",
"Goodwill": "10.7",
"Assets, Non-Current": "1.43",
"Property, Plant and Equipment, Net": "25.0",
"Other Expenses": "18.1",
"Expenses": "25.8",
"Revenues": "24.3",
"Net Income": "55.5",
"Research and Development": "16.9",
"General and Administrative Expense": "-9.17",
"Other Revenues": "24.3",
"Other Net Income": "1.76",
"Comprehensive Net Income": "53.8",
"Economic Capital Ratio": "7.51"
},
"2015": {
"Other Liabilities": "-5.10",
"Liabilities": "-44.7",
"Stockholders Equity": "-3.52",
"ECR before LimitedLiability": "31.4",
"Liabilities, Current": "23.6",
"Liabilities, Non-Current": "-68.3",
"Assets, Current": "-21.1",
"Assets": "35.6",
"Other Assets": "-5.63",
"Goodwill": "23.8",
"Assets, Non-Current": "2.30",
"Property, Plant and Equipment, Net": "37.0",
"Research and Development": "9.38",
"Expenses": "36.8",
"Revenues": "-6.46",
"Net Income": "35.9",
"General and Administrative Expense": "8.62",
"Other Expenses": "22.4",
"Other Revenues": "-6.46",
"Comprehensive Net Income": "35.9",
"Economic Capital Ratio": "-14.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000074303_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "882,800",
"Assets, Non-Current": "72,300",
"General and Administrative Expense": "1,484,300",
"Goodwill": "300,300",
"Liabilities, Current": "391,000",
"Liabilities, Non-Current": "803,900",
"Other Assets": "118,300",
"Other Compr. Net Income": "0",
"Other Expenses": "71,700",
"Other Liabilities": "23,500",
"Other Net Income": "34,900",
"Other Revenues": "1,585,900",
"Property, Plant and Equipment, Net": "675,000",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "1,218,400",
"Assets": "2,048,700",
"Expenses": "1,556,000",
"Revenues": "1,585,900",
"Stockholders Equity": "830,300",
"Net Income": "64,800",
"Comprehensive Net Income": "64,800",
"BaseVar": "3,221,950",
"ECR before LimitedLiability": "74%",
"Economic Capital Ratio": "149%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "780,300",
"Assets, Non-Current": "85,600",
"General and Administrative Expense": "1,735,300",
"Goodwill": "627,400",
"Liabilities, Current": "399,100",
"Liabilities, Non-Current": "965,100",
"Other Assets": "70,900",
"Other Compr. Net Income": "0",
"Other Expenses": "178,800",
"Other Liabilities": "99,600",
"Other Net Income": "185,900",
"Other Revenues": "1,969,900",
"Property, Plant and Equipment, Net": "885,400",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "1,463,800",
"Assets": "2,449,600",
"Expenses": "1,914,100",
"Revenues": "1,969,900",
"Stockholders Equity": "985,800",
"Net Income": "241,700",
"Comprehensive Net Income": "241,700",
"BaseVar": "3,991,650",
"ECR before LimitedLiability": "81%",
"Economic Capital Ratio": "154%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "749,100",
"Assets, Non-Current": "224,100",
"General and Administrative Expense": "1,916,600",
"Goodwill": "747,100",
"Liabilities, Current": "434,000",
"Liabilities, Non-Current": "1,234,900",
"Other Assets": "23,100",
"Other Compr. Net Income": "-77,100",
"Other Expenses": "118,800",
"Other Liabilities": "110,400",
"Other Net Income": "-7,300",
"Other Revenues": "2,192,300",
"Property, Plant and Equipment, Net": "1,034,300",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "1,779,300",
"Assets": "2,777,700",
"Expenses": "2,035,400",
"Revenues": "2,192,300",
"Stockholders Equity": "998,400",
"Net Income": "149,600",
"Comprehensive Net Income": "111,050",
"BaseVar": "4,434,550",
"ECR before LimitedLiability": "65%",
"Economic Capital Ratio": "142%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "839,900",
"Assets, Non-Current": "213,100",
"General and Administrative Expense": "2,223,700",
"Goodwill": "747,100",
"Liabilities, Current": "407,500",
"Liabilities, Non-Current": "1,176,600",
"Other Assets": "14,900",
"Other Compr. Net Income": "6,200",
"Other Expenses": "115,500",
"Other Liabilities": "117,600",
"Other Net Income": "2,100",
"Other Revenues": "2,515,700",
"Property, Plant and Equipment, Net": "987,800",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "1,701,700",
"Assets": "2,802,800",
"Expenses": "2,339,200",
"Revenues": "2,515,700",
"Stockholders Equity": "1,101,100",
"Net Income": "178,600",
"Comprehensive Net Income": "181,700",
"BaseVar": "4,683,850",
"ECR before LimitedLiability": "75%",
"Economic Capital Ratio": "150%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "816,100",
"Assets, Non-Current": "191,400",
"General and Administrative Expense": "2,023,600",
"Goodwill": "747,100",
"Liabilities, Current": "377,700",
"Liabilities, Non-Current": "1,200,000",
"Other Assets": "12,500",
"Other Compr. Net Income": "-78,000",
"Other Expenses": "176,100",
"Other Liabilities": "107,100",
"Other Net Income": "3,800",
"Other Revenues": "2,242,700",
"Property, Plant and Equipment, Net": "931,000",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "1,684,800",
"Assets": "2,698,100",
"Expenses": "2,199,700",
"Revenues": "2,242,700",
"Stockholders Equity": "1,013,300",
"Net Income": "46,800",
"Comprehensive Net Income": "7,800",
"BaseVar": "4,453,550",
"ECR before LimitedLiability": "64%",
"Economic Capital Ratio": "141%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "1,933,400",
"Assets, Non-Current": "487,500",
"General and Administrative Expense": "2,673,300",
"Goodwill": "2,851,600",
"Liabilities, Current": "1,147,700",
"Liabilities, Non-Current": "4,660,100",
"Other Assets": "95,900",
"Other Compr. Net Income": "-49,400",
"Other Expenses": "305,800",
"Other Liabilities": "1,095,200",
"Other Net Income": "3,000",
"Other Revenues": "2,900,100",
"Property, Plant and Equipment, Net": "3,953,400",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "6,903,000",
"Assets": "9,321,800",
"Expenses": "2,979,100",
"Revenues": "2,900,100",
"Stockholders Equity": "2,418,800",
"Net Income": "-76,000",
"Comprehensive Net Income": "-100,700",
"BaseVar": "11,078,200",
"ECR before LimitedLiability": "40%",
"Economic Capital Ratio": "121%"
}
}
},
"top_rated": false,
"trend": -4.0,
"value": 1.213358576813954,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000074303.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000074303.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000074303.svg"
},
{
"company_id": "0000736822",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000736822.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000736822.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000736822_main_keyfigs.svg",
"name": "Immucor INC",
"rank": 29,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000736822.svg",
"report_text": "The relative strengths and weaknesses of Immucor INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Immucor INC compared to the market average is the variable Goodwill, increasing the Economic Capital Ratio by 60% points.The greatest weakness of Immucor INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 87% points.
The company's Economic Capital Ratio, given in the ranking table, is 113%, being 23% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000736822_2016_Immucor_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "39.5",
"Liabilities": "54.4",
"Assets": "10.7",
"Stockholders Equity": "101",
"ECR before LimitedLiability": "179",
"Liabilities, Non-Current": "13.7",
"Other Liabilities": "7.43",
"Assets, Non-Current": "-0.617",
"Goodwill": "2.94",
"Assets, Current": "6.71",
"General and Administrative Expense": "38.1",
"Expenses": "36.3",
"Revenues": "17.8",
"Net Income": "48.0",
"Research and Development": "9.70",
"Other Expenses": "-12.0",
"Other Revenues": "17.8",
"Comprehensive Net Income": "47.9",
"Other Net Income": "-5.26",
"Other Compr. Net Income": "-0.0529",
"Economic Capital Ratio": "117"
},
"2013": {
"Liabilities, Current": "23.0",
"Liabilities": "-65.3",
"Stockholders Equity": "-1.14",
"ECR before LimitedLiability": "15.9",
"Other Liabilities": "-9.42",
"Liabilities, Non-Current": "-85.8",
"Goodwill": "73.0",
"Assets": "45.9",
"Assets, Non-Current": "-3.81",
"Property, Plant and Equipment, Net": "-5.30",
"Assets, Current": "-26.6",
"General and Administrative Expense": "32.9",
"Expenses": "45.9",
"Revenues": "-18.7",
"Net Income": "24.6",
"Research and Development": "7.96",
"Other Expenses": "11.5",
"Other Revenues": "-18.7",
"Other Net Income": "-6.76",
"Comprehensive Net Income": "24.5",
"Economic Capital Ratio": "-24.2"
},
"2014": {
"Liabilities, Non-Current": "-89.1",
"Liabilities": "-53.5",
"ECR before LimitedLiability": "28.0",
"Liabilities, Current": "27.6",
"Other Liabilities": "-10.5",
"Assets, Current": "-31.4",
"Assets": "29.1",
"Goodwill": "58.9",
"Other Assets": "2.71",
"Assets, Non-Current": "-4.28",
"Property, Plant and Equipment, Net": "-6.59",
"Other Expenses": "-2.42",
"Expenses": "28.6",
"Net Income": "25.8",
"Research and Development": "10.5",
"General and Administrative Expense": "28.0",
"Other Revenues": "-19.1",
"Revenues": "-19.1",
"Other Net Income": "-3.74",
"Comprehensive Net Income": "26.1",
"Economic Capital Ratio": "-21.4"
},
"2015": {
"Other Liabilities": "-9.11",
"Liabilities": "-53.8",
"Stockholders Equity": "-6.92",
"ECR before LimitedLiability": "22.6",
"Liabilities, Current": "28.0",
"Liabilities, Non-Current": "-86.9",
"Assets, Current": "-31.3",
"Assets": "28.4",
"Other Assets": "-6.86",
"Goodwill": "59.9",
"Property, Plant and Equipment, Net": "-7.06",
"Research and Development": "7.42",
"Expenses": "29.0",
"Revenues": "-13.2",
"Net Income": "28.0",
"General and Administrative Expense": "28.0",
"Other Expenses": "10.6",
"Other Revenues": "-13.2",
"Comprehensive Net Income": "27.9",
"Other Net Income": "-4.34",
"Economic Capital Ratio": "-23.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000736822_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "425,889",
"Assets, Non-Current": "1,122",
"General and Administrative Expense": "74,178",
"Goodwill": "147,900",
"Liabilities, Current": "46,910",
"Liabilities, Non-Current": "2,001",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "158,319",
"Other Liabilities": "15,344",
"Other Net Income": "4,633",
"Other Revenues": "333,091",
"Property, Plant and Equipment, Net": "58,216",
"Research and Development": "15,900"
},
"output_variables": {
"Liabilities": "64,255",
"Assets": "633,127",
"Expenses": "248,397",
"Revenues": "333,091",
"Stockholders Equity": "568,872",
"Net Income": "89,327",
"Comprehensive Net Income": "89,327",
"BaseVar": "641,752",
"ECR before LimitedLiability": "249%",
"Economic Capital Ratio": "270%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "160,282",
"Assets, Non-Current": "6,792",
"General and Administrative Expense": "92,930",
"Goodwill": "1,718,066",
"Liabilities, Current": "73,213",
"Liabilities, Non-Current": "1,051,850",
"Other Assets": "39,449",
"Other Compr. Net Income": "1,821",
"Other Expenses": "172,235",
"Other Liabilities": "231,201",
"Other Net Income": "-100,452",
"Other Revenues": "347,788",
"Property, Plant and Equipment, Net": "76,381",
"Research and Development": "21,313"
},
"output_variables": {
"Liabilities": "1,356,264",
"Assets": "2,000,970",
"Expenses": "286,478",
"Revenues": "347,788",
"Stockholders Equity": "644,706",
"Net Income": "-39,142",
"Comprehensive Net Income": "-38,232",
"BaseVar": "2,046,886",
"ECR before LimitedLiability": "50%",
"Economic Capital Ratio": "130%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "163,234",
"Assets, Non-Current": "7,320",
"General and Administrative Expense": "100,660",
"Goodwill": "1,544,433",
"Liabilities, Current": "71,317",
"Liabilities, Non-Current": "1,061,102",
"Other Assets": "33,116",
"Other Compr. Net Income": "4,655",
"Other Expenses": "352,360",
"Other Liabilities": "223,379",
"Other Net Income": "-88,223",
"Other Revenues": "388,056",
"Property, Plant and Equipment, Net": "76,311",
"Research and Development": "29,070"
},
"output_variables": {
"Liabilities": "1,355,798",
"Assets": "1,824,414",
"Expenses": "482,090",
"Revenues": "388,056",
"Stockholders Equity": "468,616",
"Net Income": "-182,257",
"Comprehensive Net Income": "-179,930",
"BaseVar": "2,071,618",
"ECR before LimitedLiability": "29%",
"Economic Capital Ratio": "112%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "139,045",
"Assets, Non-Current": "15,167",
"General and Administrative Expense": "99,024",
"Goodwill": "1,492,552",
"Liabilities, Current": "72,125",
"Liabilities, Non-Current": "1,023,206",
"Other Assets": "0",
"Other Compr. Net Income": "-26,297",
"Other Expenses": "233,812",
"Other Liabilities": "241,326",
"Other Net Income": "-88,398",
"Other Revenues": "389,300",
"Property, Plant and Equipment, Net": "73,574",
"Research and Development": "28,791"
},
"output_variables": {
"Liabilities": "1,336,657",
"Assets": "1,720,338",
"Expenses": "361,627",
"Revenues": "389,300",
"Stockholders Equity": "383,681",
"Net Income": "-60,725",
"Comprehensive Net Income": "-73,874",
"BaseVar": "1,961,308",
"ECR before LimitedLiability": "30%",
"Economic Capital Ratio": "113%"
}
}
},
"top_rated": false,
"trend": -1.0,
"value": 1.1255783450285024,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000736822.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000736822.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000736822.svg"
},
{
"company_id": "0001566978",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001566978.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001566978.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001566978_main_keyfigs.svg",
"name": "Alphabet Holding Company Inc",
"rank": 30,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001566978.svg",
"report_text": "The relative strengths and weaknesses of Alphabet Holding Company Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Alphabet Holding Company Inc compared to the market average is the variable Goodwill, increasing the Economic Capital Ratio by 19% points.The greatest weakness of Alphabet Holding Company Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 82% points.
The company's Economic Capital Ratio, given in the ranking table, is 98%, being 38% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001566978_2016_Alphabet_Holding_Company_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Liabilities, Current": "26.0",
"Liabilities": "-53.7",
"Stockholders Equity": "-33.7",
"ECR before LimitedLiability": "3.08",
"Other Liabilities": "-9.78",
"Liabilities, Non-Current": "-75.6",
"Goodwill": "37.9",
"Assets": "6.92",
"Assets, Non-Current": "-4.83",
"Other Assets": "-3.91",
"Assets, Current": "-30.1",
"General and Administrative Expense": "32.9",
"Expenses": "33.0",
"Revenues": "7.18",
"Net Income": "33.0",
"Research and Development": "13.4",
"Other Expenses": "-8.66",
"Other Revenues": "7.18",
"Other Net Income": "-6.41",
"Comprehensive Net Income": "33.0",
"Economic Capital Ratio": "-37.1"
},
"2014": {
"Liabilities, Non-Current": "-88.3",
"Liabilities": "-44.5",
"Stockholders Equity": "-29.9",
"ECR before LimitedLiability": "13.9",
"Liabilities, Current": "14.7",
"Other Liabilities": "-9.15",
"Assets, Current": "-32.9",
"Assets": "7.80",
"Goodwill": "20.3",
"Assets, Non-Current": "-5.38",
"Property, Plant and Equipment, Net": "-2.00",
"Other Expenses": "-18.8",
"Expenses": "15.0",
"Revenues": "7.77",
"Net Income": "15.6",
"Research and Development": "13.4",
"General and Administrative Expense": "15.4",
"Other Revenues": "7.77",
"Other Net Income": "-2.72",
"Comprehensive Net Income": "15.6",
"Economic Capital Ratio": "-35.6"
},
"2015": {
"Other Liabilities": "-4.05",
"Liabilities": "-40.6",
"Stockholders Equity": "-37.7",
"ECR before LimitedLiability": "8.35",
"Liabilities, Current": "14.5",
"Liabilities, Non-Current": "-81.9",
"Assets, Current": "-29.5",
"Assets": "-4.34",
"Other Assets": "-10.1",
"Goodwill": "18.9",
"Assets, Non-Current": "-5.13",
"Property, Plant and Equipment, Net": "-2.93",
"Research and Development": "13.0",
"Expenses": "14.8",
"Revenues": "13.7",
"Net Income": "16.7",
"General and Administrative Expense": "14.3",
"Other Expenses": "-7.28",
"Other Revenues": "13.7",
"Comprehensive Net Income": "16.2",
"Economic Capital Ratio": "-37.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001566978_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "1,218,214",
"Assets, Non-Current": "75,282",
"General and Administrative Expense": "910,531",
"Goodwill": "3,221,153",
"Liabilities, Current": "486,279",
"Liabilities, Non-Current": "2,758,557",
"Other Assets": "0",
"Other Compr. Net Income": "5,012",
"Other Expenses": "1,963,475",
"Other Liabilities": "751,419",
"Other Net Income": "-189,587",
"Other Revenues": "3,163,041",
"Property, Plant and Equipment, Net": "571,529",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "3,996,255",
"Assets": "5,086,178",
"Expenses": "2,874,006",
"Revenues": "3,163,041",
"Stockholders Equity": "1,089,923",
"Net Income": "99,448",
"Comprehensive Net Income": "101,954",
"BaseVar": "7,657,040",
"ECR before LimitedLiability": "35%",
"Economic Capital Ratio": "117%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "1,286,838",
"Assets, Non-Current": "63,647",
"General and Administrative Expense": "952,681",
"Goodwill": "2,954,874",
"Liabilities, Current": "456,157",
"Liabilities, Non-Current": "3,212,442",
"Other Assets": "0",
"Other Compr. Net Income": "-15,620",
"Other Expenses": "2,134,018",
"Other Liabilities": "695,959",
"Other Net Income": "-213,752",
"Other Revenues": "3,205,778",
"Property, Plant and Equipment, Net": "597,202",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "4,364,558",
"Assets": "4,902,561",
"Expenses": "3,086,699",
"Revenues": "3,205,778",
"Stockholders Equity": "538,003",
"Net Income": "-94,673",
"Comprehensive Net Income": "-102,483",
"BaseVar": "7,894,484",
"ECR before LimitedLiability": "14%",
"Economic Capital Ratio": "98%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "1,461,050",
"Assets, Non-Current": "17,852",
"General and Administrative Expense": "978,432",
"Goodwill": "2,782,558",
"Liabilities, Current": "574,814",
"Liabilities, Non-Current": "3,154,488",
"Other Assets": "0",
"Other Compr. Net Income": "-326,195",
"Other Expenses": "2,029,158",
"Other Liabilities": "701,694",
"Other Net Income": "0",
"Other Revenues": "3,226,124",
"Property, Plant and Equipment, Net": "605,708",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "4,430,996",
"Assets": "4,867,168",
"Expenses": "3,007,590",
"Revenues": "3,226,124",
"Stockholders Equity": "436,172",
"Net Income": "218,534",
"Comprehensive Net Income": "55,436",
"BaseVar": "7,929,036",
"ECR before LimitedLiability": "14%",
"Economic Capital Ratio": "98%"
}
}
},
"top_rated": false,
"trend": 2.0,
"value": 0.9830385445829133,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001566978.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001566978.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001566978.svg"
},
{
"company_id": "0001045309",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001045309.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001045309.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001045309.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001045309_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001045309_main_keyfigs.svg",
"name": "W R Grace CO",
"rank": 31,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001045309.svg",
"report_text": "The relative strengths and weaknesses of W R Grace CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of W R Grace CO compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 15% points.The greatest weakness of W R Grace CO is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 96% points.
The company's Economic Capital Ratio, given in the ranking table, is 96%, being 40% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001045309_2016_W_R_Grace_CO.pdf",
"shrinked_graph_json": {
"2014": {
"Liabilities, Non-Current": "-77.1",
"Liabilities": "-40.6",
"Stockholders Equity": "-33.8",
"ECR before LimitedLiability": "19.4",
"Liabilities, Current": "18.8",
"Other Liabilities": "10.4",
"Other Expenses": "18.9",
"Expenses": "19.7",
"Net Income": "22.0",
"Research and Development": "15.7",
"General and Administrative Expense": "1.57",
"Other Revenues": "17.7",
"Revenues": "17.7",
"Assets, Current": "-21.7",
"Goodwill": "-0.777",
"Other Assets": "22.0",
"Assets, Non-Current": "-2.05",
"Property, Plant and Equipment, Net": "-16.2",
"Other Net Income": "1.70",
"Comprehensive Net Income": "21.9",
"Economic Capital Ratio": "-30.1"
},
"2015": {
"Other Liabilities": "11.4",
"Liabilities": "-35.1",
"Stockholders Equity": "-45.4",
"Liabilities, Current": "12.0",
"Liabilities, Non-Current": "-95.6",
"Assets, Current": "-32.5",
"Assets": "-15.8",
"Other Assets": "15.2",
"Goodwill": "-0.670",
"Property, Plant and Equipment, Net": "-18.6",
"Research and Development": "11.4",
"Expenses": "11.9",
"Revenues": "11.8",
"Net Income": "15.2",
"General and Administrative Expense": "-10.4",
"Other Expenses": "11.9",
"Other Revenues": "11.8",
"ECR before LimitedLiability": "6.03",
"Comprehensive Net Income": "15.2",
"Other Net Income": "1.20",
"Economic Capital Ratio": "-39.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001045309_strength_weakness.svg",
"table_records": {
"2014": {
"input_variables": {
"Assets, Current": "1,690,900",
"Assets, Non-Current": "173,800",
"General and Administrative Expense": "2,714,600",
"Goodwill": "740,900",
"Liabilities, Current": "1,182,100",
"Liabilities, Non-Current": "2,500,800",
"Other Assets": "1,489,600",
"Other Compr. Net Income": "-35,400",
"Other Expenses": "171,600",
"Other Liabilities": "43,300",
"Other Net Income": "0",
"Other Revenues": "3,243,000",
"Property, Plant and Equipment, Net": "0",
"Research and Development": "79,500"
},
"output_variables": {
"Liabilities": "3,726,200",
"Assets": "4,095,200",
"Expenses": "2,965,700",
"Revenues": "3,243,000",
"Stockholders Equity": "369,000",
"Net Income": "277,300",
"Comprehensive Net Income": "259,600",
"BaseVar": "7,032,750",
"ECR before LimitedLiability": "20%",
"Economic Capital Ratio": "103%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "1,184,500",
"Assets, Non-Current": "176,900",
"General and Administrative Expense": "2,458,200",
"Goodwill": "699,800",
"Liabilities, Current": "707,400",
"Liabilities, Non-Current": "2,725,300",
"Other Assets": "1,614,800",
"Other Compr. Net Income": "-43,700",
"Other Expenses": "378,800",
"Other Liabilities": "30,800",
"Other Net Income": "0",
"Other Revenues": "3,051,500",
"Property, Plant and Equipment, Net": "0",
"Research and Development": "69,600"
},
"output_variables": {
"Liabilities": "3,463,500",
"Assets": "3,676,000",
"Expenses": "2,906,600",
"Revenues": "3,051,500",
"Stockholders Equity": "212,500",
"Net Income": "144,900",
"Comprehensive Net Income": "123,050",
"BaseVar": "6,570,650",
"ECR before LimitedLiability": "12%",
"Economic Capital Ratio": "96%"
}
}
},
"top_rated": false,
"trend": 0.0,
"value": 0.9597800840497963,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001045309.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001045309.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001045309.svg"
},
{
"company_id": "0000874716",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000874716.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000874716.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000874716.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000874716_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000874716_main_keyfigs.svg",
"name": "Idexx Laboratories INC DE",
"rank": 32,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000874716.svg",
"report_text": "The relative strengths and weaknesses of Idexx Laboratories INC DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Idexx Laboratories INC DE compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 12% points.The greatest weakness of Idexx Laboratories INC DE is the variable Stockholders Equity, reducing the Economic Capital Ratio by 63% points.
The company's Economic Capital Ratio, given in the ranking table, is 89%, being 47% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000874716_2016_Idexx_Laboratories_INC_DE.pdf",
"shrinked_graph_json": {
"2010": {
"Other Liabilities": "4.39",
"Liabilities": "21.9",
"Stockholders Equity": "-14.3",
"ECR before LimitedLiability": "23.6",
"Liabilities, Current": "-18.4",
"Liabilities, Non-Current": "32.6",
"Assets": "-11.3",
"Property, Plant and Equipment, Net": "0.217",
"Assets, Current": "-8.67",
"Assets, Non-Current": "28.2",
"Other Assets": "-18.8",
"Other Expenses": "21.1",
"Expenses": "-8.82",
"Revenues": "28.5",
"Net Income": "23.0",
"General and Administrative Expense": "-32.3",
"Research and Development": "1.98",
"Other Revenues": "28.5",
"Other Net Income": "3.49",
"Comprehensive Net Income": "23.1",
"Economic Capital Ratio": "25.6"
},
"2011": {
"Liabilities, Current": "-10.1",
"Liabilities": "9.33",
"Stockholders Equity": "-4.45",
"ECR before LimitedLiability": "88.9",
"Liabilities, Non-Current": "4.54",
"Other Liabilities": "14.3",
"Assets": "-5.93",
"Assets, Non-Current": "45.2",
"Other Assets": "-23.7",
"Goodwill": "5.99",
"Assets, Current": "-11.7",
"General and Administrative Expense": "-12.4",
"Expenses": "17.7",
"Revenues": "45.9",
"Net Income": "58.1",
"Research and Development": "9.32",
"Other Expenses": "21.3",
"Other Revenues": "45.9",
"Comprehensive Net Income": "58.1",
"Other Net Income": "-7.26",
"Economic Capital Ratio": "26.9"
},
"2012": {
"Liabilities, Current": "-16.6",
"Liabilities": "13.2",
"Stockholders Equity": "-4.10",
"ECR before LimitedLiability": "64.6",
"Liabilities, Non-Current": "4.25",
"Other Liabilities": "23.5",
"Assets, Current": "-9.87",
"Assets": "-6.33",
"Other Assets": "-21.8",
"Assets, Non-Current": "39.4",
"Property, Plant and Equipment, Net": "3.65",
"Goodwill": "2.84",
"Other Expenses": "24.4",
"Expenses": "17.1",
"Revenues": "43.6",
"Net Income": "63.1",
"Research and Development": "10.4",
"General and Administrative Expense": "-17.2",
"Other Revenues": "43.6",
"Comprehensive Net Income": "63.2",
"Economic Capital Ratio": "32.1"
},
"2013": {
"Liabilities, Current": "-9.09",
"Liabilities": "-3.70",
"Stockholders Equity": "-20.6",
"ECR before LimitedLiability": "47.9",
"Other Liabilities": "16.4",
"Liabilities, Non-Current": "-11.9",
"Assets": "-11.0",
"Assets, Non-Current": "48.7",
"Property, Plant and Equipment, Net": "6.04",
"Other Assets": "-28.2",
"Assets, Current": "-11.7",
"General and Administrative Expense": "-16.4",
"Expenses": "18.6",
"Revenues": "44.8",
"Net Income": "63.5",
"Research and Development": "8.33",
"Other Expenses": "28.2",
"Other Revenues": "44.8",
"Other Net Income": "-3.22",
"Comprehensive Net Income": "63.2",
"Economic Capital Ratio": "7.79"
},
"2014": {
"Liabilities, Non-Current": "-25.6",
"Liabilities": "-26.1",
"Stockholders Equity": "-39.5",
"ECR before LimitedLiability": "24.4",
"Liabilities, Current": "-14.6",
"Other Liabilities": "13.5",
"Assets, Current": "-16.9",
"Assets": "-16.4",
"Goodwill": "-4.01",
"Other Assets": "-35.5",
"Assets, Non-Current": "26.5",
"Property, Plant and Equipment, Net": "6.26",
"Other Expenses": "23.5",
"Expenses": "24.1",
"Revenues": "24.2",
"Net Income": "28.5",
"Research and Development": "12.8",
"General and Administrative Expense": "-3.18",
"Other Revenues": "24.2",
"Comprehensive Net Income": "28.4",
"Economic Capital Ratio": "-25.0"
},
"2015": {
"Other Liabilities": "4.32",
"Liabilities": "-34.1",
"Stockholders Equity": "-63.1",
"Liabilities, Current": "-12.6",
"Liabilities, Non-Current": "-42.3",
"Assets, Current": "-20.3",
"Assets": "-32.5",
"Other Assets": "-46.4",
"Goodwill": "-8.19",
"Assets, Non-Current": "10.1",
"Property, Plant and Equipment, Net": "3.92",
"Research and Development": "3.97",
"Expenses": "4.98",
"Revenues": "6.60",
"Net Income": "12.0",
"General and Administrative Expense": "-15.1",
"Other Expenses": "5.64",
"Other Revenues": "6.60",
"ECR before LimitedLiability": "-1.40",
"Comprehensive Net Income": "11.8",
"Economic Capital Ratio": "-47.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000874716_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "460,591",
"Assets, Non-Current": "436,553",
"General and Administrative Expense": "830,914",
"Goodwill": "204,864",
"Liabilities, Current": "285,112",
"Liabilities, Non-Current": "37,751",
"Other Assets": "-406,589",
"Other Compr. Net Income": "0",
"Other Expenses": "63,224",
"Other Liabilities": "0",
"Other Net Income": "663",
"Other Revenues": "1,103,392",
"Property, Plant and Equipment, Net": "201,725",
"Research and Development": "68,597"
},
"output_variables": {
"Liabilities": "322,863",
"Assets": "897,144",
"Expenses": "962,735",
"Revenues": "1,103,392",
"Stockholders Equity": "574,281",
"Net Income": "141,320",
"Comprehensive Net Income": "141,320",
"BaseVar": "1,643,398",
"ECR before LimitedLiability": "152%",
"Economic Capital Ratio": "203%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "524,227",
"Assets, Non-Current": "506,587",
"General and Administrative Expense": "906,422",
"Goodwill": "241,819",
"Liabilities, Current": "436,879",
"Liabilities, Non-Current": "54,342",
"Other Assets": "-458,596",
"Other Compr. Net Income": "0",
"Other Expenses": "76,215",
"Other Liabilities": "0",
"Other Net Income": "1,744",
"Other Revenues": "1,218,689",
"Property, Plant and Equipment, Net": "216,777",
"Research and Development": "76,042"
},
"output_variables": {
"Liabilities": "491,221",
"Assets": "1,030,814",
"Expenses": "1,058,679",
"Revenues": "1,218,689",
"Stockholders Equity": "539,593",
"Net Income": "161,754",
"Comprehensive Net Income": "161,754",
"BaseVar": "1,900,574",
"ECR before LimitedLiability": "118%",
"Economic Capital Ratio": "180%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "569,537",
"Assets, Non-Current": "534,065",
"General and Administrative Expense": "948,761",
"Goodwill": "237,827",
"Liabilities, Current": "406,333",
"Liabilities, Non-Current": "61,012",
"Other Assets": "-483,004",
"Other Compr. Net Income": "491",
"Other Expenses": "86,178",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "1,295,240",
"Property, Plant and Equipment, Net": "245,177",
"Research and Development": "82,014"
},
"output_variables": {
"Liabilities": "467,345",
"Assets": "1,103,602",
"Expenses": "1,116,953",
"Revenues": "1,295,240",
"Stockholders Equity": "636,257",
"Net Income": "178,287",
"Comprehensive Net Income": "178,532",
"BaseVar": "1,991,816",
"ECR before LimitedLiability": "134%",
"Economic Capital Ratio": "191%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "652,706",
"Assets, Non-Current": "577,810",
"General and Administrative Expense": "1,022,293",
"Goodwill": "239,365",
"Liabilities, Current": "478,353",
"Liabilities, Non-Current": "233,949",
"Other Assets": "-520,579",
"Other Compr. Net Income": "-2,326",
"Other Expenses": "80,853",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "1,378,943",
"Property, Plant and Equipment, Net": "281,214",
"Research and Development": "88,003"
},
"output_variables": {
"Liabilities": "712,302",
"Assets": "1,230,516",
"Expenses": "1,191,149",
"Revenues": "1,378,943",
"Stockholders Equity": "518,214",
"Net Income": "187,794",
"Comprehensive Net Income": "186,631",
"BaseVar": "2,257,618",
"ECR before LimitedLiability": "92%",
"Economic Capital Ratio": "162%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "759,398",
"Assets, Non-Current": "624,813",
"General and Administrative Expense": "1,127,289",
"Goodwill": "249,572",
"Liabilities, Current": "820,906",
"Liabilities, Non-Current": "445,716",
"Other Assets": "-553,159",
"Other Compr. Net Income": "-21,738",
"Other Expenses": "80,033",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "1,487,536",
"Property, Plant and Equipment, Net": "303,587",
"Research and Development": "98,263"
},
"output_variables": {
"Liabilities": "1,266,622",
"Assets": "1,384,211",
"Expenses": "1,305,585",
"Revenues": "1,487,536",
"Stockholders Equity": "117,589",
"Net Income": "181,951",
"Comprehensive Net Income": "171,082",
"BaseVar": "2,732,846",
"ECR before LimitedLiability": "25%",
"Economic Capital Ratio": "109%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "821,634",
"Assets, Non-Current": "653,359",
"General and Administrative Expense": "1,194,087",
"Goodwill": "234,843",
"Liabilities, Current": "856,761",
"Liabilities, Non-Current": "702,227",
"Other Assets": "-567,869",
"Other Compr. Net Income": "-34,251",
"Other Expenses": "118,457",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "1,604,360",
"Property, Plant and Equipment, Net": "333,026",
"Research and Development": "99,681"
},
"output_variables": {
"Liabilities": "1,558,988",
"Assets": "1,474,993",
"Expenses": "1,412,225",
"Revenues": "1,604,360",
"Stockholders Equity": "-83,995",
"Net Income": "192,135",
"Comprehensive Net Income": "175,010",
"BaseVar": "3,042,408",
"ECR before LimitedLiability": "4.0%",
"Economic Capital Ratio": "89%"
}
}
},
"top_rated": false,
"trend": -2.0,
"value": 0.8855008879893294,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000874716.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000874716.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000874716.svg"
},
{
"company_id": "0001627223",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001627223.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001627223.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001627223.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001627223_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001627223_main_keyfigs.svg",
"name": "Chemours Co",
"rank": 33,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001627223.svg",
"report_text": "The relative strengths and weaknesses of Chemours Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Chemours Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 5.7% points.The greatest weakness of Chemours Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 85% points.
The company's Economic Capital Ratio, given in the ranking table, is 85%, being 51% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001627223_2016_Chemours_Co.pdf",
"shrinked_graph_json": {
"2015": {
"Other Liabilities": "0.356",
"Liabilities": "-30.9",
"Stockholders Equity": "-54.3",
"Liabilities, Current": "1.52",
"Liabilities, Non-Current": "-84.9",
"Assets, Current": "-35.4",
"Assets": "-26.5",
"Other Assets": "-12.3",
"Goodwill": "-21.8",
"Property, Plant and Equipment, Net": "5.56",
"Research and Development": "0.386",
"Expenses": "1.07",
"Revenues": "1.68",
"Net Income": "5.71",
"General and Administrative Expense": "4.89",
"Other Expenses": "-37.9",
"Other Revenues": "1.68",
"ECR before LimitedLiability": "-5.32",
"Comprehensive Net Income": "5.42",
"Other Compr. Net Income": "-0.949",
"Economic Capital Ratio": "-51.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001627223_strength_weakness.svg",
"table_records": {
"2015": {
"input_variables": {
"Assets, Current": "2,301,000",
"Assets, Non-Current": "644,000",
"General and Administrative Expense": "632,000",
"Goodwill": "176,000",
"Liabilities, Current": "1,466,000",
"Liabilities, Non-Current": "4,468,000",
"Other Assets": "0",
"Other Compr. Net Income": "-244,000",
"Other Expenses": "5,154,000",
"Other Liabilities": "234,000",
"Other Net Income": "76,000",
"Other Revenues": "5,717,000",
"Property, Plant and Equipment, Net": "3,177,000",
"Research and Development": "97,000"
},
"output_variables": {
"Liabilities": "6,168,000",
"Assets": "6,298,000",
"Expenses": "5,883,000",
"Revenues": "5,717,000",
"Stockholders Equity": "130,000",
"Net Income": "-90,000",
"Comprehensive Net Income": "-212,000",
"BaseVar": "12,193,000",
"ECR before LimitedLiability": "-0.54%",
"Economic Capital Ratio": "85%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.8462788123413069,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001627223.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001627223.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001627223.svg"
},
{
"company_id": "0001141240",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001141240.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001141240.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001141240.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001141240_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001141240_main_keyfigs.svg",
"name": "Liquidmetal Technologies INC",
"rank": 34,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001141240.svg",
"report_text": "The relative strengths and weaknesses of Liquidmetal Technologies INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Liquidmetal Technologies INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 17% points.The greatest weakness of Liquidmetal Technologies INC is the variable Net Income, reducing the Economic Capital Ratio by 60% points.
The company's Economic Capital Ratio, given in the ranking table, is 83%, being 52% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001141240_2016_Liquidmetal_Technologies_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "-40.4",
"Liabilities": "-11.9",
"Stockholders Equity": "-217",
"ECR before LimitedLiability": "76.3",
"Liabilities, Non-Current": "-1.08",
"Other Liabilities": "24.7",
"Property, Plant and Equipment, Net": "-17.8",
"Assets": "-57.7",
"Assets, Non-Current": "-8.47",
"Goodwill": "-3.55",
"Assets, Current": "-48.1",
"General and Administrative Expense": "21.1",
"Expenses": "36.6",
"Revenues": "-96.1",
"Net Income": "132",
"Research and Development": "4.07",
"Other Expenses": "9.81",
"Other Revenues": "-96.1",
"Comprehensive Net Income": "132",
"Other Net Income": "155",
"Economic Capital Ratio": "14.3"
},
"2012": {
"Liabilities, Current": "-5.03",
"Liabilities": "-5.65",
"Stockholders Equity": "-38.6",
"ECR before LimitedLiability": "-80.0",
"Liabilities, Non-Current": "0.726",
"Other Liabilities": "-1.25",
"Assets, Current": "-20.1",
"Assets": "-37.0",
"Assets, Non-Current": "-8.45",
"Property, Plant and Equipment, Net": "-17.1",
"Goodwill": "-13.3",
"Other Expenses": "-38.3",
"Expenses": "-23.8",
"Revenues": "-33.7",
"Net Income": "-22.7",
"Research and Development": "6.92",
"General and Administrative Expense": "18.0",
"Other Revenues": "-33.7",
"Other Net Income": "31.7",
"Comprehensive Net Income": "-22.6",
"Economic Capital Ratio": "-112"
},
"2013": {
"Liabilities, Current": "-0.728",
"Liabilities": "1.82",
"Stockholders Equity": "-43.7",
"ECR before LimitedLiability": "-107",
"Other Liabilities": "3.09",
"Goodwill": "-4.36",
"Assets": "-41.9",
"Assets, Non-Current": "-0.769",
"Property, Plant and Equipment, Net": "-6.88",
"Other Assets": "-2.06",
"Assets, Current": "-21.6",
"General and Administrative Expense": "-2.65",
"Expenses": "-17.3",
"Revenues": "-11.9",
"Net Income": "-50.1",
"Research and Development": "0.0995",
"Other Expenses": "-12.4",
"Other Revenues": "-11.9",
"Other Net Income": "-4.15",
"Comprehensive Net Income": "-50.1",
"Economic Capital Ratio": "-147"
},
"2014": {
"Liabilities, Non-Current": "0.616",
"Liabilities": "11.9",
"Stockholders Equity": "59.9",
"ECR before LimitedLiability": "57.7",
"Liabilities, Current": "33.2",
"Other Liabilities": "-24.2",
"Assets, Current": "65.1",
"Assets": "59.9",
"Goodwill": "-6.11",
"Assets, Non-Current": "-3.75",
"Property, Plant and Equipment, Net": "1.03",
"Other Expenses": "44.2",
"Expenses": "5.01",
"Revenues": "-33.1",
"Net Income": "-27.4",
"Research and Development": "-3.60",
"General and Administrative Expense": "-29.4",
"Other Revenues": "-33.1",
"Other Net Income": "1.48",
"Comprehensive Net Income": "-27.4",
"Economic Capital Ratio": "8.24"
},
"2015": {
"Other Liabilities": "1.58",
"Liabilities": "1.72",
"Stockholders Equity": "11.7",
"ECR before LimitedLiability": "-6.56",
"Liabilities, Current": "0.317",
"Liabilities, Non-Current": "-0.195",
"Assets, Current": "17.4",
"Assets": "10.8",
"Other Assets": "-0.931",
"Goodwill": "-0.854",
"Assets, Non-Current": "-0.520",
"Property, Plant and Equipment, Net": "2.23",
"Research and Development": "-1.99",
"Expenses": "-16.5",
"Revenues": "-26.8",
"Net Income": "-60.4",
"General and Administrative Expense": "-58.0",
"Other Expenses": "15.9",
"Other Revenues": "-26.8",
"Comprehensive Net Income": "-60.1",
"Economic Capital Ratio": "-52.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001141240_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "811",
"Assets, Non-Current": "52",
"General and Administrative Expense": "4,616",
"Goodwill": "968",
"Liabilities, Current": "3,610",
"Liabilities, Non-Current": "609",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "1,803",
"Other Liabilities": "0",
"Other Net Income": "12,722",
"Other Revenues": "972",
"Property, Plant and Equipment, Net": "162",
"Research and Development": "1,120"
},
"output_variables": {
"Liabilities": "4,219",
"Assets": "1,993",
"Expenses": "7,539",
"Revenues": "972",
"Stockholders Equity": "-2,226",
"Net Income": "6,155",
"Comprehensive Net Income": "6,155",
"BaseVar": "13,722",
"ECR before LimitedLiability": "100%",
"Economic Capital Ratio": "168%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "7,915",
"Assets, Non-Current": "28",
"General and Administrative Expense": "5,204",
"Goodwill": "869",
"Liabilities, Current": "6,923",
"Liabilities, Non-Current": "856",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "20,063",
"Other Liabilities": "2,766",
"Other Net Income": "11,535",
"Other Revenues": "650",
"Property, Plant and Equipment, Net": "161",
"Research and Development": "943"
},
"output_variables": {
"Liabilities": "10,545",
"Assets": "8,973",
"Expenses": "26,210",
"Revenues": "650",
"Stockholders Equity": "-1,572",
"Net Income": "-14,025",
"Comprehensive Net Income": "-14,025",
"BaseVar": "28,956",
"ECR before LimitedLiability": "-166%",
"Economic Capital Ratio": "46%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "2,689",
"Assets, Non-Current": "401",
"General and Administrative Expense": "5,931",
"Goodwill": "764",
"Liabilities, Current": "1,071",
"Liabilities, Non-Current": "856",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "6,749",
"Other Liabilities": "4,921",
"Other Net Income": "-1,438",
"Other Revenues": "1,026",
"Property, Plant and Equipment, Net": "249",
"Research and Development": "1,156"
},
"output_variables": {
"Liabilities": "6,848",
"Assets": "4,103",
"Expenses": "13,836",
"Revenues": "1,026",
"Stockholders Equity": "-2,745",
"Net Income": "-14,248",
"Comprehensive Net Income": "-14,248",
"BaseVar": "13,626",
"ECR before LimitedLiability": "-329%",
"Economic Capital Ratio": "7.6%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "10,466",
"Assets, Non-Current": "31",
"General and Administrative Expense": "7,946",
"Goodwill": "669",
"Liabilities, Current": "860",
"Liabilities, Non-Current": "856",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "-2,327",
"Other Liabilities": "2,005",
"Other Net Income": "30",
"Other Revenues": "627",
"Property, Plant and Equipment, Net": "1,118",
"Research and Development": "1,596"
},
"output_variables": {
"Liabilities": "3,721",
"Assets": "12,284",
"Expenses": "7,215",
"Revenues": "627",
"Stockholders Equity": "8,563",
"Net Income": "-6,558",
"Comprehensive Net Income": "-6,558",
"BaseVar": "11,938",
"ECR before LimitedLiability": "65%",
"Economic Capital Ratio": "142%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "5,302",
"Assets, Non-Current": "31",
"General and Administrative Expense": "7,359",
"Goodwill": "570",
"Liabilities, Current": "1,974",
"Liabilities, Non-Current": "856",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "-1,942",
"Other Liabilities": "59",
"Other Net Income": "0",
"Other Revenues": "147",
"Property, Plant and Equipment, Net": "1,370",
"Research and Development": "2,047"
},
"output_variables": {
"Liabilities": "2,889",
"Assets": "7,273",
"Expenses": "7,464",
"Revenues": "147",
"Stockholders Equity": "4,384",
"Net Income": "-7,317",
"Comprehensive Net Income": "-7,317",
"BaseVar": "8,886",
"ECR before LimitedLiability": "-26%",
"Economic Capital Ratio": "83%"
}
}
},
"top_rated": false,
"trend": -11.0,
"value": 0.8338578529057854,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001141240.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001141240.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001141240.svg"
},
{
"company_id": "0001590695",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001590695.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001590695.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001590695.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001590695_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001590695_main_keyfigs.svg",
"name": "Twinlab Consolidated Holdings Inc",
"rank": 35,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001590695.svg",
"report_text": "The relative strengths and weaknesses of Twinlab Consolidated Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Twinlab Consolidated Holdings Inc compared to the market average is the variable Goodwill, increasing the Economic Capital Ratio by 22% points.The greatest weakness of Twinlab Consolidated Holdings Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 31% points.
The company's Economic Capital Ratio, given in the ranking table, is 81%, being 55% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001590695_2016_Twinlab_Consolidated_Holdings_Inc.pdf",
"shrinked_graph_json": {
"2014": {
"Liabilities, Non-Current": "-3.39",
"Liabilities": "-0.909",
"Stockholders Equity": "-34.8",
"ECR before LimitedLiability": "-7.23",
"Liabilities, Current": "-0.530",
"Other Liabilities": "3.17",
"Assets, Current": "-6.92",
"Assets": "-24.7",
"Goodwill": "-3.67",
"Other Assets": "0.285",
"Assets, Non-Current": "-2.40",
"Property, Plant and Equipment, Net": "-4.88",
"Other Revenues": "13.8",
"Revenues": "13.8",
"Net Income": "8.05",
"Other Expenses": "-15.4",
"Comprehensive Net Income": "8.08",
"General and Administrative Expense": "12.6",
"Other Net Income": "-3.66",
"Research and Development": "7.23",
"Economic Capital Ratio": "-56.6"
},
"2015": {
"Other Liabilities": "2.98",
"Liabilities": "-2.28",
"Stockholders Equity": "-30.7",
"ECR before LimitedLiability": "-8.66",
"Liabilities, Current": "-4.86",
"Assets, Current": "-21.8",
"Assets": "-10.3",
"Other Assets": "-2.09",
"Goodwill": "21.9",
"Assets, Non-Current": "-0.933",
"Property, Plant and Equipment, Net": "-2.58",
"Research and Development": "3.06",
"Expenses": "3.54",
"Revenues": "5.06",
"Net Income": "3.85",
"General and Administrative Expense": "8.05",
"Other Expenses": "-3.25",
"Other Revenues": "5.06",
"Comprehensive Net Income": "3.97",
"Other Net Income": "-2.73",
"Economic Capital Ratio": "-54.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001590695_strength_weakness.svg",
"table_records": {
"2014": {
"input_variables": {
"Assets, Current": "28,279",
"Assets, Non-Current": "986",
"General and Administrative Expense": "25,924",
"Goodwill": "7,564",
"Liabilities, Current": "29,322",
"Liabilities, Non-Current": "14,824",
"Other Assets": "0",
"Other Compr. Net Income": "-31",
"Other Expenses": "47,715",
"Other Liabilities": "0",
"Other Net Income": "-8,917",
"Other Revenues": "61,426",
"Property, Plant and Equipment, Net": "2,680",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "44,146",
"Assets": "39,509",
"Expenses": "73,639",
"Revenues": "61,426",
"Stockholders Equity": "-4,637",
"Net Income": "-21,130",
"Comprehensive Net Income": "-21,146",
"BaseVar": "113,834",
"ECR before LimitedLiability": "-66%",
"Economic Capital Ratio": "77%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "24,504",
"Assets, Non-Current": "1,475",
"General and Administrative Expense": "25,521",
"Goodwill": "56,509",
"Liabilities, Current": "71,720",
"Liabilities, Non-Current": "14,751",
"Other Assets": "0",
"Other Compr. Net Income": "83",
"Other Expenses": "70,097",
"Other Liabilities": "0",
"Other Net Income": "-22,464",
"Other Revenues": "81,672",
"Property, Plant and Equipment, Net": "3,712",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "86,471",
"Assets": "86,200",
"Expenses": "95,618",
"Revenues": "81,672",
"Stockholders Equity": "-271",
"Net Income": "-36,410",
"Comprehensive Net Income": "-36,368",
"BaseVar": "186,254",
"ECR before LimitedLiability": "-43%",
"Economic Capital Ratio": "81%"
}
}
},
"top_rated": false,
"trend": -1.0,
"value": 0.8129041946155184,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001590695.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001590695.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001590695.svg"
},
{
"company_id": "0000776008",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000776008.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000776008.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000776008_main_keyfigs.svg",
"name": "ROCK Creek Pharmaceuticals INC",
"rank": 36,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000776008.svg",
"report_text": "The relative strengths and weaknesses of ROCK Creek Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of ROCK Creek Pharmaceuticals INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 54% points.The greatest weakness of ROCK Creek Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 28% points.
The company's Economic Capital Ratio, given in the ranking table, is 72%, being 64% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000776008_2016_ROCK_Creek_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "1.21",
"Liabilities": "1.48",
"Stockholders Equity": "-2.23",
"ECR before LimitedLiability": "-57.6",
"Liabilities, Non-Current": "-1.04",
"Other Liabilities": "1.22",
"Property, Plant and Equipment, Net": "-4.08",
"Assets": "-14.2",
"Assets, Non-Current": "-7.37",
"Other Assets": "2.79",
"Goodwill": "-12.7",
"Assets, Current": "7.11",
"General and Administrative Expense": "-46.9",
"Expenses": "-44.2",
"Revenues": "-29.8",
"Net Income": "-90.7",
"Other Expenses": "4.72",
"Other Revenues": "-29.8",
"Comprehensive Net Income": "-90.8",
"Other Net Income": "-4.28",
"Economic Capital Ratio": "-120"
},
"2012": {
"Liabilities, Current": "-5.51",
"Liabilities": "24.5",
"Stockholders Equity": "53.5",
"ECR before LimitedLiability": "11.0",
"Liabilities, Non-Current": "11.2",
"Other Liabilities": "18.9",
"Assets, Current": "61.1",
"Assets": "51.2",
"Other Assets": "3.23",
"Assets, Non-Current": "-6.67",
"Property, Plant and Equipment, Net": "-9.32",
"Goodwill": "-12.6",
"Other Expenses": "15.4",
"Expenses": "-20.1",
"Revenues": "-36.0",
"Net Income": "-48.3",
"General and Administrative Expense": "-31.3",
"Other Revenues": "-36.0",
"Other Net Income": "6.72",
"Comprehensive Net Income": "-48.2",
"Economic Capital Ratio": "-21.5"
},
"2013": {
"Liabilities, Current": "-0.638",
"Liabilities": "-1.57",
"Stockholders Equity": "-12.9",
"ECR before LimitedLiability": "-105",
"Other Liabilities": "-0.575",
"Liabilities, Non-Current": "-0.663",
"Goodwill": "-20.1",
"Assets": "-63.7",
"Assets, Non-Current": "-7.83",
"Property, Plant and Equipment, Net": "-16.7",
"Other Assets": "1.57",
"Assets, Current": "-24.6",
"General and Administrative Expense": "-74.5",
"Expenses": "-73.2",
"Revenues": "-6.52",
"Net Income": "-91.1",
"Other Expenses": "2.18",
"Other Revenues": "-6.52",
"Other Net Income": "-1.05",
"Comprehensive Net Income": "-91.4",
"Economic Capital Ratio": "-145"
},
"2014": {
"Liabilities, Non-Current": "-0.466",
"Liabilities": "1.69",
"Stockholders Equity": "-30.7",
"ECR before LimitedLiability": "-80.2",
"Liabilities, Current": "2.60",
"Other Liabilities": "-0.359",
"Assets, Current": "-9.45",
"Assets": "-32.2",
"Goodwill": "-6.64",
"Other Assets": "0.806",
"Assets, Non-Current": "-1.92",
"Property, Plant and Equipment, Net": "-5.12",
"Other Expenses": "1.77",
"Expenses": "-8.09",
"Revenues": "-9.48",
"Net Income": "-39.5",
"General and Administrative Expense": "-14.3",
"Other Revenues": "-9.48",
"Other Net Income": "-3.29",
"Comprehensive Net Income": "-39.4",
"Economic Capital Ratio": "-130"
},
"2015": {
"Other Liabilities": "2.39",
"Liabilities": "-26.2",
"Stockholders Equity": "-28.3",
"ECR before LimitedLiability": "-18.2",
"Liabilities, Current": "-12.7",
"Liabilities, Non-Current": "-5.42",
"Assets, Current": "-11.9",
"Assets": "-2.36",
"Other Assets": "54.3",
"Goodwill": "-5.88",
"Assets, Non-Current": "-1.71",
"Property, Plant and Equipment, Net": "-4.84",
"Expenses": "10.3",
"Revenues": "-9.26",
"Net Income": "3.10",
"General and Administrative Expense": "1.63",
"Other Expenses": "8.31",
"Other Revenues": "-9.26",
"Comprehensive Net Income": "3.19",
"Other Net Income": "5.53",
"Economic Capital Ratio": "-64.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000776008_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "13,734",
"Assets, Non-Current": "0",
"General and Administrative Expense": "32,748",
"Goodwill": "578",
"Liabilities, Current": "5,156",
"Liabilities, Non-Current": "2,530",
"Other Assets": "418",
"Other Compr. Net Income": "0",
"Other Expenses": "3,402",
"Other Liabilities": "0",
"Other Net Income": "-222",
"Other Revenues": "1,732",
"Property, Plant and Equipment, Net": "2,347",
"Research and Development": "3,348"
},
"output_variables": {
"Liabilities": "7,686",
"Assets": "17,077",
"Expenses": "39,498",
"Revenues": "1,732",
"Stockholders Equity": "9,391",
"Net Income": "-37,988",
"Comprehensive Net Income": "-37,988",
"BaseVar": "33,108",
"ECR before LimitedLiability": "-203%",
"Economic Capital Ratio": "34%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "29,283",
"Assets, Non-Current": "0",
"General and Administrative Expense": "22,677",
"Goodwill": "541",
"Liabilities, Current": "6,940",
"Liabilities, Non-Current": "0",
"Other Assets": "762",
"Other Compr. Net Income": "0",
"Other Expenses": "3,566",
"Other Liabilities": "0",
"Other Net Income": "1,760",
"Other Revenues": "6,188",
"Property, Plant and Equipment, Net": "1,338",
"Research and Development": "4,558"
},
"output_variables": {
"Liabilities": "6,940",
"Assets": "31,924",
"Expenses": "30,801",
"Revenues": "6,188",
"Stockholders Equity": "24,984",
"Net Income": "-22,853",
"Comprehensive Net Income": "-22,853",
"BaseVar": "38,806",
"ECR before LimitedLiability": "59%",
"Economic Capital Ratio": "137%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "9,013",
"Assets, Non-Current": "0",
"General and Administrative Expense": "33,892",
"Goodwill": "472",
"Liabilities, Current": "3,973",
"Liabilities, Non-Current": "0",
"Other Assets": "1,068",
"Other Compr. Net Income": "0",
"Other Expenses": "5,174",
"Other Liabilities": "0",
"Other Net Income": "89",
"Other Revenues": "9,141",
"Property, Plant and Equipment, Net": "399",
"Research and Development": "2,998"
},
"output_variables": {
"Liabilities": "3,973",
"Assets": "10,952",
"Expenses": "42,064",
"Revenues": "9,141",
"Stockholders Equity": "6,979",
"Net Income": "-32,834",
"Comprehensive Net Income": "-32,834",
"BaseVar": "33,110",
"ECR before LimitedLiability": "-312%",
"Economic Capital Ratio": "9.7%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "7,801",
"Assets, Non-Current": "0",
"General and Administrative Expense": "28,968",
"Goodwill": "402",
"Liabilities, Current": "19,402",
"Liabilities, Non-Current": "350",
"Other Assets": "507",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-5,938",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "207",
"Research and Development": "3,611"
},
"output_variables": {
"Liabilities": "19,752",
"Assets": "8,917",
"Expenses": "32,579",
"Revenues": "0",
"Stockholders Equity": "-10,835",
"Net Income": "-38,517",
"Comprehensive Net Income": "-38,517",
"BaseVar": "33,593",
"ECR before LimitedLiability": "-372%",
"Economic Capital Ratio": "3.9%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "1,043",
"Assets, Non-Current": "0",
"General and Administrative Expense": "8,830",
"Goodwill": "55",
"Liabilities, Current": "22,193",
"Liabilities, Non-Current": "8,000",
"Other Assets": "18,279",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "4,470",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "170",
"Research and Development": "2,485"
},
"output_variables": {
"Liabilities": "30,193",
"Assets": "19,547",
"Expenses": "11,315",
"Revenues": "0",
"Stockholders Equity": "-10,646",
"Net Income": "-6,845",
"Comprehensive Net Income": "-6,845",
"BaseVar": "32,762",
"ECR before LimitedLiability": "-86%",
"Economic Capital Ratio": "72%"
}
}
},
"top_rated": false,
"trend": 10.0,
"value": 0.7175599777055843,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000776008.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000776008.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000776008.svg"
},
{
"company_id": "0000093314",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000093314.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000093314.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000093314.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000093314_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000093314_main_keyfigs.svg",
"name": "Volitionrx LTD",
"rank": 37,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000093314.svg",
"report_text": "The relative strengths and weaknesses of Volitionrx LTD are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Volitionrx LTD compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 34% points.The greatest weakness of Volitionrx LTD is the variable Net Income, reducing the Economic Capital Ratio by 105% points.
The company's Economic Capital Ratio, given in the ranking table, is 65%, being 71% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000093314_2016_Volitionrx_LTD.pdf",
"shrinked_graph_json": {
"2012": {
"Liabilities, Current": "-1.38",
"Liabilities": "-3.49",
"Stockholders Equity": "-12.6",
"ECR before LimitedLiability": "-79.6",
"Liabilities, Non-Current": "1.66",
"Other Liabilities": "-4.00",
"Assets, Current": "-25.6",
"Assets": "-7.11",
"Assets, Non-Current": "-6.42",
"Property, Plant and Equipment, Net": "-10.6",
"Goodwill": "40.5",
"Other Expenses": "-2.31",
"Expenses": "-27.4",
"Revenues": "-27.1",
"Net Income": "-45.5",
"Research and Development": "-36.7",
"General and Administrative Expense": "17.7",
"Other Revenues": "-27.1",
"Comprehensive Net Income": "-46.4",
"Other Compr. Net Income": "-0.333",
"Economic Capital Ratio": "-112"
},
"2013": {
"Goodwill": "24.7",
"Assets": "-24.4",
"Stockholders Equity": "-20.1",
"Other Liabilities": "-2.21",
"ECR before LimitedLiability": "-65.8",
"Assets, Non-Current": "-7.00",
"Property, Plant and Equipment, Net": "-12.6",
"Other Assets": "-4.27",
"Assets, Current": "-23.1",
"General and Administrative Expense": "20.8",
"Expenses": "-29.8",
"Revenues": "-28.1",
"Net Income": "-35.8",
"Research and Development": "-33.6",
"Other Expenses": "-14.7",
"Other Revenues": "-28.1",
"Liabilities, Current": "-1.64",
"Liabilities, Non-Current": "3.07",
"Other Net Income": "14.7",
"Comprehensive Net Income": "-35.8",
"Economic Capital Ratio": "-106"
},
"2014": {
"Liabilities, Non-Current": "0.713",
"Liabilities": "-0.453",
"Stockholders Equity": "-14.8",
"ECR before LimitedLiability": "-60.1",
"Liabilities, Current": "-1.44",
"Assets, Current": "-6.61",
"Assets": "-18.5",
"Other Assets": "0.401",
"Assets, Non-Current": "-5.21",
"Property, Plant and Equipment, Net": "-7.01",
"Other Expenses": "-4.16",
"Expenses": "-10.1",
"Revenues": "-25.0",
"Net Income": "-55.5",
"Research and Development": "-31.8",
"General and Administrative Expense": "15.2",
"Other Revenues": "-25.0",
"Other Net Income": "-20.4",
"Comprehensive Net Income": "-55.6",
"Other Compr. Net Income": "-0.142",
"Economic Capital Ratio": "-109"
},
"2015": {
"Liabilities": "13.4",
"Stockholders Equity": "30.8",
"ECR before LimitedLiability": "-25.2",
"Liabilities, Current": "8.27",
"Liabilities, Non-Current": "5.28",
"Assets, Current": "33.9",
"Assets": "2.13",
"Other Assets": "-6.99",
"Goodwill": "-6.83",
"Assets, Non-Current": "-3.96",
"Property, Plant and Equipment, Net": "-3.58",
"Research and Development": "-20.2",
"Expenses": "-51.8",
"Revenues": "-18.3",
"Net Income": "-105",
"General and Administrative Expense": "21.9",
"Other Expenses": "-19.7",
"Other Revenues": "-18.3",
"Comprehensive Net Income": "-105",
"Other Net Income": "3.80",
"Economic Capital Ratio": "-71.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000093314_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "695",
"Assets, Non-Current": "0",
"General and Administrative Expense": "448",
"Goodwill": "1,430",
"Liabilities, Current": "748",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "-39",
"Other Expenses": "847",
"Other Liabilities": "635",
"Other Net Income": "0",
"Other Revenues": "55",
"Property, Plant and Equipment, Net": "91",
"Research and Development": "2,843"
},
"output_variables": {
"Liabilities": "1,383",
"Assets": "2,217",
"Expenses": "4,138",
"Revenues": "55",
"Stockholders Equity": "834",
"Net Income": "-4,083",
"Comprehensive Net Income": "-4,103",
"BaseVar": "3,916",
"ECR before LimitedLiability": "-164%",
"Economic Capital Ratio": "46%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "1,005",
"Assets, Non-Current": "0",
"General and Administrative Expense": "434",
"Goodwill": "1,002",
"Liabilities, Current": "957",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "-26",
"Other Expenses": "1,638",
"Other Liabilities": "433",
"Other Net Income": "866",
"Other Revenues": "55",
"Property, Plant and Equipment, Net": "63",
"Research and Development": "2,504"
},
"output_variables": {
"Liabilities": "1,390",
"Assets": "2,071",
"Expenses": "4,576",
"Revenues": "55",
"Stockholders Equity": "681",
"Net Income": "-3,655",
"Comprehensive Net Income": "-3,668",
"BaseVar": "4,491",
"ECR before LimitedLiability": "-158%",
"Economic Capital Ratio": "49%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "2,336",
"Assets, Non-Current": "0",
"General and Administrative Expense": "299",
"Goodwill": "809",
"Liabilities, Current": "2,713",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "-44",
"Other Expenses": "1,609",
"Other Liabilities": "352",
"Other Net Income": "-2,276",
"Other Revenues": "15",
"Property, Plant and Equipment, Net": "289",
"Research and Development": "4,044"
},
"output_variables": {
"Liabilities": "3,065",
"Assets": "3,433",
"Expenses": "5,952",
"Revenues": "15",
"Stockholders Equity": "368",
"Net Income": "-8,214",
"Comprehensive Net Income": "-8,236",
"BaseVar": "7,393",
"ECR before LimitedLiability": "-238%",
"Economic Capital Ratio": "24%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "6,223",
"Assets, Non-Current": "0",
"General and Administrative Expense": "669",
"Goodwill": "705",
"Liabilities, Current": "1,120",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "20",
"Other Expenses": "7,144",
"Other Liabilities": "548",
"Other Net Income": "471",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "784",
"Research and Development": "6,102"
},
"output_variables": {
"Liabilities": "1,668",
"Assets": "7,712",
"Expenses": "13,914",
"Revenues": "0",
"Stockholders Equity": "6,044",
"Net Income": "-13,443",
"Comprehensive Net Income": "-13,434",
"BaseVar": "11,892",
"ECR before LimitedLiability": "-110%",
"Economic Capital Ratio": "65%"
}
}
},
"top_rated": false,
"trend": 2.0,
"value": 0.6471416785300466,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000093314.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000093314.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000093314.svg"
},
{
"company_id": "0001134765",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001134765.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001134765.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001134765.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001134765_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001134765_main_keyfigs.svg",
"name": "Charlie s Holdings Inc",
"rank": 38,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001134765.svg",
"report_text": "The relative strengths and weaknesses of Charlie s Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Charlie s Holdings Inc compared to the market average is the variable Goodwill, increasing the Economic Capital Ratio by 10% points.The greatest weakness of Charlie s Holdings Inc is the variable Assets, reducing the Economic Capital Ratio by 25% points.
The company's Economic Capital Ratio, given in the ranking table, is 54%, being 82% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001134765_2016_Charlie_s_Holdings_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "0.0772",
"Liabilities": "0.0755",
"Stockholders Equity": "-37.6",
"ECR before LimitedLiability": "-91.4",
"Liabilities, Non-Current": "-0.0549",
"Other Liabilities": "-0.0251",
"Property, Plant and Equipment, Net": "-1.14",
"Assets": "-55.6",
"Assets, Non-Current": "-0.226",
"Other Assets": "0",
"Goodwill": "-0.885",
"Assets, Current": "-23.9",
"General and Administrative Expense": "-1.71",
"Expenses": "-0.811",
"Revenues": "-0.117",
"Net Income": "-11.9",
"Research and Development": "0.0474",
"Other Revenues": "-0.117",
"Comprehensive Net Income": "-11.9",
"Other Net Income": "-0.996",
"Economic Capital Ratio": "-153"
},
"2012": {
"Liabilities, Current": "-6.69",
"Liabilities": "-5.98",
"Stockholders Equity": "58.2",
"ECR before LimitedLiability": "17.6",
"Liabilities, Non-Current": "9.03",
"Other Liabilities": "-8.56",
"Assets, Current": "-21.0",
"Assets": "59.1",
"Other Assets": "39.8",
"Assets, Non-Current": "-5.07",
"Property, Plant and Equipment, Net": "-10.5",
"Goodwill": "62.2",
"Other Expenses": "9.56",
"Expenses": "9.06",
"Revenues": "-29.7",
"Net Income": "-24.1",
"Research and Development": "13.2",
"General and Administrative Expense": "-12.9",
"Other Revenues": "-29.7",
"Comprehensive Net Income": "-24.0",
"Economic Capital Ratio": "-14.8"
},
"2013": {
"Liabilities, Current": "-30.3",
"Liabilities": "-1.06",
"ECR before LimitedLiability": "-30.9",
"Other Liabilities": "1.40",
"Liabilities, Non-Current": "1.67",
"Goodwill": "7.73",
"Assets": "2.45",
"Assets, Non-Current": "-0.749",
"Property, Plant and Equipment, Net": "-1.12",
"Other Assets": "3.23",
"Assets, Current": "-0.669",
"General and Administrative Expense": "-0.797",
"Expenses": "-0.983",
"Net Income": "-32.8",
"Research and Development": "1.99",
"Other Expenses": "-1.11",
"Other Revenues": "-10.3",
"Revenues": "-10.3",
"Other Net Income": "-0.658",
"Comprehensive Net Income": "-32.9",
"Economic Capital Ratio": "-71.0"
},
"2014": {
"Liabilities, Non-Current": "4.06",
"Liabilities": "-4.97",
"Stockholders Equity": "-14.6",
"ECR before LimitedLiability": "-17.2",
"Liabilities, Current": "-12.6",
"Other Liabilities": "2.73",
"Assets, Current": "-14.7",
"Assets": "-11.6",
"Goodwill": "14.4",
"Other Assets": "12.1",
"Assets, Non-Current": "-4.01",
"Property, Plant and Equipment, Net": "-8.76",
"Other Expenses": "-6.80",
"Expenses": "-8.05",
"Revenues": "-5.19",
"Net Income": "-10.4",
"Research and Development": "7.15",
"General and Administrative Expense": "-7.63",
"Other Revenues": "-5.19",
"Comprehensive Net Income": "-10.4",
"Economic Capital Ratio": "-66.6"
},
"2015": {
"Other Liabilities": "3.47",
"Liabilities": "-2.30",
"Stockholders Equity": "-25.1",
"ECR before LimitedLiability": "-36.3",
"Liabilities, Current": "-13.2",
"Liabilities, Non-Current": "4.15",
"Assets, Current": "-21.7",
"Assets": "-25.4",
"Goodwill": "10.1",
"Assets, Non-Current": "-4.45",
"Property, Plant and Equipment, Net": "-13.2",
"Research and Development": "6.34",
"Expenses": "-15.3",
"Revenues": "-2.13",
"Net Income": "-20.5",
"General and Administrative Expense": "-14.5",
"Other Expenses": "-7.08",
"Other Revenues": "-2.13",
"Comprehensive Net Income": "-20.4",
"Other Net Income": "-4.35",
"Economic Capital Ratio": "-82.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001134765_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "238",
"Assets, Non-Current": "0",
"General and Administrative Expense": "3,369",
"Goodwill": "19",
"Liabilities, Current": "1,869",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "718",
"Other Liabilities": "103",
"Other Net Income": "-1,126",
"Other Revenues": "1,267",
"Property, Plant and Equipment, Net": "9.7",
"Research and Development": "0.29"
},
"output_variables": {
"Liabilities": "1,972",
"Assets": "267",
"Expenses": "4,087",
"Revenues": "1,267",
"Stockholders Equity": "-1,705",
"Net Income": "-3,946",
"Comprehensive Net Income": "-3,946",
"BaseVar": "4,359",
"ECR before LimitedLiability": "-561%",
"Economic Capital Ratio": "0.077%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "1,237",
"Assets, Non-Current": "0",
"General and Administrative Expense": "3,273",
"Goodwill": "3,573",
"Liabilities, Current": "1,292",
"Liabilities, Non-Current": "0",
"Other Assets": "1,579",
"Other Compr. Net Income": "0",
"Other Expenses": "750",
"Other Liabilities": "772",
"Other Net Income": "-118",
"Other Revenues": "1,022",
"Property, Plant and Equipment, Net": "25",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "2,064",
"Assets": "6,415",
"Expenses": "4,023",
"Revenues": "1,022",
"Stockholders Equity": "4,351",
"Net Income": "-3,119",
"Comprehensive Net Income": "-3,119",
"BaseVar": "6,821",
"ECR before LimitedLiability": "67%",
"Economic Capital Ratio": "144%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "4,960",
"Assets, Non-Current": "0",
"General and Administrative Expense": "5,926",
"Goodwill": "3,523",
"Liabilities, Current": "5,438",
"Liabilities, Non-Current": "0",
"Other Assets": "1,486",
"Other Compr. Net Income": "0",
"Other Expenses": "4,448",
"Other Liabilities": "0",
"Other Net Income": "-391",
"Other Revenues": "2,649",
"Property, Plant and Equipment, Net": "8.4",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "5,438",
"Assets": "9,977",
"Expenses": "10,374",
"Revenues": "2,649",
"Stockholders Equity": "4,539",
"Net Income": "-8,115",
"Comprehensive Net Income": "-8,115",
"BaseVar": "14,415",
"ECR before LimitedLiability": "-25%",
"Economic Capital Ratio": "83%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "3,004",
"Assets, Non-Current": "0",
"General and Administrative Expense": "8,838",
"Goodwill": "3,475",
"Liabilities, Current": "7,755",
"Liabilities, Non-Current": "0",
"Other Assets": "1,352",
"Other Compr. Net Income": "0",
"Other Expenses": "4,402",
"Other Liabilities": "0",
"Other Net Income": "430",
"Other Revenues": "4,693",
"Property, Plant and Equipment, Net": "4.6",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "7,755",
"Assets": "7,835",
"Expenses": "13,240",
"Revenues": "4,693",
"Stockholders Equity": "80",
"Net Income": "-8,117",
"Comprehensive Net Income": "-8,117",
"BaseVar": "16,977",
"ECR before LimitedLiability": "-103%",
"Economic Capital Ratio": "67%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "3,855",
"Assets, Non-Current": "0",
"General and Administrative Expense": "10,549",
"Goodwill": "3,475",
"Liabilities, Current": "9,159",
"Liabilities, Non-Current": "0",
"Other Assets": "1,280",
"Other Compr. Net Income": "0",
"Other Expenses": "6,282",
"Other Liabilities": "0",
"Other Net Income": "-1,281",
"Other Revenues": "6,121",
"Property, Plant and Equipment, Net": "4.5",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "9,159",
"Assets": "8,614",
"Expenses": "16,831",
"Revenues": "6,121",
"Stockholders Equity": "-545",
"Net Income": "-11,991",
"Comprehensive Net Income": "-11,991",
"BaseVar": "21,003",
"ECR before LimitedLiability": "-143%",
"Economic Capital Ratio": "54%"
}
}
},
"top_rated": false,
"trend": -3.0,
"value": 0.5360924383958897,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001134765.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001134765.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001134765.svg"
},
{
"company_id": "0001037649",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001037649.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001037649.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001037649_main_keyfigs.svg",
"name": "Interleukin Genetics INC",
"rank": 39,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001037649.svg",
"report_text": "The relative strengths and weaknesses of Interleukin Genetics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Interleukin Genetics INC compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 11% points.The greatest weakness of Interleukin Genetics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 28% points.
The company's Economic Capital Ratio, given in the ranking table, is 53%, being 83% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001037649_2016_Interleukin_Genetics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "-21.5",
"Liabilities": "-15.3",
"Stockholders Equity": "-69.9",
"ECR before LimitedLiability": "-67.6",
"Liabilities, Non-Current": "0.297",
"Other Liabilities": "0.312",
"Property, Plant and Equipment, Net": "-7.69",
"Assets": "-38.3",
"Assets, Non-Current": "-3.79",
"Other Assets": "0.180",
"Goodwill": "-5.10",
"Assets, Current": "-24.4",
"General and Administrative Expense": "-1.64",
"Expenses": "4.32",
"Revenues": "-8.30",
"Net Income": "-5.77",
"Other Expenses": "5.82",
"Other Revenues": "-8.30",
"Comprehensive Net Income": "-5.79",
"Other Net Income": "-2.47",
"Economic Capital Ratio": "-130"
},
"2012": {
"Liabilities": "-16.0",
"Stockholders Equity": "-77.9",
"ECR before LimitedLiability": "-103",
"Liabilities, Non-Current": "0.235",
"Other Liabilities": "-18.9",
"Assets, Current": "-21.2",
"Assets": "-37.9",
"Other Assets": "-0.118",
"Assets, Non-Current": "-3.72",
"Property, Plant and Equipment, Net": "-8.29",
"Goodwill": "-6.69",
"Other Expenses": "5.91",
"Expenses": "6.21",
"Revenues": "-10.3",
"Net Income": "-3.78",
"Research and Development": "0.466",
"General and Administrative Expense": "-0.0995",
"Other Revenues": "-10.3",
"Other Net Income": "-1.29",
"Comprehensive Net Income": "-3.76",
"Economic Capital Ratio": "-136"
},
"2013": {
"Liabilities, Current": "-47.5",
"Liabilities": "-14.8",
"Stockholders Equity": "2.25",
"Other Liabilities": "2.09",
"Liabilities, Non-Current": "2.18",
"Goodwill": "-17.5",
"Assets": "3.84",
"ECR before LimitedLiability": "-27.9",
"Assets, Non-Current": "-8.22",
"Property, Plant and Equipment, Net": "-5.61",
"Other Assets": "-5.39",
"Assets, Current": "16.7",
"General and Administrative Expense": "-42.1",
"Expenses": "-6.21",
"Revenues": "-30.8",
"Net Income": "-44.3",
"Other Expenses": "3.74",
"Other Revenues": "-30.8",
"Other Net Income": "-9.39",
"Comprehensive Net Income": "-44.4",
"Economic Capital Ratio": "-68.1"
},
"2014": {
"Liabilities, Non-Current": "0.441",
"Liabilities": "-35.4",
"Stockholders Equity": "0.438",
"Other Liabilities": "-52.1",
"Assets, Current": "21.5",
"Assets": "6.65",
"Goodwill": "-16.2",
"Other Assets": "0",
"Assets, Non-Current": "-3.96",
"Property, Plant and Equipment, Net": "-5.77",
"Other Expenses": "0.914",
"Expenses": "0.850",
"Revenues": "-32.1",
"Net Income": "-12.6",
"Research and Development": "0.134",
"General and Administrative Expense": "-6.59",
"Other Revenues": "-32.1",
"ECR before LimitedLiability": "0.515",
"Other Net Income": "0.0110",
"Comprehensive Net Income": "-12.5",
"Economic Capital Ratio": "-48.9"
},
"2015": {
"Other Liabilities": "2.50",
"Liabilities": "-13.7",
"Stockholders Equity": "-28.0",
"ECR before LimitedLiability": "-37.2",
"Liabilities, Current": "-7.85",
"Liabilities, Non-Current": "-7.72",
"Assets, Current": "10.1",
"Assets": "-14.6",
"Other Assets": "-5.96",
"Goodwill": "-11.5",
"Assets, Non-Current": "-2.43",
"Property, Plant and Equipment, Net": "-4.86",
"Expenses": "-3.67",
"Revenues": "-11.8",
"Net Income": "-17.1",
"General and Administrative Expense": "-13.6",
"Other Expenses": "11.5",
"Other Revenues": "-11.8",
"Comprehensive Net Income": "-17.0",
"Other Net Income": "-2.30",
"Economic Capital Ratio": "-83.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001037649_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "2,112",
"Assets, Non-Current": "38",
"General and Administrative Expense": "6,193",
"Goodwill": "515",
"Liabilities, Current": "14,377",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "115",
"Other Liabilities": "0",
"Other Net Income": "-198",
"Other Revenues": "2,857",
"Property, Plant and Equipment, Net": "289",
"Research and Development": "1,376"
},
"output_variables": {
"Liabilities": "14,377",
"Assets": "2,954",
"Expenses": "7,684",
"Revenues": "2,857",
"Stockholders Equity": "-11,423",
"Net Income": "-5,025",
"Comprehensive Net Income": "-5,025",
"BaseVar": "14,035",
"ECR before LimitedLiability": "-239%",
"Economic Capital Ratio": "24%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "2,402",
"Assets, Non-Current": "38",
"General and Administrative Expense": "5,479",
"Goodwill": "399",
"Liabilities, Current": "2,273",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "115",
"Other Liabilities": "14,316",
"Other Net Income": "-450",
"Other Revenues": "2,236",
"Property, Plant and Equipment, Net": "127",
"Research and Development": "1,312"
},
"output_variables": {
"Liabilities": "16,589",
"Assets": "2,966",
"Expenses": "6,906",
"Revenues": "2,236",
"Stockholders Equity": "-13,624",
"Net Income": "-5,120",
"Comprehensive Net Income": "-5,120",
"BaseVar": "14,574",
"ECR before LimitedLiability": "-243%",
"Economic Capital Ratio": "23%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "8,953",
"Assets, Non-Current": "38",
"General and Administrative Expense": "8,197",
"Goodwill": "290",
"Liabilities, Current": "4,872",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "109",
"Other Liabilities": "0",
"Other Net Income": "-459",
"Other Revenues": "2,430",
"Property, Plant and Equipment, Net": "845",
"Research and Development": "722"
},
"output_variables": {
"Liabilities": "4,872",
"Assets": "10,125",
"Expenses": "9,028",
"Revenues": "2,430",
"Stockholders Equity": "5,253",
"Net Income": "-7,058",
"Comprehensive Net Income": "-7,058",
"BaseVar": "13,457",
"ECR before LimitedLiability": "1.9%",
"Economic Capital Ratio": "86%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "12,181",
"Assets, Non-Current": "117",
"General and Administrative Expense": "7,203",
"Goodwill": "196",
"Liabilities, Current": "4,012",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "94",
"Other Liabilities": "4,739",
"Other Net Income": "-6.3",
"Other Revenues": "1,810",
"Property, Plant and Equipment, Net": "774",
"Research and Development": "843"
},
"output_variables": {
"Liabilities": "8,750",
"Assets": "13,267",
"Expenses": "8,140",
"Revenues": "1,810",
"Stockholders Equity": "4,517",
"Net Income": "-6,336",
"Comprehensive Net Income": "-6,336",
"BaseVar": "15,987",
"ECR before LimitedLiability": "-1.3%",
"Economic Capital Ratio": "85%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "5,696",
"Assets, Non-Current": "93",
"General and Administrative Expense": "7,293",
"Goodwill": "59",
"Liabilities, Current": "5,478",
"Liabilities, Non-Current": "3,475",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "137",
"Other Liabilities": "0",
"Other Net Income": "-609",
"Other Revenues": "1,441",
"Property, Plant and Equipment, Net": "644",
"Research and Development": "1,300"
},
"output_variables": {
"Liabilities": "8,953",
"Assets": "6,492",
"Expenses": "8,729",
"Revenues": "1,441",
"Stockholders Equity": "-2,461",
"Net Income": "-7,898",
"Comprehensive Net Income": "-7,898",
"BaseVar": "13,112",
"ECR before LimitedLiability": "-146%",
"Economic Capital Ratio": "53%"
}
}
},
"top_rated": false,
"trend": -6.0,
"value": 0.5271729467917017,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001037649.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001037649.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001037649.svg"
},
{
"company_id": "0001498380",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001498380.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001498380.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001498380.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001498380_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001498380_main_keyfigs.svg",
"name": "Savicell Corp",
"rank": 40,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001498380.svg",
"report_text": "The relative strengths and weaknesses of Savicell Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Savicell Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 36% points.The greatest weakness of Savicell Corp is the variable Net Income, reducing the Economic Capital Ratio by 84% points.
The company's Economic Capital Ratio, given in the ranking table, is 46%, being 90% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001498380_2016_Savicell_Corp.pdf",
"shrinked_graph_json": {
"2015": {
"Other Liabilities": "-5.22",
"Liabilities": "6.04",
"Stockholders Equity": "13.0",
"ECR before LimitedLiability": "-43.9",
"Liabilities, Current": "6.47",
"Liabilities, Non-Current": "3.48",
"Assets, Current": "36.0",
"Assets": "-7.53",
"Other Assets": "-7.89",
"Goodwill": "-17.4",
"Assets, Non-Current": "-4.84",
"Property, Plant and Equipment, Net": "-10.8",
"Research and Development": "-17.3",
"Expenses": "-36.9",
"Revenues": "-25.2",
"Net Income": "-83.9",
"General and Administrative Expense": "23.0",
"Other Expenses": "-38.5",
"Other Revenues": "-25.2",
"Comprehensive Net Income": "-83.2",
"Economic Capital Ratio": "-89.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001498380_strength_weakness.svg",
"table_records": {
"2015": {
"input_variables": {
"Assets, Current": "1,232",
"Assets, Non-Current": "0",
"General and Administrative Expense": "0",
"Goodwill": "0",
"Liabilities, Current": "127",
"Liabilities, Non-Current": "0",
"Other Assets": "13",
"Other Compr. Net Income": "5.2",
"Other Expenses": "1,914",
"Other Liabilities": "380",
"Other Net Income": "-37",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "58",
"Research and Development": "638"
},
"output_variables": {
"Liabilities": "507",
"Assets": "1,303",
"Expenses": "2,552",
"Revenues": "0",
"Stockholders Equity": "796",
"Net Income": "-2,589",
"Comprehensive Net Income": "-2,587",
"BaseVar": "2,202",
"ECR before LimitedLiability": "-165%",
"Economic Capital Ratio": "46%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.46091044521447827,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001498380.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001498380.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001498380.svg"
},
{
"company_id": "0000810509",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000810509.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000810509.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000810509.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000810509_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000810509_main_keyfigs.svg",
"name": "Navidea Biopharmaceuticals Inc",
"rank": 41,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000810509.svg",
"report_text": "The relative strengths and weaknesses of Navidea Biopharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Navidea Biopharmaceuticals Inc compared to the market average is the variable General and Administrative Expense, increasing the Economic Capital Ratio by 11% points.The greatest weakness of Navidea Biopharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 61% points.
The company's Economic Capital Ratio, given in the ranking table, is 23%, being 113% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000810509_2016_Navidea_Biopharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "29.9",
"Liabilities": "10.3",
"Stockholders Equity": "39.4",
"ECR before LimitedLiability": "121",
"Liabilities, Non-Current": "9.91",
"Other Liabilities": "-38.6",
"Property, Plant and Equipment, Net": "-5.14",
"Assets": "15.4",
"Assets, Non-Current": "-1.57",
"Goodwill": "-5.25",
"Assets, Current": "39.7",
"General and Administrative Expense": "21.2",
"Expenses": "31.2",
"Revenues": "-53.2",
"Net Income": "47.8",
"Research and Development": "-37.8",
"Other Expenses": "46.8",
"Other Revenues": "-53.2",
"Comprehensive Net Income": "47.7",
"Other Net Income": "69.0",
"Economic Capital Ratio": "59.4"
},
"2012": {
"Liabilities, Current": "-0.559",
"Liabilities": "-2.16",
"Stockholders Equity": "-35.8",
"ECR before LimitedLiability": "-104",
"Liabilities, Non-Current": "0.244",
"Other Liabilities": "-1.72",
"Assets, Current": "1.12",
"Assets": "-24.6",
"Assets, Non-Current": "-4.04",
"Property, Plant and Equipment, Net": "-8.32",
"Goodwill": "-13.2",
"Other Expenses": "8.35",
"Expenses": "-23.5",
"Revenues": "-26.1",
"Net Income": "-53.7",
"Research and Development": "-34.5",
"General and Administrative Expense": "-1.92",
"Other Revenues": "-26.1",
"Other Net Income": "-2.51",
"Comprehensive Net Income": "-53.7",
"Economic Capital Ratio": "-136"
},
"2013": {
"Liabilities": "-17.0",
"Stockholders Equity": "-19.2",
"ECR before LimitedLiability": "-50.9",
"Other Liabilities": "-18.8",
"Liabilities, Non-Current": "1.46",
"Goodwill": "-8.26",
"Assets": "-0.428",
"Assets, Non-Current": "-2.50",
"Property, Plant and Equipment, Net": "-4.77",
"Other Assets": "-2.12",
"Assets, Current": "23.4",
"General and Administrative Expense": "5.62",
"Expenses": "1.24",
"Revenues": "-14.5",
"Net Income": "-16.4",
"Research and Development": "-12.1",
"Other Expenses": "9.77",
"Other Revenues": "-14.5",
"Other Net Income": "-4.08",
"Comprehensive Net Income": "-16.4",
"Economic Capital Ratio": "-91.1"
},
"2014": {
"Liabilities": "-3.68",
"Stockholders Equity": "-59.8",
"ECR before LimitedLiability": "-64.2",
"Liabilities, Current": "0.195",
"Other Liabilities": "-4.67",
"Assets, Current": "-19.8",
"Assets": "-36.1",
"Goodwill": "-11.7",
"Other Assets": "0.816",
"Assets, Non-Current": "-2.79",
"Property, Plant and Equipment, Net": "-3.40",
"Other Expenses": "4.21",
"Expenses": "-3.14",
"Revenues": "-10.1",
"Net Income": "-13.5",
"Research and Development": "-11.7",
"General and Administrative Expense": "2.42",
"Other Revenues": "-10.1",
"Other Net Income": "0.399",
"Comprehensive Net Income": "-13.5",
"Economic Capital Ratio": "-114"
},
"2015": {
"Other Liabilities": "-19.1",
"Liabilities": "-8.64",
"Stockholders Equity": "-61.3",
"ECR before LimitedLiability": "-66.9",
"Liabilities, Current": "0.848",
"Assets, Current": "-19.0",
"Assets": "-41.6",
"Other Assets": "-5.55",
"Goodwill": "-11.7",
"Assets, Non-Current": "-2.50",
"Property, Plant and Equipment, Net": "-6.77",
"Research and Development": "3.07",
"Expenses": "5.52",
"Revenues": "-5.47",
"Net Income": "-4.69",
"General and Administrative Expense": "10.6",
"Other Expenses": "-11.2",
"Other Revenues": "-5.47",
"Comprehensive Net Income": "-4.59",
"Other Net Income": "-5.68",
"Economic Capital Ratio": "-113"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000810509_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "30,047",
"Assets, Non-Current": "599",
"General and Administrative Expense": "9,548",
"Goodwill": "85",
"Liabilities, Current": "3,348",
"Liabilities, Non-Current": "257",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "-7,880",
"Other Liabilities": "6,456",
"Other Net Income": "22,435",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "463",
"Research and Development": "15,154"
},
"output_variables": {
"Liabilities": "10,062",
"Assets": "31,194",
"Expenses": "16,822",
"Revenues": "0",
"Stockholders Equity": "21,132",
"Net Income": "5,613",
"Comprehensive Net Income": "5,613",
"BaseVar": "40,257",
"ECR before LimitedLiability": "168%",
"Economic Capital Ratio": "213%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "10,617",
"Assets, Non-Current": "328",
"General and Administrative Expense": "11,178",
"Goodwill": "92",
"Liabilities, Current": "6,191",
"Liabilities, Non-Current": "257",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "6,930",
"Other Net Income": "-1,168",
"Other Revenues": "79",
"Property, Plant and Equipment, Net": "935",
"Research and Development": "16,890"
},
"output_variables": {
"Liabilities": "13,378",
"Assets": "11,972",
"Expenses": "28,068",
"Revenues": "79",
"Stockholders Equity": "-1,405",
"Net Income": "-29,157",
"Comprehensive Net Income": "-29,157",
"BaseVar": "27,332",
"ECR before LimitedLiability": "-245%",
"Economic Capital Ratio": "22%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "37,331",
"Assets, Non-Current": "723",
"General and Administrative Expense": "15,526",
"Goodwill": "137",
"Liabilities, Current": "11,291",
"Liabilities, Non-Current": "1,770",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "333",
"Other Liabilities": "31,265",
"Other Net Income": "-4,261",
"Other Revenues": "1,131",
"Property, Plant and Equipment, Net": "2,125",
"Research and Development": "23,710"
},
"output_variables": {
"Liabilities": "44,326",
"Assets": "40,317",
"Expenses": "39,569",
"Revenues": "1,131",
"Stockholders Equity": "-4,010",
"Net Income": "-42,699",
"Comprehensive Net Income": "-42,699",
"BaseVar": "64,802",
"ECR before LimitedLiability": "-114%",
"Economic Capital Ratio": "63%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "8,599",
"Assets, Non-Current": "389",
"General and Administrative Expense": "15,542",
"Goodwill": "181",
"Liabilities, Current": "9,095",
"Liabilities, Non-Current": "3,089",
"Other Assets": "242",
"Other Compr. Net Income": "0",
"Other Expenses": "1,586",
"Other Liabilities": "29,539",
"Other Net Income": "0",
"Other Revenues": "6,275",
"Property, Plant and Equipment, Net": "2,510",
"Research and Development": "16,780"
},
"output_variables": {
"Liabilities": "41,724",
"Assets": "11,920",
"Expenses": "33,908",
"Revenues": "6,275",
"Stockholders Equity": "-29,803",
"Net Income": "-27,633",
"Comprehensive Net Income": "-27,633",
"BaseVar": "46,913",
"ECR before LimitedLiability": "-255%",
"Economic Capital Ratio": "20%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "12,577",
"Assets, Non-Current": "274",
"General and Administrative Expense": "0",
"Goodwill": "186",
"Liabilities, Current": "6,184",
"Liabilities, Non-Current": "1,678",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "31,364",
"Other Liabilities": "60,939",
"Other Net Income": "-9,449",
"Other Revenues": "13,249",
"Property, Plant and Equipment, Net": "1,928",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "68,800",
"Assets": "14,965",
"Expenses": "31,364",
"Revenues": "13,249",
"Stockholders Equity": "-53,836",
"Net Income": "-27,564",
"Comprehensive Net Income": "-27,564",
"BaseVar": "68,913",
"ECR before LimitedLiability": "-242%",
"Economic Capital Ratio": "23%"
}
}
},
"top_rated": false,
"trend": -1.0,
"value": 0.23052976820491672,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000810509.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000810509.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000810509.svg"
},
{
"company_id": "0000880242",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0000880242.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0000880242.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000880242_main_keyfigs.svg",
"name": "Biolargo INC",
"rank": 42,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0000880242.svg",
"report_text": "The relative strengths and weaknesses of Biolargo INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Biolargo INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 15% points.The greatest weakness of Biolargo INC is the variable Net Income, reducing the Economic Capital Ratio by 94% points.
The company's Economic Capital Ratio, given in the ranking table, is 18%, being 117% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0000880242_2016_Biolargo_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "0.0281",
"Liabilities": "0.0282",
"Stockholders Equity": "-18.0",
"ECR before LimitedLiability": "-91.4",
"Liabilities, Non-Current": "0.0207",
"Other Liabilities": "-0.0211",
"Property, Plant and Equipment, Net": "-0.367",
"Assets": "-31.2",
"Assets, Non-Current": "-0.0710",
"Other Assets": "0.0122",
"Goodwill": "-0.309",
"Assets, Current": "-9.59",
"General and Administrative Expense": "-1.96",
"Expenses": "-2.51",
"Revenues": "-0.342",
"Net Income": "-15.3",
"Other Expenses": "-0.0388",
"Other Revenues": "-0.342",
"Comprehensive Net Income": "-15.3",
"Other Net Income": "-0.0124",
"Economic Capital Ratio": "-153"
},
"2013": {
"Liabilities, Current": "0",
"Liabilities": "0",
"Assets": "-31.8",
"Stockholders Equity": "-1.11",
"ECR before LimitedLiability": "-114",
"Other Liabilities": "0",
"Liabilities, Non-Current": "0",
"Goodwill": "-0.0215",
"Assets, Non-Current": "0",
"Property, Plant and Equipment, Net": "-0.0105",
"Other Assets": "0",
"Assets, Current": "-4.90",
"General and Administrative Expense": "-0.154",
"Expenses": "-1.47",
"Revenues": "0",
"Net Income": "-13.5",
"Research and Development": "0",
"Other Expenses": "0",
"Other Revenues": "0",
"Comprehensive Net Income": "-13.5",
"Economic Capital Ratio": "-155"
},
"2014": {
"Liabilities, Non-Current": "0",
"Liabilities": "0",
"ECR before LimitedLiability": "-84.1",
"Liabilities, Current": "0",
"Other Liabilities": "0",
"Assets, Current": "-1.26",
"Assets": "-19.4",
"Goodwill": "0",
"Other Assets": "0",
"Assets, Non-Current": "0",
"Property, Plant and Equipment, Net": "0",
"Other Expenses": "0",
"Expenses": "-1.18",
"Net Income": "-15.4",
"Research and Development": "0",
"General and Administrative Expense": "-0.143",
"Other Revenues": "0",
"Revenues": "0",
"Stockholders Equity": "0",
"Comprehensive Net Income": "-15.3",
"Economic Capital Ratio": "-134"
},
"2015": {
"Other Liabilities": "0.241",
"Liabilities": "0.577",
"Stockholders Equity": "3.62",
"ECR before LimitedLiability": "-71.6",
"Liabilities, Current": "0.384",
"Assets, Current": "14.6",
"Assets": "-29.7",
"Other Assets": "-9.41",
"Goodwill": "-20.6",
"Assets, Non-Current": "-4.02",
"Property, Plant and Equipment, Net": "-17.0",
"Research and Development": "-6.54",
"Expenses": "-42.9",
"Revenues": "-23.9",
"Net Income": "-94.3",
"General and Administrative Expense": "-52.1",
"Other Expenses": "9.62",
"Other Revenues": "-23.9",
"Comprehensive Net Income": "-93.7",
"Other Net Income": "-17.2",
"Economic Capital Ratio": "-117"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0000880242_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "202",
"Assets, Non-Current": "0",
"General and Administrative Expense": "3,165",
"Goodwill": "0",
"Liabilities, Current": "1,374",
"Liabilities, Non-Current": "390",
"Other Assets": "42",
"Other Compr. Net Income": "0",
"Other Expenses": "846",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "156",
"Property, Plant and Equipment, Net": "2.7",
"Research and Development": "99"
},
"output_variables": {
"Liabilities": "1,764",
"Assets": "246",
"Expenses": "4,111",
"Revenues": "156",
"Stockholders Equity": "-1,518",
"Net Income": "-3,954",
"Comprehensive Net Income": "-3,954",
"BaseVar": "3,139",
"ECR before LimitedLiability": "-600%",
"Economic Capital Ratio": "0.028%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "126",
"Assets, Non-Current": "41",
"General and Administrative Expense": "2,005",
"Goodwill": "0",
"Liabilities, Current": "732",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "322",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "168",
"Property, Plant and Equipment, Net": "0",
"Research and Development": "742"
},
"output_variables": {
"Liabilities": "732",
"Assets": "167",
"Expenses": "3,069",
"Revenues": "168",
"Stockholders Equity": "-565",
"Net Income": "-2,901",
"Comprehensive Net Income": "-2,901",
"BaseVar": "2,068",
"ECR before LimitedLiability": "-817%",
"Economic Capital Ratio": "0.000030%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "231",
"Assets, Non-Current": "30",
"General and Administrative Expense": "2,793",
"Goodwill": "0",
"Liabilities, Current": "653",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "415",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "112",
"Property, Plant and Equipment, Net": "0",
"Research and Development": "643"
},
"output_variables": {
"Liabilities": "653",
"Assets": "261",
"Expenses": "3,851",
"Revenues": "112",
"Stockholders Equity": "-392",
"Net Income": "-3,740",
"Comprehensive Net Income": "-3,740",
"BaseVar": "2,438",
"ECR before LimitedLiability": "-936%",
"Economic Capital Ratio": "0.00000029%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "1,891",
"Assets, Non-Current": "19",
"General and Administrative Expense": "3,552",
"Goodwill": "0",
"Liabilities, Current": "460",
"Liabilities, Non-Current": "309",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "73",
"Other Liabilities": "0",
"Other Net Income": "-896",
"Other Revenues": "128",
"Property, Plant and Equipment, Net": "0",
"Research and Development": "685"
},
"output_variables": {
"Liabilities": "769",
"Assets": "1,910",
"Expenses": "4,309",
"Revenues": "128",
"Stockholders Equity": "1,141",
"Net Income": "-5,077",
"Comprehensive Net Income": "-5,077",
"BaseVar": "4,006",
"ECR before LimitedLiability": "-262%",
"Economic Capital Ratio": "18%"
}
}
},
"top_rated": false,
"trend": 5.0,
"value": 0.1835238486701441,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0000880242.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0000880242.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0000880242.svg"
},
{
"company_id": "0001310630",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001310630.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001310630.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001310630_main_keyfigs.svg",
"name": "China Foods Holdings Ltd",
"rank": 43,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001310630.svg",
"report_text": "The relative strengths and weaknesses of China Foods Holdings Ltd are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of China Foods Holdings Ltd compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 5.2% points.The greatest weakness of China Foods Holdings Ltd is the variable Stockholders Equity, reducing the Economic Capital Ratio by 70% points.
The company's Economic Capital Ratio, given in the ranking table, is 15%, being 121% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001310630_2016_China_Foods_Holdings_Ltd.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "-1.06",
"Liabilities": "-11.5",
"Stockholders Equity": "-72.1",
"ECR before LimitedLiability": "-71.8",
"Other Liabilities": "-4.85",
"Property, Plant and Equipment, Net": "-6.95",
"Assets": "-31.4",
"Assets, Non-Current": "-2.82",
"Other Assets": "11.4",
"Goodwill": "-6.35",
"Assets, Current": "-29.3",
"General and Administrative Expense": "3.53",
"Expenses": "7.12",
"Revenues": "-12.4",
"Net Income": "-3.76",
"Research and Development": "2.47",
"Other Expenses": "1.83",
"Other Revenues": "-12.4",
"Comprehensive Net Income": "-3.78",
"Other Net Income": "-1.24",
"Economic Capital Ratio": "-134"
},
"2012": {
"Liabilities, Current": "-0.547",
"Liabilities": "-6.29",
"Stockholders Equity": "-79.5",
"ECR before LimitedLiability": "-108",
"Other Liabilities": "-2.62",
"Assets, Current": "-28.9",
"Assets": "-34.1",
"Other Assets": "9.35",
"Assets, Non-Current": "-2.91",
"Property, Plant and Equipment, Net": "-6.78",
"Goodwill": "-6.98",
"Other Expenses": "2.11",
"Expenses": "6.71",
"Revenues": "-12.3",
"Net Income": "-2.71",
"Research and Development": "2.50",
"General and Administrative Expense": "2.85",
"Other Revenues": "-12.3",
"Other Net Income": "-0.0949",
"Comprehensive Net Income": "-2.70",
"Economic Capital Ratio": "-141"
},
"2013": {
"Liabilities, Current": "0.221",
"Liabilities": "0.706",
"Stockholders Equity": "-81.0",
"ECR before LimitedLiability": "-98.7",
"Other Liabilities": "0.110",
"Goodwill": "-6.94",
"Assets": "-36.7",
"Assets, Non-Current": "-2.51",
"Property, Plant and Equipment, Net": "-5.86",
"Other Assets": "5.65",
"Assets, Current": "-27.6",
"General and Administrative Expense": "2.35",
"Expenses": "7.31",
"Revenues": "-10.1",
"Net Income": "-2.17",
"Research and Development": "1.96",
"Other Expenses": "4.07",
"Other Revenues": "-10.1",
"Other Net Income": "-2.84",
"Comprehensive Net Income": "-2.19",
"Economic Capital Ratio": "-139"
},
"2014": {
"Liabilities": "2.73",
"Stockholders Equity": "-69.8",
"ECR before LimitedLiability": "-69.3",
"Liabilities, Current": "2.29",
"Other Liabilities": "0.103",
"Assets, Current": "-25.4",
"Assets": "-34.7",
"Goodwill": "-7.12",
"Other Assets": "5.31",
"Assets, Non-Current": "-2.14",
"Property, Plant and Equipment, Net": "-5.49",
"Other Expenses": "2.98",
"Expenses": "7.69",
"Revenues": "-9.32",
"Net Income": "-0.242",
"Research and Development": "2.11",
"General and Administrative Expense": "3.97",
"Other Revenues": "-9.32",
"Other Net Income": "-2.45",
"Comprehensive Net Income": "-0.231",
"Economic Capital Ratio": "-119"
},
"2015": {
"Other Liabilities": "0.105",
"Liabilities": "2.44",
"Stockholders Equity": "-70.0",
"ECR before LimitedLiability": "-75.1",
"Liabilities, Current": "2.08",
"Assets, Current": "-25.5",
"Assets": "-37.9",
"Other Assets": "2.91",
"Goodwill": "-7.24",
"Assets, Non-Current": "-1.72",
"Property, Plant and Equipment, Net": "-5.93",
"Research and Development": "1.66",
"Expenses": "5.21",
"Revenues": "-8.22",
"Net Income": "-0.817",
"General and Administrative Expense": "2.62",
"Other Expenses": "1.47",
"Other Revenues": "-8.22",
"Comprehensive Net Income": "-0.763",
"Other Net Income": "0.149",
"Economic Capital Ratio": "-121"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001310630_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "0",
"Assets, Non-Current": "0",
"General and Administrative Expense": "14",
"Goodwill": "0",
"Liabilities, Current": "29",
"Liabilities, Non-Current": "0",
"Other Assets": "10.0",
"Other Compr. Net Income": "0",
"Other Expenses": "5.1",
"Other Liabilities": "50",
"Other Net Income": "0",
"Other Revenues": "0.050",
"Property, Plant and Equipment, Net": "0",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "79",
"Assets": "10.0",
"Expenses": "19",
"Revenues": "0.050",
"Stockholders Equity": "-69",
"Net Income": "-19",
"Comprehensive Net Income": "-19",
"BaseVar": "54",
"ECR before LimitedLiability": "-256%",
"Economic Capital Ratio": "20%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "0",
"Assets, Non-Current": "0",
"General and Administrative Expense": "18",
"Goodwill": "0",
"Liabilities, Current": "36",
"Liabilities, Non-Current": "0",
"Other Assets": "11",
"Other Compr. Net Income": "0",
"Other Expenses": "7.1",
"Other Liabilities": "70",
"Other Net Income": "0",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "0",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "106",
"Assets": "11",
"Expenses": "25",
"Revenues": "0",
"Stockholders Equity": "-95",
"Net Income": "-25",
"Comprehensive Net Income": "-25",
"BaseVar": "71",
"ECR before LimitedLiability": "-264%",
"Economic Capital Ratio": "18%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "0",
"Assets, Non-Current": "0",
"General and Administrative Expense": "21",
"Goodwill": "0",
"Liabilities, Current": "85",
"Liabilities, Non-Current": "0",
"Other Assets": "11",
"Other Compr. Net Income": "0",
"Other Expenses": "0.10",
"Other Liabilities": "50",
"Other Net Income": "-8.4",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "0",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "135",
"Assets": "11",
"Expenses": "21",
"Revenues": "0",
"Stockholders Equity": "-125",
"Net Income": "-30",
"Comprehensive Net Income": "-30",
"BaseVar": "88",
"ECR before LimitedLiability": "-275%",
"Economic Capital Ratio": "16%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "0",
"Assets, Non-Current": "0",
"General and Administrative Expense": "20",
"Goodwill": "0",
"Liabilities, Current": "147",
"Liabilities, Non-Current": "0",
"Other Assets": "9.8",
"Other Compr. Net Income": "0",
"Other Expenses": "0.10",
"Other Liabilities": "20",
"Other Net Income": "-12",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "0",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "167",
"Assets": "9.8",
"Expenses": "20",
"Revenues": "0",
"Stockholders Equity": "-157",
"Net Income": "-32",
"Comprehensive Net Income": "-32",
"BaseVar": "104",
"ECR before LimitedLiability": "-280%",
"Economic Capital Ratio": "15%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "0",
"Assets, Non-Current": "0",
"General and Administrative Expense": "26",
"Goodwill": "0",
"Liabilities, Current": "186",
"Liabilities, Non-Current": "0",
"Other Assets": "14",
"Other Compr. Net Income": "0",
"Other Expenses": "19",
"Other Liabilities": "30",
"Other Net Income": "0",
"Other Revenues": "0.011",
"Property, Plant and Equipment, Net": "0",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "216",
"Assets": "14",
"Expenses": "45",
"Revenues": "0.011",
"Stockholders Equity": "-202",
"Net Income": "-45",
"Comprehensive Net Income": "-45",
"BaseVar": "137",
"ECR before LimitedLiability": "-280%",
"Economic Capital Ratio": "15%"
}
}
},
"top_rated": false,
"trend": -1.0,
"value": 0.148337635352039,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001310630.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001310630.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001310630.svg"
},
{
"company_id": "0001598323",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001598323.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001598323.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001598323.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001598323_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001598323_main_keyfigs.svg",
"name": "AGRO Capital Management CORP",
"rank": 44,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001598323.svg",
"report_text": "The relative strengths and weaknesses of AGRO Capital Management CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of AGRO Capital Management CORP compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 12% points.The greatest weakness of AGRO Capital Management CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 59% points.
The company's Economic Capital Ratio, given in the ranking table, is 14%, being 122% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001598323_2016_AGRO_Capital_Management_CORP.pdf",
"shrinked_graph_json": {
"2015": {
"Other Liabilities": "4.48",
"Liabilities": "1.56",
"Stockholders Equity": "-58.6",
"ECR before LimitedLiability": "-76.3",
"Liabilities, Current": "-0.365",
"Assets, Current": "-35.6",
"Assets": "-36.0",
"Other Assets": "11.9",
"Goodwill": "-10.2",
"Assets, Non-Current": "-2.36",
"Property, Plant and Equipment, Net": "-8.32",
"Research and Development": "2.19",
"Expenses": "-7.80",
"Revenues": "-11.8",
"Net Income": "-22.5",
"General and Administrative Expense": "7.16",
"Other Expenses": "-26.9",
"Other Revenues": "-11.8",
"Comprehensive Net Income": "-22.4",
"Other Net Income": "0.200",
"Economic Capital Ratio": "-122"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001598323_strength_weakness.svg",
"table_records": {
"2015": {
"input_variables": {
"Assets, Current": "0",
"Assets, Non-Current": "0",
"General and Administrative Expense": "0.025",
"Goodwill": "0",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "15",
"Other Compr. Net Income": "0",
"Other Expenses": "46",
"Other Liabilities": "51",
"Other Net Income": "0",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "0",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "51",
"Assets": "15",
"Expenses": "46",
"Revenues": "0",
"Stockholders Equity": "-35",
"Net Income": "-46",
"Comprehensive Net Income": "-46",
"BaseVar": "56",
"ECR before LimitedLiability": "-286%",
"Economic Capital Ratio": "14%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.13680433525023722,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001598323.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001598323.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001598323.svg"
},
{
"company_id": "0001402785",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001402785.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001402785.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001402785_main_keyfigs.svg",
"name": "Fluoropharma Medical INC",
"rank": 45,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001402785.svg",
"report_text": "The relative strengths and weaknesses of Fluoropharma Medical INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Fluoropharma Medical INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 7.1% points.The greatest weakness of Fluoropharma Medical INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 71% points.
The company's Economic Capital Ratio, given in the ranking table, is 12%, being 124% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001402785_2016_Fluoropharma_Medical_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "1.82",
"Liabilities": "4.56",
"Stockholders Equity": "28.6",
"Liabilities, Non-Current": "0.407",
"Other Liabilities": "0.441",
"Property, Plant and Equipment, Net": "-10.6",
"Assets": "19.8",
"Assets, Non-Current": "-7.25",
"Goodwill": "-15.2",
"Assets, Current": "56.9",
"General and Administrative Expense": "-16.4",
"Expenses": "-30.0",
"Revenues": "-68.1",
"Net Income": "-132",
"Research and Development": "-8.94",
"Other Expenses": "-0.0203",
"Other Revenues": "-68.1",
"ECR before LimitedLiability": "-6.86",
"Comprehensive Net Income": "-132",
"Other Net Income": "-49.6",
"Economic Capital Ratio": "-68.9"
},
"2012": {
"Liabilities, Current": "0.693",
"Liabilities": "1.44",
"Stockholders Equity": "10.3",
"ECR before LimitedLiability": "-104",
"Liabilities, Non-Current": "0.397",
"Other Liabilities": "0.641",
"Assets, Current": "13.3",
"Assets": "-16.5",
"Assets, Non-Current": "-8.67",
"Property, Plant and Equipment, Net": "-7.28",
"Goodwill": "-16.6",
"Other Expenses": "-19.2",
"Expenses": "-62.7",
"Revenues": "-41.1",
"Net Income": "-161",
"Research and Development": "-37.3",
"General and Administrative Expense": "-12.5",
"Other Revenues": "-41.1",
"Other Net Income": "-1.21",
"Comprehensive Net Income": "-161",
"Economic Capital Ratio": "-137"
},
"2013": {
"Liabilities, Current": "2.89",
"Liabilities": "1.67",
"Stockholders Equity": "-33.7",
"ECR before LimitedLiability": "-109",
"Liabilities, Non-Current": "-0.513",
"Goodwill": "-7.87",
"Assets": "-36.0",
"Assets, Non-Current": "-2.73",
"Property, Plant and Equipment, Net": "-6.56",
"Other Assets": "-1.55",
"Assets, Current": "-6.10",
"General and Administrative Expense": "-3.75",
"Expenses": "-1.82",
"Revenues": "-12.5",
"Net Income": "-55.9",
"Research and Development": "-3.06",
"Other Expenses": "2.80",
"Other Revenues": "-12.5",
"Other Net Income": "-20.4",
"Comprehensive Net Income": "-56.0",
"Economic Capital Ratio": "-150"
},
"2014": {
"Liabilities, Non-Current": "-0.445",
"Liabilities": "4.25",
"Stockholders Equity": "-64.8",
"ECR before LimitedLiability": "-78.5",
"Liabilities, Current": "5.10",
"Other Liabilities": "-0.297",
"Assets, Current": "-23.8",
"Assets": "-40.7",
"Goodwill": "-2.88",
"Assets, Non-Current": "-1.92",
"Property, Plant and Equipment, Net": "-5.18",
"Other Expenses": "2.03",
"Expenses": "-4.32",
"Revenues": "-8.78",
"Net Income": "-13.2",
"Research and Development": "-3.80",
"General and Administrative Expense": "-3.37",
"Other Revenues": "-8.78",
"Other Net Income": "1.30",
"Comprehensive Net Income": "-13.2",
"Economic Capital Ratio": "-128"
},
"2015": {
"Liabilities": "4.86",
"Stockholders Equity": "-70.8",
"ECR before LimitedLiability": "-77.8",
"Liabilities, Current": "7.11",
"Liabilities, Non-Current": "-0.197",
"Assets, Current": "-20.0",
"Assets": "-38.7",
"Other Assets": "-3.42",
"Goodwill": "-4.19",
"Assets, Non-Current": "-1.78",
"Property, Plant and Equipment, Net": "-6.13",
"Research and Development": "-0.625",
"Expenses": "2.65",
"Revenues": "-8.56",
"Net Income": "-6.78",
"General and Administrative Expense": "-1.15",
"Other Expenses": "4.00",
"Other Revenues": "-8.56",
"Comprehensive Net Income": "-6.71",
"Other Net Income": "-1.72",
"Economic Capital Ratio": "-124"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001402785_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "3,315",
"Assets, Non-Current": "0",
"General and Administrative Expense": "2,075",
"Goodwill": "61",
"Liabilities, Current": "380",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "724",
"Other Liabilities": "0",
"Other Net Income": "-966",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "170",
"Research and Development": "641"
},
"output_variables": {
"Liabilities": "380",
"Assets": "3,546",
"Expenses": "3,440",
"Revenues": "0",
"Stockholders Equity": "3,166",
"Net Income": "-4,405",
"Comprehensive Net Income": "-4,405",
"BaseVar": "4,166",
"ECR before LimitedLiability": "-3.5%",
"Economic Capital Ratio": "85%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "1,381",
"Assets, Non-Current": "0",
"General and Administrative Expense": "1,550",
"Goodwill": "55",
"Liabilities, Current": "236",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "1,177",
"Other Liabilities": "0",
"Other Net Income": "-35",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "177",
"Research and Development": "1,423"
},
"output_variables": {
"Liabilities": "236",
"Assets": "1,614",
"Expenses": "4,150",
"Revenues": "0",
"Stockholders Equity": "1,378",
"Net Income": "-4,185",
"Comprehensive Net Income": "-4,185",
"BaseVar": "3,017",
"ECR before LimitedLiability": "-248%",
"Economic Capital Ratio": "21%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "1,831",
"Assets, Non-Current": "0",
"General and Administrative Expense": "3,050",
"Goodwill": "49",
"Liabilities, Current": "2,972",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-2,922",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "35",
"Research and Development": "1,313"
},
"output_variables": {
"Liabilities": "2,972",
"Assets": "1,916",
"Expenses": "4,362",
"Revenues": "0",
"Stockholders Equity": "-1,056",
"Net Income": "-7,284",
"Comprehensive Net Income": "-7,284",
"BaseVar": "6,086",
"ECR before LimitedLiability": "-357%",
"Economic Capital Ratio": "5.0%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "451",
"Assets, Non-Current": "0",
"General and Administrative Expense": "3,415",
"Goodwill": "358",
"Liabilities, Current": "5,617",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "477",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "12",
"Research and Development": "1,754"
},
"output_variables": {
"Liabilities": "5,617",
"Assets": "820",
"Expenses": "5,169",
"Revenues": "0",
"Stockholders Equity": "-4,797",
"Net Income": "-4,692",
"Comprehensive Net Income": "-4,692",
"BaseVar": "6,041",
"ECR before LimitedLiability": "-350%",
"Economic Capital Ratio": "5.6%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "645",
"Assets, Non-Current": "0",
"General and Administrative Expense": "2,465",
"Goodwill": "319",
"Liabilities, Current": "8,835",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-551",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "11",
"Research and Development": "721"
},
"output_variables": {
"Liabilities": "8,835",
"Assets": "975",
"Expenses": "3,186",
"Revenues": "0",
"Stockholders Equity": "-7,860",
"Net Income": "-3,738",
"Comprehensive Net Income": "-3,738",
"BaseVar": "6,774",
"ECR before LimitedLiability": "-296%",
"Economic Capital Ratio": "12%"
}
}
},
"top_rated": false,
"trend": 0.0,
"value": 0.12116976626338696,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001402785.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001402785.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001402785.svg"
},
{
"company_id": "0001552189",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001552189.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001552189.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001552189.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001552189_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001552189_main_keyfigs.svg",
"name": "Panacea LIFE Sciences Holdings INC",
"rank": 46,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001552189.svg",
"report_text": "The relative strengths and weaknesses of Panacea LIFE Sciences Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Panacea LIFE Sciences Holdings INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 2.6% points.The greatest weakness of Panacea LIFE Sciences Holdings INC is the variable Assets, reducing the Economic Capital Ratio by 46% points.
The company's Economic Capital Ratio, given in the ranking table, is 4.1%, being 132% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001552189_2016_Panacea_LIFE_Sciences_Holdings_INC.pdf",
"shrinked_graph_json": {
"2015": {
"Other Liabilities": "-0.572",
"Liabilities": "1.11",
"Stockholders Equity": "-35.0",
"ECR before LimitedLiability": "-85.9",
"Liabilities, Current": "2.56",
"Liabilities, Non-Current": "-0.690",
"Assets, Current": "-10.7",
"Assets": "-45.8",
"Other Assets": "-3.55",
"Goodwill": "-7.83",
"Assets, Non-Current": "-1.73",
"Property, Plant and Equipment, Net": "-6.71",
"Research and Development": "-3.34",
"Expenses": "-22.1",
"Revenues": "-9.51",
"Net Income": "-39.5",
"Other Expenses": "-12.8",
"Other Revenues": "-9.51",
"Comprehensive Net Income": "-39.3",
"Other Net Income": "1.43",
"Economic Capital Ratio": "-132"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001552189_strength_weakness.svg",
"table_records": {
"2015": {
"input_variables": {
"Assets, Current": "79",
"Assets, Non-Current": "0",
"General and Administrative Expense": "108",
"Goodwill": "4.1",
"Liabilities, Current": "178",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "204",
"Other Liabilities": "0",
"Other Net Income": "31",
"Other Revenues": "0.21",
"Property, Plant and Equipment, Net": "1.5",
"Research and Development": "77"
},
"output_variables": {
"Liabilities": "178",
"Assets": "85",
"Expenses": "389",
"Revenues": "0.21",
"Stockholders Equity": "-93",
"Net Income": "-358",
"Comprehensive Net Income": "-358",
"BaseVar": "342",
"ECR before LimitedLiability": "-369%",
"Economic Capital Ratio": "4.1%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.04084411177399274,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001552189.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001552189.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001552189.svg"
},
{
"company_id": "0001408299",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001408299.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001408299.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001408299_main_keyfigs.svg",
"name": "Entia Biosciences Inc",
"rank": 47,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001408299.svg",
"report_text": "The relative strengths and weaknesses of Entia Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Entia Biosciences Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 2.1% points.The greatest weakness of Entia Biosciences Inc is the variable Assets, reducing the Economic Capital Ratio by 51% points.
The company's Economic Capital Ratio, given in the ranking table, is 2.6%, being 133% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001408299_2016_Entia_Biosciences_Inc.pdf",
"shrinked_graph_json": {
"2014": {
"Assets, Current": "-33.2",
"Assets": "-46.0",
"Liabilities, Non-Current": "0.199",
"Stockholders Equity": "-29.4",
"ECR before LimitedLiability": "-66.2",
"Goodwill": "2.65",
"Other Assets": "0.450",
"Assets, Non-Current": "-6.03",
"Property, Plant and Equipment, Net": "-12.5",
"Other Expenses": "-27.0",
"Expenses": "-32.1",
"Revenues": "-8.36",
"Net Income": "-48.3",
"Research and Development": "5.59",
"General and Administrative Expense": "-11.1",
"Other Revenues": "-8.36",
"Liabilities, Current": "-0.401",
"Other Liabilities": "0.136",
"Other Net Income": "-3.13",
"Comprehensive Net Income": "-48.3",
"Economic Capital Ratio": "-116"
},
"2015": {
"Other Liabilities": "-0.539",
"Liabilities": "1.06",
"Stockholders Equity": "-39.6",
"ECR before LimitedLiability": "-87.4",
"Liabilities, Current": "2.09",
"Liabilities, Non-Current": "-0.653",
"Assets, Current": "-32.2",
"Assets": "-51.2",
"Other Assets": "-1.35",
"Goodwill": "-0.407",
"Assets, Non-Current": "-1.34",
"Property, Plant and Equipment, Net": "-4.68",
"Research and Development": "0.837",
"Expenses": "-16.2",
"Revenues": "-2.99",
"Net Income": "-29.6",
"General and Administrative Expense": "-7.00",
"Other Expenses": "-5.90",
"Other Revenues": "-2.99",
"Comprehensive Net Income": "-29.4",
"Economic Capital Ratio": "-133"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001408299_strength_weakness.svg",
"table_records": {
"2014": {
"input_variables": {
"Assets, Current": "485",
"Assets, Non-Current": "0",
"General and Administrative Expense": "1,499",
"Goodwill": "343",
"Liabilities, Current": "987",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "1,295",
"Other Liabilities": "0",
"Other Net Income": "-159",
"Other Revenues": "656",
"Property, Plant and Equipment, Net": "43",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "987",
"Assets": "871",
"Expenses": "2,794",
"Revenues": "656",
"Stockholders Equity": "-117",
"Net Income": "-2,297",
"Comprehensive Net Income": "-2,297",
"BaseVar": "2,734",
"ECR before LimitedLiability": "-264%",
"Economic Capital Ratio": "18%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "128",
"Assets, Non-Current": "0",
"General and Administrative Expense": "1,429",
"Goodwill": "233",
"Liabilities, Current": "1,240",
"Liabilities, Non-Current": "0",
"Other Assets": "55",
"Other Compr. Net Income": "0",
"Other Expenses": "1,116",
"Other Liabilities": "0",
"Other Net Income": "-61",
"Other Revenues": "347",
"Property, Plant and Equipment, Net": "33",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "1,240",
"Assets": "449",
"Expenses": "2,545",
"Revenues": "347",
"Stockholders Equity": "-791",
"Net Income": "-2,260",
"Comprehensive Net Income": "-2,260",
"BaseVar": "2,321",
"ECR before LimitedLiability": "-396%",
"Economic Capital Ratio": "2.6%"
}
}
},
"top_rated": false,
"trend": -6.0,
"value": 0.025895879117844665,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001408299.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001408299.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001408299.svg"
},
{
"company_id": "0001119643",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001119643.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001119643.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001119643.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001119643_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001119643_main_keyfigs.svg",
"name": "Nutra Pharma CORP",
"rank": 48,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001119643.svg",
"report_text": "The relative strengths and weaknesses of Nutra Pharma CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Nutra Pharma CORP compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 0.58% points.The greatest weakness of Nutra Pharma CORP is the variable Assets, reducing the Economic Capital Ratio by 47% points.
The company's Economic Capital Ratio, given in the ranking table, is 0.59%, being 135% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001119643_2016_Nutra_Pharma_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Liabilities, Current": "0.986",
"Liabilities": "0.985",
"Stockholders Equity": "-61.8",
"ECR before LimitedLiability": "-90.5",
"Liabilities, Non-Current": "-0.154",
"Other Liabilities": "-0.163",
"Property, Plant and Equipment, Net": "-1.79",
"Assets": "-37.7",
"Assets, Non-Current": "-0.615",
"Goodwill": "-1.93",
"Assets, Current": "-18.4",
"General and Administrative Expense": "-4.49",
"Expenses": "-2.65",
"Revenues": "-2.80",
"Net Income": "-11.7",
"Research and Development": "0.266",
"Other Expenses": "0.176",
"Other Revenues": "-2.80",
"Comprehensive Net Income": "-11.7",
"Other Net Income": "-0.221",
"Economic Capital Ratio": "-152"
},
"2012": {
"Liabilities, Current": "2.13",
"Liabilities": "2.12",
"Stockholders Equity": "-70.7",
"ECR before LimitedLiability": "-124",
"Liabilities, Non-Current": "-0.217",
"Other Liabilities": "-0.369",
"Assets, Current": "-20.3",
"Assets": "-41.8",
"Assets, Non-Current": "-1.11",
"Property, Plant and Equipment, Net": "-2.98",
"Goodwill": "-3.57",
"Other Expenses": "1.06",
"Expenses": "-0.178",
"Revenues": "-4.61",
"Net Income": "-12.0",
"Research and Development": "0.660",
"General and Administrative Expense": "-3.76",
"Other Revenues": "-4.61",
"Other Net Income": "-2.78",
"Comprehensive Net Income": "-12.0",
"Economic Capital Ratio": "-156"
},
"2014": {
"Liabilities, Non-Current": "-0.432",
"Liabilities": "4.94",
"Stockholders Equity": "-71.3",
"ECR before LimitedLiability": "-77.8",
"Liabilities, Current": "5.85",
"Other Liabilities": "-0.247",
"Assets, Current": "-23.5",
"Assets": "-45.2",
"Goodwill": "-7.58",
"Assets, Non-Current": "-1.81",
"Property, Plant and Equipment, Net": "-5.11",
"Other Expenses": "2.24",
"Expenses": "-0.831",
"Revenues": "-4.78",
"Net Income": "-8.34",
"Research and Development": "1.63",
"General and Administrative Expense": "-7.29",
"Other Revenues": "-4.78",
"Other Net Income": "-1.38",
"Comprehensive Net Income": "-8.33",
"Economic Capital Ratio": "-127"
},
"2015": {
"Liabilities": "0.564",
"Stockholders Equity": "-45.9",
"ECR before LimitedLiability": "-89.4",
"Liabilities, Current": "0.585",
"Liabilities, Non-Current": "-0.294",
"Assets, Current": "-16.1",
"Assets": "-47.1",
"Other Assets": "-0.882",
"Goodwill": "-2.73",
"Assets, Non-Current": "-0.337",
"Property, Plant and Equipment, Net": "-1.90",
"Research and Development": "0.204",
"Expenses": "-5.16",
"Revenues": "-1.60",
"Net Income": "-11.0",
"General and Administrative Expense": "-15.3",
"Other Expenses": "0.407",
"Other Revenues": "-1.60",
"Comprehensive Net Income": "-10.9",
"Other Net Income": "0.195",
"Economic Capital Ratio": "-135"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001119643_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "158",
"Assets, Non-Current": "17",
"General and Administrative Expense": "3,919",
"Goodwill": "0",
"Liabilities, Current": "4,112",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "524",
"Other Liabilities": "0",
"Other Net Income": "-23",
"Other Revenues": "160",
"Property, Plant and Equipment, Net": "55",
"Research and Development": "91"
},
"output_variables": {
"Liabilities": "4,112",
"Assets": "229",
"Expenses": "4,534",
"Revenues": "160",
"Stockholders Equity": "-3,883",
"Net Income": "-4,397",
"Comprehensive Net Income": "-4,397",
"BaseVar": "4,529",
"ECR before LimitedLiability": "-448%",
"Economic Capital Ratio": "0.99%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "247",
"Assets, Non-Current": "17",
"General and Administrative Expense": "2,801",
"Goodwill": "0",
"Liabilities, Current": "3,879",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-1,011",
"Other Revenues": "203",
"Property, Plant and Equipment, Net": "40",
"Research and Development": "3.0"
},
"output_variables": {
"Liabilities": "3,879",
"Assets": "303",
"Expenses": "2,804",
"Revenues": "203",
"Stockholders Equity": "-3,576",
"Net Income": "-3,612",
"Comprehensive Net Income": "-3,612",
"BaseVar": "4,101",
"ECR before LimitedLiability": "-407%",
"Economic Capital Ratio": "2.1%"
}
},
"2014": {
"input_variables": {
"Assets, Current": "342",
"Assets, Non-Current": "16",
"General and Administrative Expense": "2,797",
"Goodwill": "0",
"Liabilities, Current": "3,952",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "30",
"Other Net Income": "-331",
"Other Revenues": "595",
"Property, Plant and Equipment, Net": "29",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "3,982",
"Assets": "387",
"Expenses": "2,797",
"Revenues": "595",
"Stockholders Equity": "-3,595",
"Net Income": "-2,533",
"Comprehensive Net Income": "-2,533",
"BaseVar": "4,046",
"ECR before LimitedLiability": "-341%",
"Economic Capital Ratio": "6.4%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "349",
"Assets, Non-Current": "19",
"General and Administrative Expense": "6,057",
"Goodwill": "0",
"Liabilities, Current": "3,754",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "208",
"Other Net Income": "374",
"Other Revenues": "291",
"Property, Plant and Equipment, Net": "19",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "3,962",
"Assets": "388",
"Expenses": "6,057",
"Revenues": "291",
"Stockholders Equity": "-3,574",
"Net Income": "-5,392",
"Comprehensive Net Income": "-5,392",
"BaseVar": "5,536",
"ECR before LimitedLiability": "-473%",
"Economic Capital Ratio": "0.59%"
}
}
},
"top_rated": false,
"trend": -5.0,
"value": 0.00585477610520963,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001119643.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001119643.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001119643.svg"
},
{
"company_id": "0001142790",
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution_0001142790.svg",
"graph_url": "https://www.realrate-archive.com/us_medicinal_products/2015/graphs/IME_0001142790.svg",
"logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001142790.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001142790_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001142790_main_keyfigs.svg",
"name": "Tauriga Sciences INC",
"rank": 49,
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_0001142790.svg",
"report_text": "The relative strengths and weaknesses of Tauriga Sciences INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Tauriga Sciences INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 0.0029% points.The greatest weakness of Tauriga Sciences INC is the variable Assets, reducing the Economic Capital Ratio by 30% points.
The company's Economic Capital Ratio, given in the ranking table, is 0.0029%, being 136% points below the market average of 136%.",
"report_url": "https://www.realrate-archive.com/us_medicinal_products/2015/report/0001142790_2016_Tauriga_Sciences_INC.pdf",
"shrinked_graph_json": {
"2012": {
"Liabilities, Current": "0",
"Liabilities": "0",
"ECR before LimitedLiability": "-126",
"Liabilities, Non-Current": "0",
"Other Liabilities": "0",
"Assets, Current": "-0.696",
"Assets": "-18.7",
"Assets, Non-Current": "0",
"Property, Plant and Equipment, Net": "0",
"Goodwill": "0",
"Other Expenses": "0",
"Expenses": "-0.0228",
"Net Income": "-51.4",
"Research and Development": "0",
"General and Administrative Expense": "-0.0655",
"Other Revenues": "0",
"Revenues": "0",
"Stockholders Equity": "-0.0113",
"Other Net Income": "0",
"Comprehensive Net Income": "-50.6",
"Economic Capital Ratio": "-158"
},
"2015": {
"Other Liabilities": "0",
"Liabilities": "0",
"Stockholders Equity": "-3.08",
"ECR before LimitedLiability": "-89.9",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "-0.0110",
"Assets, Current": "-3.56",
"Assets": "-29.8",
"Other Assets": "-0.0251",
"Goodwill": "-0.180",
"Assets, Non-Current": "0",
"Property, Plant and Equipment, Net": "-0.0821",
"Expenses": "-0.320",
"Revenues": "-0.0626",
"Net Income": "-14.3",
"General and Administrative Expense": "-1.48",
"Other Expenses": "0",
"Other Revenues": "-0.0626",
"Comprehensive Net Income": "-14.6",
"Other Net Income": "-0.0527",
"Economic Capital Ratio": "-136"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/plot_over_time/0001142790_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "632",
"Assets, Non-Current": "0",
"General and Administrative Expense": "3,767",
"Goodwill": "0",
"Liabilities, Current": "738",
"Liabilities, Non-Current": "0",
"Other Assets": "0.0010",
"Other Compr. Net Income": "29",
"Other Expenses": "822",
"Other Liabilities": "0",
"Other Net Income": "-1,657",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "36",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "738",
"Assets": "668",
"Expenses": "4,589",
"Revenues": "0",
"Stockholders Equity": "-70",
"Net Income": "-6,246",
"Comprehensive Net Income": "-6,231",
"BaseVar": "3,841",
"ECR before LimitedLiability": "-900%",
"Economic Capital Ratio": "0.0000013%"
}
},
"2015": {
"input_variables": {
"Assets, Current": "333",
"Assets, Non-Current": "0",
"General and Administrative Expense": "3,704",
"Goodwill": "0",
"Liabilities, Current": "1,679",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "-55",
"Other Expenses": "285",
"Other Liabilities": "0",
"Other Net Income": "-1,100",
"Other Revenues": "0",
"Property, Plant and Equipment, Net": "25",
"Research and Development": "0"
},
"output_variables": {
"Liabilities": "1,679",
"Assets": "359",
"Expenses": "3,989",
"Revenues": "0",
"Stockholders Equity": "-1,320",
"Net Income": "-5,089",
"Comprehensive Net Income": "-5,116",
"BaseVar": "3,591",
"ECR before LimitedLiability": "-680%",
"Economic Capital Ratio": "0.0029%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.934797668956216e-05,
"company_index": "https://www.realrate-archive.com/us_medicinal_products/2015/industry_indexes/0001142790.svg",
"analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/equity/0001142790.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2015/analytics/profit_loss/0001142790.svg"
}
],
"feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_distribution/feature_distribution.svg",
"final_var_label": "Economic Capital Ratio",
"industry_box": [
[
"Revenues",
"25.5 B"
],
[
"Assets",
"40.3 B"
],
[
"Expenses",
"25.1 B"
],
[
"Stockholders Equity",
"12.9 B"
]
],
"industry_id": "us_medicinal_products",
"industry_label": "Medicinal Products",
"num_companies": 49,
"num_top_companies": 12,
"ecr_records": {
"2009": {
"0000794172": {
"rank": 1,
"ecr": "278"
},
"0000037785": {
"rank": 2,
"ecr": "225"
},
"0001056358": {
"rank": 3,
"ecr": "145"
}
},
"2010": {
"0000899923": {
"rank": 1,
"ecr": "304"
},
"0000794172": {
"rank": 2,
"ecr": "279"
},
"0000037785": {
"rank": 3,
"ecr": "209"
},
"0000874716": {
"rank": 4,
"ecr": "203"
},
"0001056358": {
"rank": 5,
"ecr": "150"
},
"0000074303": {
"rank": 6,
"ecr": "149"
},
"0001315695": {
"rank": 7,
"ecr": "132"
},
"0001145460": {
"rank": 8,
"ecr": "130"
},
"0001307954": {
"rank": 9,
"ecr": "115"
},
"0000722104": {
"rank": 10,
"ecr": "102"
}
},
"2011": {
"0000885462": {
"rank": 1,
"ecr": "287"
},
"0000899923": {
"rank": 2,
"ecr": "285"
},
"0000794172": {
"rank": 3,
"ecr": "276"
},
"0000736822": {
"rank": 4,
"ecr": "270"
},
"0000787253": {
"rank": 5,
"ecr": "256"
},
"0000711377": {
"rank": 6,
"ecr": "253"
},
"0000353569": {
"rank": 7,
"ecr": "250"
},
"0000768408": {
"rank": 8,
"ecr": "238"
},
"0000896264": {
"rank": 9,
"ecr": "235"
},
"0000811641": {
"rank": 10,
"ecr": "224"
},
"0000037785": {
"rank": 11,
"ecr": "221"
},
"0001054905": {
"rank": 12,
"ecr": "219"
},
"0001086303": {
"rank": 13,
"ecr": "216"
},
"0000810509": {
"rank": 14,
"ecr": "213"
},
"0001050007": {
"rank": 15,
"ecr": "208"
},
"0001374328": {
"rank": 16,
"ecr": "199"
},
"0000722830": {
"rank": 17,
"ecr": "183"
},
"0000874716": {
"rank": 18,
"ecr": "180"
},
"0000722104": {
"rank": 19,
"ecr": "176"
},
"0001063665": {
"rank": 20,
"ecr": "175"
},
"0001141240": {
"rank": 21,
"ecr": "168"
},
"0000074303": {
"rank": 22,
"ecr": "154"
},
"0000744218": {
"rank": 23,
"ecr": "152"
},
"0001315695": {
"rank": 24,
"ecr": "148"
},
"0001407038": {
"rank": 25,
"ecr": "146"
},
"0000949858": {
"rank": 26,
"ecr": "132"
},
"0001145460": {
"rank": 27,
"ecr": "127"
},
"0001307954": {
"rank": 28,
"ecr": "115"
},
"0001056358": {
"rank": 29,
"ecr": "104"
},
"0001402785": {
"rank": 30,
"ecr": "85"
},
"0000926617": {
"rank": 31,
"ecr": "84"
},
"0001124608": {
"rank": 32,
"ecr": "80"
},
"0001346526": {
"rank": 33,
"ecr": "80"
},
"0001386570": {
"rank": 34,
"ecr": "73"
},
"0000776008": {
"rank": 35,
"ecr": "34"
},
"0001037649": {
"rank": 36,
"ecr": "24"
},
"0001310630": {
"rank": 37,
"ecr": "20"
},
"0001119643": {
"rank": 38,
"ecr": "0.99"
},
"0001134765": {
"rank": 39,
"ecr": "0.077"
},
"0000880242": {
"rank": 40,
"ecr": "0.028"
},
"0000907654": {
"rank": 41,
"ecr": "0.0000000000000000000015"
}
},
"2012": {
"0000899923": {
"rank": 1,
"ecr": "282"
},
"0000885462": {
"rank": 2,
"ecr": "278"
},
"0000794172": {
"rank": 3,
"ecr": "275"
},
"0000073290": {
"rank": 4,
"ecr": "263"
},
"0000009326": {
"rank": 5,
"ecr": "260"
},
"0000353569": {
"rank": 6,
"ecr": "256"
},
"0000711377": {
"rank": 7,
"ecr": "254"
},
"0000787253": {
"rank": 8,
"ecr": "246"
},
"0000768408": {
"rank": 9,
"ecr": "245"
},
"0000722830": {
"rank": 10,
"ecr": "240"
},
"0001374328": {
"rank": 11,
"ecr": "239"
},
"0000896264": {
"rank": 12,
"ecr": "234"
},
"0000811641": {
"rank": 13,
"ecr": "233"
},
"0001054905": {
"rank": 14,
"ecr": "232"
},
"0000037785": {
"rank": 15,
"ecr": "219"
},
"0001086303": {
"rank": 16,
"ecr": "211"
},
"0001050007": {
"rank": 17,
"ecr": "209"
},
"0001510518": {
"rank": 18,
"ecr": "204"
},
"0001063665": {
"rank": 19,
"ecr": "199"
},
"0000949858": {
"rank": 20,
"ecr": "196"
},
"0001028215": {
"rank": 21,
"ecr": "194"
},
"0000874716": {
"rank": 22,
"ecr": "191"
},
"0000744218": {
"rank": 23,
"ecr": "163"
},
"0001056358": {
"rank": 24,
"ecr": "146"
},
"0001124608": {
"rank": 25,
"ecr": "146"
},
"0001134765": {
"rank": 26,
"ecr": "144"
},
"0000074303": {
"rank": 27,
"ecr": "142"
},
"0001315695": {
"rank": 28,
"ecr": "138"
},
"0000776008": {
"rank": 29,
"ecr": "137"
},
"0001145460": {
"rank": 30,
"ecr": "129"
},
"0001307954": {
"rank": 31,
"ecr": "118"
},
"0000722104": {
"rank": 32,
"ecr": "87"
},
"0000926617": {
"rank": 33,
"ecr": "84"
},
"0001346526": {
"rank": 34,
"ecr": "77"
},
"0001386570": {
"rank": 35,
"ecr": "72"
},
"0001407038": {
"rank": 36,
"ecr": "50"
},
"0000093314": {
"rank": 37,
"ecr": "46"
},
"0001141240": {
"rank": 38,
"ecr": "46"
},
"0001037649": {
"rank": 39,
"ecr": "23"
},
"0000810509": {
"rank": 40,
"ecr": "22"
},
"0001402785": {
"rank": 41,
"ecr": "21"
},
"0001310630": {
"rank": 42,
"ecr": "18"
},
"0001119643": {
"rank": 43,
"ecr": "2.1"
},
"0001142790": {
"rank": 44,
"ecr": "0.0000013"
}
},
"2013": {
"0000907654": {
"rank": 1,
"ecr": "474"
},
"0000885462": {
"rank": 2,
"ecr": "283"
},
"0000899923": {
"rank": 3,
"ecr": "279"
},
"0000794172": {
"rank": 4,
"ecr": "273"
},
"0000073290": {
"rank": 5,
"ecr": "268"
},
"0000009326": {
"rank": 6,
"ecr": "261"
},
"0000711377": {
"rank": 7,
"ecr": "261"
},
"0000353569": {
"rank": 8,
"ecr": "259"
},
"0000811641": {
"rank": 9,
"ecr": "240"
},
"0001054905": {
"rank": 10,
"ecr": "235"
},
"0000896264": {
"rank": 11,
"ecr": "231"
},
"0001063665": {
"rank": 12,
"ecr": "229"
},
"0000744218": {
"rank": 13,
"ecr": "228"
},
"0000768408": {
"rank": 14,
"ecr": "216"
},
"0001050007": {
"rank": 15,
"ecr": "212"
},
"0000722830": {
"rank": 16,
"ecr": "211"
},
"0000926617": {
"rank": 17,
"ecr": "209"
},
"0000037785": {
"rank": 18,
"ecr": "191"
},
"0001324736": {
"rank": 19,
"ecr": "185"
},
"0001374328": {
"rank": 20,
"ecr": "179"
},
"0000874716": {
"rank": 21,
"ecr": "162"
},
"0001086303": {
"rank": 22,
"ecr": "158"
},
"0001028215": {
"rank": 23,
"ecr": "156"
},
"0001056358": {
"rank": 24,
"ecr": "153"
},
"0000074303": {
"rank": 25,
"ecr": "150"
},
"0001578932": {
"rank": 26,
"ecr": "145"
},
"0001386570": {
"rank": 27,
"ecr": "144"
},
"0001124608": {
"rank": 28,
"ecr": "138"
},
"0000949858": {
"rank": 29,
"ecr": "131"
},
"0000736822": {
"rank": 30,
"ecr": "130"
},
"0001145460": {
"rank": 31,
"ecr": "127"
},
"0001307954": {
"rank": 32,
"ecr": "121"
},
"0001566978": {
"rank": 33,
"ecr": "117"
},
"0001037649": {
"rank": 34,
"ecr": "86"
},
"0001134765": {
"rank": 35,
"ecr": "83"
},
"0001510518": {
"rank": 36,
"ecr": "79"
},
"0000810509": {
"rank": 37,
"ecr": "63"
},
"0001346526": {
"rank": 38,
"ecr": "56"
},
"0000093314": {
"rank": 39,
"ecr": "49"
},
"0001407038": {
"rank": 40,
"ecr": "43"
},
"0001310630": {
"rank": 41,
"ecr": "16"
},
"0000776008": {
"rank": 42,
"ecr": "9.7"
},
"0001141240": {
"rank": 43,
"ecr": "7.6"
},
"0001569737": {
"rank": 44,
"ecr": "6.5"
},
"0001402785": {
"rank": 45,
"ecr": "5.0"
},
"0001504678": {
"rank": 46,
"ecr": "0.42"
},
"0000880242": {
"rank": 47,
"ecr": "0.000030"
}
},
"2014": {
"0000885462": {
"rank": 1,
"ecr": "284"
},
"0000794172": {
"rank": 2,
"ecr": "282"
},
"0000899923": {
"rank": 3,
"ecr": "271"
},
"0000711377": {
"rank": 4,
"ecr": "259"
},
"0000353569": {
"rank": 5,
"ecr": "256"
},
"0000073290": {
"rank": 6,
"ecr": "252"
},
"0001086303": {
"rank": 7,
"ecr": "237"
},
"0000811641": {
"rank": 8,
"ecr": "231"
},
"0000787253": {
"rank": 9,
"ecr": "230"
},
"0001054905": {
"rank": 10,
"ecr": "229"
},
"0001321834": {
"rank": 11,
"ecr": "225"
},
"0001374328": {
"rank": 12,
"ecr": "210"
},
"0001050007": {
"rank": 13,
"ecr": "206"
},
"0000768408": {
"rank": 14,
"ecr": "195"
},
"0000037785": {
"rank": 15,
"ecr": "192"
},
"0000907654": {
"rank": 16,
"ecr": "181"
},
"0000744218": {
"rank": 17,
"ecr": "181"
},
"0001056358": {
"rank": 18,
"ecr": "165"
},
"0000009326": {
"rank": 19,
"ecr": "160"
},
"0001028215": {
"rank": 20,
"ecr": "158"
},
"0000722830": {
"rank": 21,
"ecr": "148"
},
"0001578932": {
"rank": 22,
"ecr": "142"
},
"0001141240": {
"rank": 23,
"ecr": "142"
},
"0000074303": {
"rank": 24,
"ecr": "141"
},
"0000949858": {
"rank": 25,
"ecr": "132"
},
"0000926617": {
"rank": 26,
"ecr": "129"
},
"0001145460": {
"rank": 27,
"ecr": "125"
},
"0000736822": {
"rank": 28,
"ecr": "112"
},
"0001307954": {
"rank": 29,
"ecr": "111"
},
"0000874716": {
"rank": 30,
"ecr": "109"
},
"0001045309": {
"rank": 31,
"ecr": "103"
},
"0001566978": {
"rank": 32,
"ecr": "98"
},
"0001037649": {
"rank": 33,
"ecr": "85"
},
"0001590695": {
"rank": 34,
"ecr": "77"
},
"0001134765": {
"rank": 35,
"ecr": "67"
},
"0001346526": {
"rank": 36,
"ecr": "67"
},
"0001124608": {
"rank": 37,
"ecr": "65"
},
"0001407038": {
"rank": 38,
"ecr": "52"
},
"0000093314": {
"rank": 39,
"ecr": "24"
},
"0000810509": {
"rank": 40,
"ecr": "20"
},
"0001408299": {
"rank": 41,
"ecr": "18"
},
"0001310630": {
"rank": 42,
"ecr": "15"
},
"0001119643": {
"rank": 43,
"ecr": "6.4"
},
"0001569737": {
"rank": 44,
"ecr": "5.9"
},
"0001402785": {
"rank": 45,
"ecr": "5.6"
},
"0000776008": {
"rank": 46,
"ecr": "3.9"
},
"0000880242": {
"rank": 47,
"ecr": "0.00000029"
},
"0001562733": {
"rank": 48,
"ecr": "0.00000012"
}
},
"2015": {
"0000794172": {
"rank": 1,
"ecr": "279"
},
"0000885462": {
"rank": 2,
"ecr": "278"
},
"0000711377": {
"rank": 3,
"ecr": "261"
},
"0000353569": {
"rank": 4,
"ecr": "258"
},
"0000899923": {
"rank": 5,
"ecr": "253"
},
"0000073290": {
"rank": 6,
"ecr": "249"
},
"0001054905": {
"rank": 7,
"ecr": "236"
},
"0000787253": {
"rank": 8,
"ecr": "234"
},
"0000907654": {
"rank": 9,
"ecr": "234"
},
"0000037785": {
"rank": 10,
"ecr": "223"
},
"0001050007": {
"rank": 11,
"ecr": "219"
},
"0000896264": {
"rank": 12,
"ecr": "219"
},
"0000811641": {
"rank": 13,
"ecr": "214"
},
"0001038133": {
"rank": 14,
"ecr": "210"
},
"0000768408": {
"rank": 15,
"ecr": "199"
},
"0000744218": {
"rank": 16,
"ecr": "195"
},
"0000722830": {
"rank": 17,
"ecr": "192"
},
"0001056358": {
"rank": 18,
"ecr": "181"
},
"0001324736": {
"rank": 19,
"ecr": "176"
},
"0000009326": {
"rank": 20,
"ecr": "173"
},
"0001374328": {
"rank": 21,
"ecr": "169"
},
"0001028215": {
"rank": 22,
"ecr": "166"
},
"0000949858": {
"rank": 23,
"ecr": "159"
},
"0001562733": {
"rank": 24,
"ecr": "141"
},
"0001578932": {
"rank": 25,
"ecr": "139"
},
"0001569737": {
"rank": 26,
"ecr": "132"
},
"0000926617": {
"rank": 27,
"ecr": "122"
},
"0000074303": {
"rank": 28,
"ecr": "121"
},
"0000736822": {
"rank": 29,
"ecr": "113"
},
"0001566978": {
"rank": 30,
"ecr": "98"
},
"0001045309": {
"rank": 31,
"ecr": "96"
},
"0000874716": {
"rank": 32,
"ecr": "89"
},
"0001627223": {
"rank": 33,
"ecr": "85"
},
"0001141240": {
"rank": 34,
"ecr": "83"
},
"0001590695": {
"rank": 35,
"ecr": "81"
},
"0000776008": {
"rank": 36,
"ecr": "72"
},
"0000093314": {
"rank": 37,
"ecr": "65"
},
"0001134765": {
"rank": 38,
"ecr": "54"
},
"0001037649": {
"rank": 39,
"ecr": "53"
},
"0001498380": {
"rank": 40,
"ecr": "46"
},
"0000810509": {
"rank": 41,
"ecr": "23"
},
"0000880242": {
"rank": 42,
"ecr": "18"
},
"0001310630": {
"rank": 43,
"ecr": "15"
},
"0001598323": {
"rank": 44,
"ecr": "14"
},
"0001402785": {
"rank": 45,
"ecr": "12"
},
"0001552189": {
"rank": 46,
"ecr": "4.1"
},
"0001408299": {
"rank": 47,
"ecr": "2.6"
},
"0001119643": {
"rank": 48,
"ecr": "0.59"
},
"0001142790": {
"rank": 49,
"ecr": "0.0029"
}
}
},
"rating_box": [
[
"Top rated",
"12 of 49"
],
[
"Best, worst rating",
"279 %, 0.00293 %"
],
[
"New companies",
"8"
]
],
"regression_plot": "https://www.realrate-archive.com/us_medicinal_products/2015/backtesting_correlation/regression_2015.svg",
"scentences": [
"Synergy CHC Corp climbed 24 positions from 48 to 24 due to its excellent Comprehensive Net Income.",
"Liquidmetal Technologies INC lost 11 positions from 23 to 34 due to its bad Net Income.",
"Usana Health Sciences INC entered the 2016 ranking at rank 12, making it the best newcomer."
],
"url_segment": "2016-us-medicinal-products",
"year": 2016,
"feature_importance": "https://www.realrate-archive.com/us_medicinal_products/2015/feature_importance/feature_importance.svg",
"obs_ecr": {
"0000037785": {
"2011": {
"obs_EconomicCapitalRatio": 1.9637052598410045
},
"2012": {
"obs_EconomicCapitalRatio": 2.2187352745223867
},
"2013": {
"obs_EconomicCapitalRatio": 2.0998789372222704
},
"2014": {
"obs_EconomicCapitalRatio": 1.641537801830664
},
"2015": {
"obs_EconomicCapitalRatio": 1.0723385245823782
},
"2016": {
"obs_EconomicCapitalRatio": 1.6108835909734713
},
"2017": {
"obs_EconomicCapitalRatio": 1.8056499758638158
},
"2018": {
"obs_EconomicCapitalRatio": 1.2287717494570867
},
"2019": {
"obs_EconomicCapitalRatio": 1.7092843014022376
},
"2020": {
"obs_EconomicCapitalRatio": 1.9284688934634902
},
"2021": {
"obs_EconomicCapitalRatio": 1.6770740146552199
},
"2022": {
"obs_EconomicCapitalRatio": 1.834863173719622
},
"2023": {
"obs_EconomicCapitalRatio": 0.9158901623685305
}
},
"0001056358": {
"2011": {
"obs_EconomicCapitalRatio": 0.18783097649548078
},
"2012": {
"obs_EconomicCapitalRatio": 0.3196597323000155
},
"2013": {
"obs_EconomicCapitalRatio": 0.7370346023559032
},
"2014": {
"obs_EconomicCapitalRatio": 1.0406162753683343
},
"2015": {
"obs_EconomicCapitalRatio": 0.7323625964348088
},
"2016": {
"obs_EconomicCapitalRatio": 0.753066668490597
},
"2017": {
"obs_EconomicCapitalRatio": 0.5232637759318683
},
"2018": {
"obs_EconomicCapitalRatio": 0.7338326629079127
},
"2019": {
"obs_EconomicCapitalRatio": 0.6223996309643847
},
"2020": {
"obs_EconomicCapitalRatio": 0.6307022721006672
},
"2021": {
"obs_EconomicCapitalRatio": 1.4634619355072704
},
"2022": {
"obs_EconomicCapitalRatio": 0.820186420650827
},
"2023": {
"obs_EconomicCapitalRatio": 0.42412588511273297
},
"2024": {
"obs_EconomicCapitalRatio": 0.6963642400059836
},
"2025": {
"obs_EconomicCapitalRatio": 0.47545840734858463
}
},
"0000074303": {
"2011": {
"obs_EconomicCapitalRatio": 0.5221628155371295
},
"2012": {
"obs_EconomicCapitalRatio": 0.5016941351915414
},
"2013": {
"obs_EconomicCapitalRatio": 0.7067485666124749
},
"2014": {
"obs_EconomicCapitalRatio": 0.5800072775923082
},
"2015": {
"obs_EconomicCapitalRatio": 0.26932516949788865
},
"2016": {
"obs_EconomicCapitalRatio": 0.4320388824657905
},
"2017": {
"obs_EconomicCapitalRatio": 0.5856850809511247
},
"2018": {
"obs_EconomicCapitalRatio": 0.3494568183316394
},
"2019": {
"obs_EconomicCapitalRatio": 0.2952768225185927
},
"2020": {
"obs_EconomicCapitalRatio": 0.48260038439530095
},
"2021": {
"obs_EconomicCapitalRatio": 1.1559183950584917
},
"2022": {
"obs_EconomicCapitalRatio": 0.9955682298738215
},
"2023": {
"obs_EconomicCapitalRatio": 0.939616887252673
},
"2024": {
"obs_EconomicCapitalRatio": 0.5703504787209263
},
"2025": {
"obs_EconomicCapitalRatio": 0.3659536949506686
}
},
"0001307954": {
"2011": {
"obs_EconomicCapitalRatio": 0.18938003655153654
},
"2012": {
"obs_EconomicCapitalRatio": 0.3154058367754545
},
"2013": {
"obs_EconomicCapitalRatio": 0.4780017903384275
},
"2014": {
"obs_EconomicCapitalRatio": 0.384792729924332
},
"2018": {
"obs_EconomicCapitalRatio": 0.5095392164405845
},
"2019": {
"obs_EconomicCapitalRatio": 0.6235372978487372
},
"2020": {
"obs_EconomicCapitalRatio": 0.6619386066086855
},
"2021": {
"obs_EconomicCapitalRatio": 0.8463350886179348
},
"2022": {
"obs_EconomicCapitalRatio": 0.7115101902118032
},
"2023": {
"obs_EconomicCapitalRatio": 0.7137373813546445
},
"2024": {
"obs_EconomicCapitalRatio": 0.5244746605193847
},
"2025": {
"obs_EconomicCapitalRatio": 0.3141640811372542
}
},
"0000874716": {
"2011": {
"obs_EconomicCapitalRatio": 5.678189619495421
},
"2012": {
"obs_EconomicCapitalRatio": 6.62985272864075
},
"2013": {
"obs_EconomicCapitalRatio": 5.637583008591172
},
"2014": {
"obs_EconomicCapitalRatio": 5.3378472038789315
},
"2015": {
"obs_EconomicCapitalRatio": 4.359021798706142
},
"2016": {
"obs_EconomicCapitalRatio": 6.735635676724686
},
"2017": {
"obs_EconomicCapitalRatio": 7.882744231502931
},
"2018": {
"obs_EconomicCapitalRatio": 10.363928250251758
},
"2019": {
"obs_EconomicCapitalRatio": 12.865202087427075
},
"2020": {
"obs_EconomicCapitalRatio": 21.31825222425334
},
"2021": {
"obs_EconomicCapitalRatio": 26.268423294328166
},
"2022": {
"obs_EconomicCapitalRatio": 13.828898358817076
},
"2023": {
"obs_EconomicCapitalRatio": 18.252894151087883
},
"2024": {
"obs_EconomicCapitalRatio": 13.560026821642062
},
"2025": {
"obs_EconomicCapitalRatio": 21.570882602865723
}
},
"0000899923": {
"2011": {
"obs_EconomicCapitalRatio": 5.286603114326388
},
"2012": {
"obs_EconomicCapitalRatio": 5.947932077650038
},
"2013": {
"obs_EconomicCapitalRatio": 4.09378437010731
},
"2014": {
"obs_EconomicCapitalRatio": 5.490507086553531
},
"2015": {
"obs_EconomicCapitalRatio": 6.944372988710795
},
"2016": {
"obs_EconomicCapitalRatio": 2.339757271124506
},
"2017": {
"obs_EconomicCapitalRatio": 2.8740508316547966
},
"2018": {
"obs_EconomicCapitalRatio": 3.0914586906825567
},
"2019": {
"obs_EconomicCapitalRatio": 1.9630081673133826
},
"2021": {
"obs_EconomicCapitalRatio": 2.606632146369483
},
"2022": {
"obs_EconomicCapitalRatio": 1.7004450020894173
},
"2023": {
"obs_EconomicCapitalRatio": 2.215290054291016
},
"2024": {
"obs_EconomicCapitalRatio": 1.823931615329854
},
"2025": {
"obs_EconomicCapitalRatio": 1.1682929523136367
}
},
"0000885462": {
"2011": {
"obs_EconomicCapitalRatio": 0.477594589877508
},
"2012": {
"obs_EconomicCapitalRatio": 0.2925556156090612
},
"2013": {
"obs_EconomicCapitalRatio": 0.5361327962905387
},
"2014": {
"obs_EconomicCapitalRatio": 0.2505281175819798
},
"2015": {
"obs_EconomicCapitalRatio": 0.43387267254203915
},
"2016": {
"obs_EconomicCapitalRatio": 0.5022902813318385
},
"2017": {
"obs_EconomicCapitalRatio": 0.34065719753844165
},
"2018": {
"obs_EconomicCapitalRatio": 0.22997496410238202
},
"2019": {
"obs_EconomicCapitalRatio": 0.1659154208060553
},
"2020": {
"obs_EconomicCapitalRatio": 0.26901950354979465
},
"2021": {
"obs_EconomicCapitalRatio": 0.2838385361778253
},
"2022": {
"obs_EconomicCapitalRatio": 0.2067987843408893
},
"2023": {
"obs_EconomicCapitalRatio": 0.11983703427943283
},
"2024": {
"obs_EconomicCapitalRatio": 0.06649192725741328
}
},
"0001054905": {
"2011": {
"obs_EconomicCapitalRatio": 1.4579074706215878
},
"2012": {
"obs_EconomicCapitalRatio": 1.7997149963883579
},
"2013": {
"obs_EconomicCapitalRatio": 1.964317914289097
},
"2014": {
"obs_EconomicCapitalRatio": 1.4734327096252018
},
"2015": {
"obs_EconomicCapitalRatio": 1.8591617658964918
},
"2016": {
"obs_EconomicCapitalRatio": 2.185789648905985
},
"2017": {
"obs_EconomicCapitalRatio": 1.7880006703658458
},
"2018": {
"obs_EconomicCapitalRatio": 1.5318875768219857
},
"2019": {
"obs_EconomicCapitalRatio": 2.6164701172132556
},
"2020": {
"obs_EconomicCapitalRatio": 2.4715120247319406
},
"2021": {
"obs_EconomicCapitalRatio": 2.201354917056966
},
"2022": {
"obs_EconomicCapitalRatio": 2.262740511238834
}
},
"0001141240": {
"2011": {
"obs_EconomicCapitalRatio": 5.502360615827963
},
"2012": {
"obs_EconomicCapitalRatio": 2.4369547526522646
},
"2013": {
"obs_EconomicCapitalRatio": 11.581935819020808
},
"2014": {
"obs_EconomicCapitalRatio": 7.5454875670319685
},
"2015": {
"obs_EconomicCapitalRatio": 5.634514556207966
},
"2016": {
"obs_EconomicCapitalRatio": 5.458003060729301
},
"2017": {
"obs_EconomicCapitalRatio": 6.7960569922086025
},
"2018": {
"obs_EconomicCapitalRatio": 4.351678898468258
},
"2019": {
"obs_EconomicCapitalRatio": 4.24355658618375
},
"2020": {
"obs_EconomicCapitalRatio": 3.6370684560423614
},
"2021": {
"obs_EconomicCapitalRatio": 4.458556769073509
},
"2022": {
"obs_EconomicCapitalRatio": 3.1784879275692157
},
"2023": {
"obs_EconomicCapitalRatio": 3.3273144132655075
},
"2024": {
"obs_EconomicCapitalRatio": 2.3178398698599603
},
"2025": {
"obs_EconomicCapitalRatio": 5.890984282760348
}
},
"0000768408": {
"2011": {
"obs_EconomicCapitalRatio": 5.715133312847765
},
"2012": {
"obs_EconomicCapitalRatio": 2.3017018284798714
},
"2013": {
"obs_EconomicCapitalRatio": 1.425277475641039
},
"2014": {
"obs_EconomicCapitalRatio": 1.8803973873475237
},
"2015": {
"obs_EconomicCapitalRatio": 1.4412650279511978
},
"2016": {
"obs_EconomicCapitalRatio": 1.0071551396713583
},
"2017": {
"obs_EconomicCapitalRatio": 1.1153169457297638
},
"2018": {
"obs_EconomicCapitalRatio": 0.924011890899123
},
"2019": {
"obs_EconomicCapitalRatio": 0.6138635192851674
},
"2020": {
"obs_EconomicCapitalRatio": 0.7664774974857526
},
"2021": {
"obs_EconomicCapitalRatio": 0.871286208388657
},
"2022": {
"obs_EconomicCapitalRatio": 0.27420450138403873
},
"2023": {
"obs_EconomicCapitalRatio": 0.26934082796065434
},
"2024": {
"obs_EconomicCapitalRatio": 0.14158948221183076
}
},
"0000787253": {
"2011": {
"obs_EconomicCapitalRatio": 2.526353775920534
},
"2012": {
"obs_EconomicCapitalRatio": 1.3160543270878733
},
"2014": {
"obs_EconomicCapitalRatio": 1.1960142220158665
},
"2015": {
"obs_EconomicCapitalRatio": 2.1497060764213507
},
"2016": {
"obs_EconomicCapitalRatio": 1.6596075035664513
},
"2017": {
"obs_EconomicCapitalRatio": 1.820275172276164
},
"2018": {
"obs_EconomicCapitalRatio": 1.4250126839098163
},
"2019": {
"obs_EconomicCapitalRatio": 0.8714870157425864
},
"2020": {
"obs_EconomicCapitalRatio": 0.8186963761612863
},
"2021": {
"obs_EconomicCapitalRatio": 0.9963355986876283
},
"2022": {
"obs_EconomicCapitalRatio": 0.4935946735445941
},
"2023": {
"obs_EconomicCapitalRatio": 0.4463203114259345
},
"2024": {
"obs_EconomicCapitalRatio": 0.21764563032603712
}
},
"0000896264": {
"2011": {
"obs_EconomicCapitalRatio": 2.987080353491173
},
"2012": {
"obs_EconomicCapitalRatio": 2.8476111068826424
},
"2013": {
"obs_EconomicCapitalRatio": 4.5724271596679005
},
"2015": {
"obs_EconomicCapitalRatio": 7.320772852461824
},
"2016": {
"obs_EconomicCapitalRatio": 2.5202405198959905
},
"2017": {
"obs_EconomicCapitalRatio": 5.400078197143357
},
"2018": {
"obs_EconomicCapitalRatio": 7.8437625855710635
},
"2019": {
"obs_EconomicCapitalRatio": 5.208661448534275
},
"2022": {
"obs_EconomicCapitalRatio": 2.794889038132937
},
"2023": {
"obs_EconomicCapitalRatio": 2.6884992698433976
},
"2024": {
"obs_EconomicCapitalRatio": 1.4865583930571376
}
},
"0001086303": {
"2012": {
"obs_EconomicCapitalRatio": 0.050408616621473605
},
"2013": {
"obs_EconomicCapitalRatio": 0.3592188918384183
},
"2014": {
"obs_EconomicCapitalRatio": 0.5202291430401021
},
"2018": {
"obs_EconomicCapitalRatio": 75.60385532024324
},
"2023": {
"obs_EconomicCapitalRatio": 5.825073650532234
}
},
"0001134765": {
"2013": {
"obs_EconomicCapitalRatio": 84.83868255676903
},
"2014": {
"obs_EconomicCapitalRatio": 93.1111485713505
},
"2015": {
"obs_EconomicCapitalRatio": 199.2672351710133
},
"2016": {
"obs_EconomicCapitalRatio": 216.93321071912177
},
"2017": {
"obs_EconomicCapitalRatio": 60.02178473917171
},
"2018": {
"obs_EconomicCapitalRatio": 12.822507944414118
},
"2019": {
"obs_EconomicCapitalRatio": 455.3649181791688
},
"2020": {
"obs_EconomicCapitalRatio": 668.0565240083155
},
"2021": {
"obs_EconomicCapitalRatio": 3.604592501252785
},
"2022": {
"obs_EconomicCapitalRatio": 3.9983823737615998
},
"2023": {
"obs_EconomicCapitalRatio": 4.432317616137024
},
"2024": {
"obs_EconomicCapitalRatio": 2.934393508015559
},
"2025": {
"obs_EconomicCapitalRatio": 7.17941906968866
}
},
"0001310630": {
"2011": {
"obs_EconomicCapitalRatio": 118.5920894437218
},
"2012": {
"obs_EconomicCapitalRatio": 90.47339849409984
},
"2013": {
"obs_EconomicCapitalRatio": 72.75975087344283
},
"2014": {
"obs_EconomicCapitalRatio": 60.05301282758653
},
"2015": {
"obs_EconomicCapitalRatio": 46.147679617159916
},
"2016": {
"obs_EconomicCapitalRatio": 37.04924725418156
},
"2017": {
"obs_EconomicCapitalRatio": 30.944660874575487
},
"2019": {
"obs_EconomicCapitalRatio": 85.1712892994052
},
"2020": {
"obs_EconomicCapitalRatio": 24.70852870017063
},
"2023": {
"obs_EconomicCapitalRatio": 90.31718007058653
},
"2024": {
"obs_EconomicCapitalRatio": 18.12427183566627
},
"2025": {
"obs_EconomicCapitalRatio": 15.788052734849284
}
},
"0001374328": {
"2011": {
"obs_EconomicCapitalRatio": 1.843040104492836
},
"2012": {
"obs_EconomicCapitalRatio": 1.406513180725925
},
"2013": {
"obs_EconomicCapitalRatio": 2.5629155706742086
},
"2014": {
"obs_EconomicCapitalRatio": 3.2200542353297674
},
"2015": {
"obs_EconomicCapitalRatio": 1.2965403490667224
},
"2016": {
"obs_EconomicCapitalRatio": 0.9353195843240845
},
"2017": {
"obs_EconomicCapitalRatio": 0.4394415225694401
},
"2018": {
"obs_EconomicCapitalRatio": 0.9423630321081906
},
"2019": {
"obs_EconomicCapitalRatio": 2.6565609559613317
},
"2020": {
"obs_EconomicCapitalRatio": 9.948498907383927
},
"2022": {
"obs_EconomicCapitalRatio": 4.994024545393992
},
"2023": {
"obs_EconomicCapitalRatio": 2.2965761578523303
},
"2024": {
"obs_EconomicCapitalRatio": 3.6843422189586965
},
"2025": {
"obs_EconomicCapitalRatio": 1.821523711080343
}
},
"0001386570": {
"2011": {
"obs_EconomicCapitalRatio": 8.338141326290996
},
"2012": {
"obs_EconomicCapitalRatio": 8.392729648541112
},
"2013": {
"obs_EconomicCapitalRatio": 26.219216155099797
},
"2019": {
"obs_EconomicCapitalRatio": 8.591985092140105
},
"2020": {
"obs_EconomicCapitalRatio": 10.063615397839953
},
"2021": {
"obs_EconomicCapitalRatio": 6.442513704241379
},
"2022": {
"obs_EconomicCapitalRatio": 2.8215640716473835
},
"2023": {
"obs_EconomicCapitalRatio": 2.6556157143776864
},
"2024": {
"obs_EconomicCapitalRatio": 9.237391489557004
},
"2025": {
"obs_EconomicCapitalRatio": 7.630478708487693
}
},
"0000711377": {
"2011": {
"obs_EconomicCapitalRatio": 5.820904874555574
},
"2012": {
"obs_EconomicCapitalRatio": 7.7503288458074415
},
"2013": {
"obs_EconomicCapitalRatio": 10.377788751403328
},
"2014": {
"obs_EconomicCapitalRatio": 9.392743252183534
},
"2015": {
"obs_EconomicCapitalRatio": 10.034849829461312
},
"2016": {
"obs_EconomicCapitalRatio": 10.103194801881472
},
"2017": {
"obs_EconomicCapitalRatio": 14.452119850474038
},
"2018": {
"obs_EconomicCapitalRatio": 8.566992718065048
},
"2019": {
"obs_EconomicCapitalRatio": 9.17563055998759
},
"2020": {
"obs_EconomicCapitalRatio": 9.88631712937769
},
"2021": {
"obs_EconomicCapitalRatio": 9.735723882656965
},
"2022": {
"obs_EconomicCapitalRatio": 5.856026588966056
}
},
"0000744218": {
"2011": {
"obs_EconomicCapitalRatio": 1.8965131603685095
},
"2012": {
"obs_EconomicCapitalRatio": 5.333855573956268
},
"2013": {
"obs_EconomicCapitalRatio": 10.230725112264693
},
"2014": {
"obs_EconomicCapitalRatio": 11.553522232787866
},
"2015": {
"obs_EconomicCapitalRatio": 8.22074780222265
},
"2016": {
"obs_EconomicCapitalRatio": 1.4980547705405713
},
"2017": {
"obs_EconomicCapitalRatio": 2.021188969442516
},
"2018": {
"obs_EconomicCapitalRatio": 0.3696518300152486
},
"2019": {
"obs_EconomicCapitalRatio": 0.48016381910130834
},
"2020": {
"obs_EconomicCapitalRatio": 5.262656817463394
},
"2021": {
"obs_EconomicCapitalRatio": 7.793666490988671
},
"2022": {
"obs_EconomicCapitalRatio": 10.883731101898258
},
"2023": {
"obs_EconomicCapitalRatio": 7.286143405813059
}
},
"0000811641": {
"2011": {
"obs_EconomicCapitalRatio": 2.136690390726703
},
"2012": {
"obs_EconomicCapitalRatio": 1.849039798017059
},
"2013": {
"obs_EconomicCapitalRatio": 2.010189247495304
},
"2014": {
"obs_EconomicCapitalRatio": 2.34474040567545
},
"2015": {
"obs_EconomicCapitalRatio": 2.4785461696903734
},
"2016": {
"obs_EconomicCapitalRatio": 1.9865134449583703
},
"2017": {
"obs_EconomicCapitalRatio": 1.6949100276813254
},
"2018": {
"obs_EconomicCapitalRatio": 1.7852801061870174
},
"2019": {
"obs_EconomicCapitalRatio": 1.5240857269328754
},
"2020": {
"obs_EconomicCapitalRatio": 1.7195565413895542
},
"2021": {
"obs_EconomicCapitalRatio": 2.367024189117178
},
"2022": {
"obs_EconomicCapitalRatio": 1.6292353884860042
},
"2023": {
"obs_EconomicCapitalRatio": 1.1622002191801761
},
"2025": {
"obs_EconomicCapitalRatio": 1.9024392280197613
}
},
"0000907654": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 2.2151696375266194
},
"2014": {
"obs_EconomicCapitalRatio": 1.8158262418443614
},
"2015": {
"obs_EconomicCapitalRatio": 1.28497308211443
},
"2016": {
"obs_EconomicCapitalRatio": 1.0818389503384735
},
"2017": {
"obs_EconomicCapitalRatio": 1.3032495591532267
},
"2018": {
"obs_EconomicCapitalRatio": 0.6794655548784231
},
"2019": {
"obs_EconomicCapitalRatio": 1.027889384231902
},
"2020": {
"obs_EconomicCapitalRatio": 0.7572061787169263
},
"2021": {
"obs_EconomicCapitalRatio": 0.6116995115921646
},
"2022": {
"obs_EconomicCapitalRatio": 0.8326777832489594
}
},
"0000926617": {
"2011": {
"obs_EconomicCapitalRatio": 0.936747166508658
},
"2012": {
"obs_EconomicCapitalRatio": 3.2987773210340476
},
"2013": {
"obs_EconomicCapitalRatio": 3.310250104657181
},
"2014": {
"obs_EconomicCapitalRatio": 4.317801092124128
},
"2015": {
"obs_EconomicCapitalRatio": 7.655824111431128
},
"2016": {
"obs_EconomicCapitalRatio": 8.900428301796273
},
"2017": {
"obs_EconomicCapitalRatio": 20.503758003717643
},
"2018": {
"obs_EconomicCapitalRatio": 3.2888488055796508
},
"2019": {
"obs_EconomicCapitalRatio": 8.83333842031845
},
"2020": {
"obs_EconomicCapitalRatio": 45.47327065656971
},
"2021": {
"obs_EconomicCapitalRatio": 7.933579854593867
},
"2022": {
"obs_EconomicCapitalRatio": 2.857163597552752
},
"2023": {
"obs_EconomicCapitalRatio": 3.901740100848714
},
"2024": {
"obs_EconomicCapitalRatio": 1.8703748454852225
}
},
"0000949858": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 2.518997627887442
},
"2018": {
"obs_EconomicCapitalRatio": 0.7422482465262066
},
"2019": {
"obs_EconomicCapitalRatio": 0.35343147435010663
},
"2020": {
"obs_EconomicCapitalRatio": 1.3239430629183255
},
"2021": {
"obs_EconomicCapitalRatio": 2.1718168400927897
},
"2022": {
"obs_EconomicCapitalRatio": 0.9346116862802668
}
},
"0000009326": {
"2012": {
"obs_EconomicCapitalRatio": 5.656587982913678
},
"2013": {
"obs_EconomicCapitalRatio": 7.79966708407013
},
"2014": {
"obs_EconomicCapitalRatio": 2.9084764827636236
},
"2015": {
"obs_EconomicCapitalRatio": 2.8483648673741246
},
"2016": {
"obs_EconomicCapitalRatio": 3.648755401436501
},
"2017": {
"obs_EconomicCapitalRatio": 3.787889348418163
},
"2019": {
"obs_EconomicCapitalRatio": 4.035821822778718
},
"2020": {
"obs_EconomicCapitalRatio": 4.735832660774467
},
"2021": {
"obs_EconomicCapitalRatio": 6.878840843345401
},
"2022": {
"obs_EconomicCapitalRatio": 3.32579266803479
},
"2023": {
"obs_EconomicCapitalRatio": 4.327515096253764
},
"2024": {
"obs_EconomicCapitalRatio": 5.341740174720832
},
"2025": {
"obs_EconomicCapitalRatio": 4.797400698850301
}
},
"0000073290": {
"2012": {
"obs_EconomicCapitalRatio": 1.8838244732270972
},
"2013": {
"obs_EconomicCapitalRatio": 1.6432390281123206
},
"2014": {
"obs_EconomicCapitalRatio": 1.9239557658497293
},
"2015": {
"obs_EconomicCapitalRatio": 2.669474942212977
},
"2016": {
"obs_EconomicCapitalRatio": 5.686234008415378
},
"2017": {
"obs_EconomicCapitalRatio": 12.426535116483144
},
"2018": {
"obs_EconomicCapitalRatio": 6.023112230267755
},
"2019": {
"obs_EconomicCapitalRatio": 8.71810270966778
},
"2020": {
"obs_EconomicCapitalRatio": 5.758603861413226
},
"2021": {
"obs_EconomicCapitalRatio": 7.171288908839465
},
"2022": {
"obs_EconomicCapitalRatio": 6.5820905271862715
},
"2023": {
"obs_EconomicCapitalRatio": 2.3689702399551757
},
"2024": {
"obs_EconomicCapitalRatio": 0.8328246370864223
}
},
"0000093314": {
"2012": {
"obs_EconomicCapitalRatio": 17.719277991697727
},
"2013": {
"obs_EconomicCapitalRatio": 16.172791954794842
},
"2014": {
"obs_EconomicCapitalRatio": 17.12412941207431
},
"2015": {
"obs_EconomicCapitalRatio": 17.094853012648368
},
"2016": {
"obs_EconomicCapitalRatio": 7.646119704869701
},
"2017": {
"obs_EconomicCapitalRatio": 7.835630820870826
},
"2018": {
"obs_EconomicCapitalRatio": 5.69389490958303
},
"2020": {
"obs_EconomicCapitalRatio": 10.494231213006202
},
"2021": {
"obs_EconomicCapitalRatio": 9.325363829987609
},
"2022": {
"obs_EconomicCapitalRatio": 7.038632118707036
},
"2023": {
"obs_EconomicCapitalRatio": 1.692739776873626
},
"2024": {
"obs_EconomicCapitalRatio": 2.538095829463765
},
"2025": {
"obs_EconomicCapitalRatio": 1.267911014322384
}
},
"0001504678": {
"2021": {
"obs_EconomicCapitalRatio": 21.761860501462678
},
"2023": {
"obs_EconomicCapitalRatio": 7.712264043121101
},
"2024": {
"obs_EconomicCapitalRatio": 4.273885183694472
}
},
"0001321834": {
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.0
},
"2023": {
"obs_EconomicCapitalRatio": 0.0
},
"2024": {
"obs_EconomicCapitalRatio": 0.25079529133050554
},
"2025": {
"obs_EconomicCapitalRatio": 0.6661650116856921
}
},
"0001627223": {
"2015": {
"obs_EconomicCapitalRatio": 0.11531512461593406
},
"2016": {
"obs_EconomicCapitalRatio": 0.5041107353269599
},
"2017": {
"obs_EconomicCapitalRatio": 0.9792616137942283
},
"2018": {
"obs_EconomicCapitalRatio": 0.5037929444305274
},
"2019": {
"obs_EconomicCapitalRatio": 0.33457321143007535
},
"2020": {
"obs_EconomicCapitalRatio": 0.5470460275521768
},
"2021": {
"obs_EconomicCapitalRatio": 0.6499364328629865
},
"2022": {
"obs_EconomicCapitalRatio": 0.5809502304277893
}
},
"0001552189": {
"2022": {
"obs_EconomicCapitalRatio": 0.051966645127577905
},
"2023": {
"obs_EconomicCapitalRatio": 0.16744960403999323
}
},
"0001653477": {
"2016": {
"obs_EconomicCapitalRatio": 2.9965230053381644
},
"2017": {
"obs_EconomicCapitalRatio": 3.7915367442390675
},
"2018": {
"obs_EconomicCapitalRatio": 2.922808947052789
},
"2019": {
"obs_EconomicCapitalRatio": 1.959253575073628
},
"2020": {
"obs_EconomicCapitalRatio": 1.5143708031469667
},
"2021": {
"obs_EconomicCapitalRatio": 1.3249257731828572
},
"2022": {
"obs_EconomicCapitalRatio": 1.1004777222391815
},
"2023": {
"obs_EconomicCapitalRatio": 0.7369191018660393
},
"2024": {
"obs_EconomicCapitalRatio": 0.7736223011953498
},
"2025": {
"obs_EconomicCapitalRatio": 1.3076730606119293
}
},
"0001586554": {
"2016": {
"obs_EconomicCapitalRatio": 0.48058259081278015
},
"2018": {
"obs_EconomicCapitalRatio": 1.4962619054091728
},
"2019": {
"obs_EconomicCapitalRatio": 0.891464023479221
},
"2020": {
"obs_EconomicCapitalRatio": 0.5424015614406267
},
"2021": {
"obs_EconomicCapitalRatio": 0.4143393157324369
},
"2022": {
"obs_EconomicCapitalRatio": 0.23894685685583492
},
"2023": {
"obs_EconomicCapitalRatio": 0.10261033505859418
}
},
"0001642380": {
"2016": {
"obs_EconomicCapitalRatio": 21.72207919293821
},
"2017": {
"obs_EconomicCapitalRatio": 21.3709545386487
},
"2019": {
"obs_EconomicCapitalRatio": 4.529546805842379
},
"2021": {
"obs_EconomicCapitalRatio": 1.6309746744371012
},
"2022": {
"obs_EconomicCapitalRatio": 0.4521509520900019
},
"2023": {
"obs_EconomicCapitalRatio": 0.3591924761920325
}
},
"0001652130": {
"2016": {
"obs_EconomicCapitalRatio": 3.199958649296
},
"2017": {
"obs_EconomicCapitalRatio": 3.3067347442937
},
"2018": {
"obs_EconomicCapitalRatio": 2.957402513032481
},
"2019": {
"obs_EconomicCapitalRatio": 4.091879539456148
},
"2020": {
"obs_EconomicCapitalRatio": 9.369785151591545
},
"2021": {
"obs_EconomicCapitalRatio": 12.780171311702386
},
"2022": {
"obs_EconomicCapitalRatio": 3.4031614469183005
}
},
"0001708035": {
"2017": {
"obs_EconomicCapitalRatio": 0.4391634781975079
},
"2018": {
"obs_EconomicCapitalRatio": 0.3838203482983531
},
"2019": {
"obs_EconomicCapitalRatio": 0.48129649674893044
},
"2020": {
"obs_EconomicCapitalRatio": 0.6013288369758395
},
"2021": {
"obs_EconomicCapitalRatio": 0.8978665871292398
},
"2022": {
"obs_EconomicCapitalRatio": 0.7567918532035208
},
"2023": {
"obs_EconomicCapitalRatio": 0.7709750516345434
},
"2024": {
"obs_EconomicCapitalRatio": 0.6033738356189466
},
"2025": {
"obs_EconomicCapitalRatio": 1.152367959333189
}
},
"0001522767": {
"2017": {
"obs_EconomicCapitalRatio": 4.28352597297854
},
"2018": {
"obs_EconomicCapitalRatio": 11.84484946199016
},
"2019": {
"obs_EconomicCapitalRatio": 1.6647152363257145
},
"2020": {
"obs_EconomicCapitalRatio": 1.8939909944990796
},
"2023": {
"obs_EconomicCapitalRatio": 0.7154614969958419
},
"2024": {
"obs_EconomicCapitalRatio": 0.2730915686403338
},
"2025": {
"obs_EconomicCapitalRatio": 0.22748336782703915
}
},
"0001731348": {
"2020": {
"obs_EconomicCapitalRatio": 1.0343902967287055
},
"2021": {
"obs_EconomicCapitalRatio": 0.9151944120269997
},
"2022": {
"obs_EconomicCapitalRatio": 0.5292237994678327
},
"2023": {
"obs_EconomicCapitalRatio": 0.5873188828335296
},
"2024": {
"obs_EconomicCapitalRatio": 0.48595324362468467
}
},
"0001656472": {
"2020": {
"obs_EconomicCapitalRatio": 2.4846037628909143
},
"2021": {
"obs_EconomicCapitalRatio": 2.1068641047612973
},
"2022": {
"obs_EconomicCapitalRatio": 1.5226433295914465
},
"2023": {
"obs_EconomicCapitalRatio": 1.2617458734917226
},
"2024": {
"obs_EconomicCapitalRatio": 1.2298351104750205
},
"2025": {
"obs_EconomicCapitalRatio": 1.6798919218022832
}
},
"0001737927": {
"2020": {
"obs_EconomicCapitalRatio": 2.2413009969523126
},
"2021": {
"obs_EconomicCapitalRatio": 0.722105723732089
},
"2022": {
"obs_EconomicCapitalRatio": 0.49880311487341555
}
},
"0001754195": {
"2025": {
"obs_EconomicCapitalRatio": 0.6572335792654658
}
},
"0001756390": {
"2021": {
"obs_EconomicCapitalRatio": 1.6656381745552173
},
"2022": {
"obs_EconomicCapitalRatio": 0.2766604451340951
},
"2023": {
"obs_EconomicCapitalRatio": 0.2521606213881799
},
"2024": {
"obs_EconomicCapitalRatio": 0.09670274277596863
},
"2025": {
"obs_EconomicCapitalRatio": 0.15693027900478207
}
},
"0001813814": {
"2022": {
"obs_EconomicCapitalRatio": 1.017428702644666
}
},
"0001850902": {
"2021": {
"obs_EconomicCapitalRatio": 5.898441690535421
},
"2022": {
"obs_EconomicCapitalRatio": 1.4117684980890728
}
},
"0001906324": {
"2022": {
"obs_EconomicCapitalRatio": 3.794104483895451
},
"2023": {
"obs_EconomicCapitalRatio": 0.8130511823271402
},
"2024": {
"obs_EconomicCapitalRatio": 0.6055538968322262
},
"2025": {
"obs_EconomicCapitalRatio": 0.4114130862644389
}
}
}
}